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ABSTRACT 
 
This study compared the efficacy of the Curves® Complete 90-day Challenge 
(CC), Weight Watchers® Points Plus (WW), Jenny Craig® At Home (JC), and 
Nutrisystem® Advance Select™ (NS) on weight loss, body composition and/or markers 
of health and fitness in sedentary overweight women. One hundred thirty-three women 
(47±11 yr, 86±14 kg, 46±5%, 35.4±6 kg/m2) were randomized into CC (n=29), WW 
(n=29), JC (n=27), NS (n=28), or control (n=20) for 12-wks. Self-recorded food logs (4-
d), International Physical Activity Questionnaires, weight, resting energy expenditure 
(REE), dual energy x-ray absorptiometry, anthropometrics, and fasting blood samples 
were obtained at 0, 4, 8, & 12 wks. Peak aerobic capacity and muscular strength were 
measured at 0 and 12 wks. Data were analyzed by ANOVA or MANOVA with repeated 
measures.  
Average energy intake was 1,403±427 kcal/day with no differences among groups. 
CC was the only group with an increase in protein (0.15±0.30, p=0.039) combined with a 
reduction in carbohydrate (-0.63±0.95 g/kg/day, p=0.005) intake. CC was the only group 
with a significant increase in total physical activity (3,801±8,668 MET-min/wk, p=0.012) 
through week 8. All diet groups experienced a decrease in weight (-4.0±4.2 kg, p<0.001), 
body mass index (-4.0±2.1 kg/m2, p<0.001), waist circumference (-2.7±5.9, p<0.001), and 
hip circumference (-3.4±4.4 cm, p<0.001), and all maintained REE (0.09±2.0 kcal/kg/day, 
p=0.008). CC had the greatest decrease in fat mass (-3.8±4.0 kg, p<0.001) and body fat % 
(-2.7±3.4%, p<0.001) and was the only group that maintained fat-free mass (-0.19±2.00 
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kg, p=0.631). All groups, except WW, had a decrease in resting heart (-3.0±9.8 bpm, 
p<0.001). CC was the only group with a decrease in systolic (-7.6±14.2, p=0.002) and 
diastolic blood pressure (-3.6±7.3 mmHg, p=0.045). CC had the greatest increase in peak 
aerobic capacity (2.5±2.9 ml/kg/min, p<0.001) and was the only diet group that increased 
in lower (15.0±21.9 p=0.001) and upper body (8.7±12.5% p=0.001) strength. CC trended 
toward a decrease in total cholesterol to HDL-cholesterol ratio (-4.9±11.3%, p=0.053). 
Though all diet groups lost weight and had improvements in anthropometrics, CC 
experienced greater improvements in body composition, blood pressure, peak aerobic 
capacity, and muscular strength and trended toward improvements in blood lipid ratios.  
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NOMENCLATURE 
 
 
BMI  Body Mass Index 
 
BP   Blood pressure 
 
C   Control 
 
CC   Curves Complete 
 
DBP  Diastolic blood pressure 
 
DEXA  Dual energy x-ray absorptiometry  
 
FFM  Fat-free mass 
 
FM  Fat mass 
 
GXT  Graded Exercise Test 
 
HR   Heart rate 
 
IR  Insulin Resistance 
 
JC  Jenny Craig 
 
NS  Nutrisystem 
 
REE   Resting energy expenditure 
 
SBP  Systolic blood pressure 
 
TG   Triglycerides 
 
VO2max  Maximal oxygen consumption attained during a graded exercise test
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CHAPTER I 
 
INTRODUCTION AND RATIONALE 
 
Background 
 The epidemic of obesity is continuing to rise in the United States, and 
approximately two-thirds of Americans are classified as overweight (a body mass index 
25-29.9 kg/m2) or obese (a body mass index of ≥ 30 kg/m2) [1]. Obesity is a chronic 
disease, and it is rising as a major health problem in the Unites States [2]. Abdominal 
obesity specifically, is one of the risk factors for cardiovascular disease around the world 
[3, 4], and cardiovascular disease is the number one contributing factor of death and 
disability for women in the United States [5]. Additionally, in 1997, the World Health 
Organization recognized obesity as a worldwide disease that has an immense impact on 
public health and stated that overweight or obese individuals have a significantly higher 
probability of developing numerous chronic disorders such as diabetes, hypertension, and 
cardiovascular disease [6-11]. Unfortunately, there are no adequate treatment programs 
for obese individuals. Those who successfully lose weight often regain it within five years 
[12, 13]. Physical activity is an important contributing factor in losing weight as well as 
helping to reduce the risk of obesity and numerous other chronic diseases, such as 
cardiovascular disease, diabetes, depression, and certain cancers [14]. 
The importance of physical activity is widely accepted as a means to manage 
weight, and weight-loss interventions that incorporate quality exercise protocols are more 
effective in yielding long-term weight loss in overweight individuals compared to 
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interventions that involve dietary changes alone [15-18]. High intensity resistance training 
improves body composition and muscular strength [19-21]. Inadequate protein intake 
along with a decrease in physical activity may contribute to sarcopenia, an extreme muscle 
loss [22-24]. Contracting skeletal muscle can directly stimulate the growth or maintenance 
of muscle to prevent or treat sarcopenia [25]. 
Nutritional intake can impact skeletal muscle adaptations and hypertrophy when 
accompanying resistance training [26]. Nutrients from food can help maintain skeletal 
muscle and protein synthesis in the presence of resistance training [27]. Layman and 
colleagues [28] revealed the combined effects of a high protein diet with exercise on 
improving body composition and reducing total body weight and fat in healthy, 
overweight and obese women. Similar results were found by Meckling and colleagues 
[29] as well. An additional study by Cauza et al. [30] examined individuals with Type 2 
Diabetes. They compared the effects of both endurance and resistance training and found 
resistance training helped maintain or increase lean tissue during weight loss. Kerksick 
and colleagues [31] also conducted a 14-week resistance study with obese individuals and 
found greater improvements in body composition when a high protein diet was utilized in 
place of a high carbohydrate diet. This further supported that a high protein diet combined 
with resistance training may help to promote weight loss, body composition improvements 
and a decrease in metabolic risk factors. Higher protein diets accompanied with resistance 
training may also lead to a greater maintenance of fat-free mass and resting energy 
expenditure. 
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Nutrient-deficient diets and physical inactivity have both contributed to the 
increase in obese individuals in the United States and also worldwide [32]. Because of the 
negative side-effects that are able to result from being overweight or obese, it is important 
to integrate a weight loss program with proven weight loss strategies and that can 
affectively lead to changes in body composition and improve markers of fitness and health. 
Curves® International, Inc., Weight Watchers® International, Inc., Jenny Craig®, Inc., and 
Nutrisystem® are four widely recognized commercial companies that provide weight 
management services that are supported by scientifically validated research.  
Statement of the Problem 
Do different weight-loss approaches implemented by Curves® Complete 90-day 
Challenge (CC), Weight Watchers® Points Plus (WW), Jenny Craig® (JC), and 
Nutrisystem® Advance Select™ (NS) promote significantly different results in weight 
loss, body composition and/or markers of health and fitness in sedentary overweight 
women? 
Purpose 
The purpose of this study was to determine whether following  the control group 
(C) or the Curves Complete® 90-day Challenge, Weight Watchers® Points Plus, Jenny 
Craig®, or Nutrisystem® Advance Select™  weight loss programs for 12-weeks promoted 
significantly different changes in weight loss, body composition, fitness and health 
markers in previously sedentary overweight women. 
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General Study Overview 
 Four hundred sedentary women were randomized into four different diet and 
exercise groups or a control group (C). The independent variables were the C group, a 
Curves group (CC), a Weight Watchers group (WW), a Jenny Craig group (JC), and a 
Nutrisystem group. The CC group followed the Curves Complete 90-Day Fitness 
Challenge. The diet included consuming a high protein diet of a 45:30:25 protein to 
carbohydrate to fat ratio. It consisted of 1,200 kilocalories per day for one week and 1,500 
kilocalories per day for the remaining 11 weeks. Subjects in the CC group also participated 
in a supervised 30-min resistance training circuit training program four days a week, which 
was interspersed with calisthenics exercises or Zumba dance. CC participants were also 
encouraged to walk for 30 minutes on the other three days of the week. They were 
provided with a pedometer to track the number of steps taken each day. 10,000 steps was 
the encouraged goal by the end of the 12 weeks. Subjects in the WW group followed  the 
Weight Watchers® Points Plus Program. It consisted of food plans based on a points 
system, and the particpants were  required to attend a weekly meeting at a local Weight 
Watchers facility. Exercise recommendations, point tracking methods, and weight 
reductions strategies were presented and weekly weigh-ins were obtained. Exercise was 
encouraged but not mandatory. Subjects in the JC program participated in Jenny Craig At 
Home. They received their meals for the 12 weeks of the study. These participants were 
required to speak with a JC consultant on the phone once a week to discuss weight loss 
goals and exercise recommendations. Participants in the NS program followed the 
Nutrisystem Advance Select Program and also received meals for 12 weeks but were given 
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the option of calling a NS consultant each week with questions regarding their weight 
changes and exercise protocol. Online resources were available to both the JC and NS 
groups. Exercise was encouraged but not mandatory for both the JC and NS groups as 
well. Those in the C group did not make any changes in diet or exercise for the 12 weeks.  
The dependent variables that were measured at 0, 4, 8, and 12 weeks included 
weight, anthropometric measurements, and scanned body composition. Scanned body 
composition included total scanned mass, fat mass, fat-free mass, and percent body fat 
using the Hologic Discovery W QDR series Dual Energy X-ray Absorptiometry (DEXA) 
system (Watham, MA). Resting Energy Expenditure (REE) was also assessed at 0, 4, 8, 
and 12 weeks using the Parvo Medics TrueMax 2400 Metabolic Measurement System 
(Sandy, UT). Serum blood panels, including triglycerides, total cholesterol, HDL-
cholesterol, LDL-cholesterol, and total cholesterol to HDL cholesterol ratio, whole blood 
panels, hormone levels, which included glucose, insulin, glucose to insulin ratio, HOMA, 
and leptin were also measured at 0, 4, 8, and 12 weeks of intervention. Additional 
dependent variables measured at 0, 4, 8, and 12 weeks included dietary intake with a 4-
day self-reported food log and an Eating Satisfaction Survey, physical activity with a 
pedometer and an International Physical Activity Questionnaire (IPAQ) and psychosocial 
questionnaires, including an SF-36 Quality of Life Inventory and a Body Image 
Questionnaire. Peak oxygen consumption as well as lower and upper body maximal 
strength and endurance were measured at only 0 and 12 weeks.  
Data were analyzed by ANOVA or MANOVA with repeated measures using IBM 
SPSS for Windows version 20.0 software (Chicago, IL) and were presented as means ± 
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standard deviation, unless otherwise noted, and are presented as delta change from 
baseline or percent change from baseline. 
Hypotheses 
Ho1: Statistically significant differences will be observed among groups in macronutrient 
intake. 
Ho2: Statistically significant differences will be observed among groups in physical 
activity levels. 
Ho3: Statistically significant differences will be observed among groups in body 
composition related variables. 
Ho4: Statistically significant differences will be observed among groups in variables 
relating to markers of health. 
Ho5: Statistically significant differences will be observed among groups in variables 
relating to markers of fitness. 
Ho6: Statistically significant differences will be observed among groups in blood lipid 
panels.  
Ho7: Statistically significant differences will be observed among groups in hormone 
levels. 
Ho8: Statistically significant differences will be observed among groups in variables 
relating to psychological evaluations. 
Delimitations 
The study was conducted under the following guidelines: 
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1. 200 sedentary women between the ages of 18 and 70 years, with a BMI of 27-50 
kg/m2 were recruited from Texas A&M University and nearby communities to 
participate. 
2. Eligible participants took part in a familiarization session where they were 
informed of all testing protocols and requirements. They completed paperwork 
which included signing an informed consent and were scheduled for testing. 
3. Participants did not consume any nutritional supplementation that may have 
affected muscle mass or metabolism for at least three months prior to the start of 
the study.  
4. Participants did not participate in a planned exercise program for at least three 
months prior to the start of the study. 
5. Participants did not have a weight change of ±7 pounds within the three months 
leading up to the study. 
6. Participants did not have had a child within 12 months prior to the study, they were 
not breastfeeding, and they were not planning on becoming pregnant within the 
upcoming 12 months. 
7. Participants did not have any uncontrolled metabolic disorders. 
8. Participants refrained from strenuous exercise for 48 hours prior to baseline 
testing. 
9. Participants did not consume any NSAIDs or alcohol 24 hours prior to baseline 
testing. 
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Limitations 
1. The participants were individuals of the Texas A&M University and nearby 
communities who responded to radio advertisements as well as school and local 
paper advertisements. Therefore, the selection process was not truly random. This 
may have affected the ability to apply the results to the general population.  
2. There were inherent limitations of the laboratory equipment that were used for data 
collection and analysis.  
3. The participants completed the Eating Satisfaction Survey, which has not been 
scientifically proven to be valid or reliable. 
Assumptions 
1. Participants were fasted for the 12 hours prior to each testing session. 
2. Participants had not exercised 48 hours prior to teach testing session. 
3. Participants did not consume any over the counter medications or alcohol 24 hours 
prior to each testing session.  
4. Participants accurately answered the entrance criteria screening questions as well 
as the personal and medical history forms. 
5. Participants adhered to all of the guidelines during their involvement in the study, 
including following the assigned diet and exercise protocol. 
6. All laboratory equipment was calibrated and functioning properly for all testing 
sessions.  
7. There was consistency by the lab personnel when performing testing sessions. 
8. The sample of the population that was used in the study was normally distributed.  
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9. The variability among the samples was approximately equal.  
10. The sample was randomly selected and assigned to the different diet groups. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
Introduction 
Obesity is a chronic disease, and it is seen as a growing health problem in the 
United States as well as in many parts of the world [2]. It is often defined as having a body 
weight that is 10 percent greater than the standard weight or a BMI ≥30kg/m2 [33]. 
Obesity-related health risks are augmented when excess fat is most prevalent in the 
abdominal region and is associated with an increase in visceral fat. The quantity of visceral 
fat is a better predictor of CVD and metabolic disease than solely the amount of body fat 
that is present [34-38]. Direct medical expenses related to cardiovascular disease and other 
obesity related illness, such as hypertension, type 2 diabetes, stroke, asthma, and arthritis 
is expected to increase as the prevalence of obesity increases [39]. This knowledge 
underscores the need for effective weight loss strategies to help prevent and reduce obesity 
and for treatments that help reduce abdominal and therefore visceral fat [40].  
Etiology of Obesity 
Though the etiology of obesity is not well understood, it is thought that both 
genetics and environmental factors play a role in its development [41]. Genetics, 
environmental factors, and psychosocial factors all contribute to body weight, body 
composition, and storage of energy in the form of triglycerides in adipose tissue [32]. 
Nutrient-deficient diets and a decrease in energy expenditure are also contributing factors 
to the rise in overweight and obese individuals through the years. Spiegelman and Flier 
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[32] addressed that both the quality and quantity of our food sources, as well as the 
attenuated requirement for physical activity in our society have greatly contributed to the 
rise in obesity. It was also noted that the genes that contribute to an individual’s weight 
have been present prior to the last few decades. Therefore, it can be concluded that our 
environment has had a greater impact on the rise of obesity. Given that absorption of 
nutrients is not impaired, the increase in stored energy is based on the fact that energy 
intake is exceeding energy output. Physical activity, basal metabolism, and adaptive 
thermogenesis are all components of energy expenditure. When discussing efforts to 
balance energy intake versus energy output, a lack of physical activity is a key contributing 
factor to obesity [41]. 
Numerous researchers [34-38] have concluded that health risks relating to obesity 
are increased when there is a greater prevalence of abdominal fat and visceral fat. It is not 
solely the quantity of whole body fat but the quantity of visceral fat specifically, which is 
a better predictor of CVD and metabolic disease. 
Energy-dense foods, which may also be nutrient-deficient foods, have been linked 
to the rise in obesity over the past few decades [42-45]. There has been an increased 
consumption of snacks [46], calorie-filled beverages [47, 48], and fast food [49]. Dietary 
sugar and fat intake [47, 50], the larger portion sizes that are being consumed [51], as well 
as the decreased number of nutrient-dense meals that are consumed outside the home [52] 
have also been studied to evaluate their contribution to the overall weight increase in the 
U.S. 
 
12 
 
Prevalence of Obesity 
 Data on the ratio of height and weight, which can then be used to calculate body 
mass index (BMI), from the National Health and Nutrition Examination Survey 
(NHANES) has been utilized since the 1960’s to measure obesity prevalence in the United 
States [53]. Using BMI to define the standards, the percentage of children and adolescents 
who are overweight has increased significantly in the last 20 years [54, 55]. Seventy 
percent of children aged 10 to 13 years who are obese will then become obese as an adult 
[56]. Also, in spite of the more than 54 million Americans who are dieting, there is still a 
continued epidemic of obesity [53, 55]. The prevalence of overweight and obese 
individuals continues to rise in the United States (U.S.) with 33.8% of adults obese, 
according to a national survey in 2007-2008, and about 68% of individuals in the U.S. are 
overweight and obese combined [57]. From 1980-2002, the prevalence of obesity 
increased two-fold in adults 20 years of age or older, and the occurrence of overweight 
children between six and 19 years of age tripled [53, 55, 58]. The rise in the pervasiveness 
of obesity in both men and women presents a major public health problem which further 
emphasizes the need to ascertain effective treatments [53, 59].  
Implications of Obesity 
Atherogenic Abnormalities 
Cardiovascular (CVD) disease is the leading cause of death worldwide [60, 61]. 
More specifically, Coronary Heart Disease (CHD) is the leading cause of death in women 
in the United State, and dyslipidemia is one of the major risk factors, which is often 
characterized by inadequate lipid and lipid-cholesterol concentrations [62, 63]. Further, 
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CVD is the leading cause of mortality in the United States overall, and recent data suggests 
that between 360,000 and 500,000 women die each year from diseases of the heart [64, 
65]. Additionally, in the American Heart Association found the estimated costs of CVD 
to be more than $430 billion in 2007 [65]. Treating obesity is of highest importance in the 
efforts to decrease CVD, in that when obesity is left unaddressed, the risk of 
cardiovascular disease increases [41]. Further, obesity is associated with 
hyperinsulinemia, which is an independent risk factor for Coronary Artery Disease 
(CAD), and is linked to insulin resistance (IR) and atherogenic changes [66]. In combating 
the risk of developing CVD, physically active individuals have a reduced risk of 
developing CVD compared with those who are sedentary [67]. A meta-analysis of five 
different studies by Allison and colleagues [68] found that CVD is more common in those 
who are obese and physically inactive. 
Extensive research has been conducted to assess the impact of exercise on lipid 
metabolism, and increased physical activity may decrease the risk of CVD by positively 
changing the lipoprotein profile [69, 70]. The mechanisms by which exercise training 
influences serum lipoprotein levels are not fully understood, but regular physical activity 
and exercise training is able to improve lipid and glucose metabolism [70, 71]. Insulin 
sensitivity is improved with exercise and high density lipoprotein-cholesterol (HDL-C) 
concentrations can increase in some cases, as well [72]. Also, there is some evidence for 
a decrease in total cholesterol (TC), triglycerides (TG), and low-density lipoprotein 
cholesterol (LDL-C) [73-83]. 
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Greene and colleagues [84] conducted a study with 18 physically inactive, 
overweight and obese men (n=10) and women (n=8). They assessed the effects of acute 
bouts of exercise and an acute training effect on blood lipids-lipoproteins, and high-
sensitivity C-reactive protein (hsCRP). Prior to the exercise training, the subjects 
participated in an acute exercise session on a treadmill at 70% VO2max. They then had 12 
weeks of endurance exercise training three days per week. During the acute exercise 
session, participants expended 400 kilocalories and progressed to 500 kilocalories during 
the 12 weeks. Subjects maintained their normal dietary habits and were either exercising 
on a land-based treadmill or an aquatic-based treadmill. The acute exercise bout was 
repeated after the 12 weeks of training. Blood samples were collected right before and 24 
hours after the acute exercise sessions. When looking at HDL-C subfractions in women, 
the HDL2b-C concentration and particle number increased due to exercise training 
(p<0.05). Exercise training also increased HDL2a-C concentrations as well (p<0.01). 
Additionally, there was a decrease in HDL3-C (p<0.01) and HDL mean density (p<0.05) 
after exercise training. Further, a decrease in LDL3-C (p<0.05) and particle number 
(p<0.05) was also seen in women after the exercise training. 
Insulin Resistance and Diabetes Mellitus 
Along with the severe rise in obesity in the Western and developing countries, is 
the rise in metabolic complications such as diabetes, dyslipidemia, cardiovascular 
complications, and cancer. The majority of obesity-related deaths are attributed to 
secondary metabolic complications [85]. Excessive fatty acid mobilization that is present 
in abdominal obesity (waist/hip ratio >1.0 for men and >0.85 for women) [86] plays a key 
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role in many obesity-related metabolic conditions, including insulin resistance. High 
levels of fatty acid availability and therefore high levels of fatty acid uptake by skeletal 
muscle can contribute to an increase in intramuscular triglyceride (IMTG) levels [87-89]. 
There is a strong correlation between IMTG levels and the severity of insulin resistance 
in that IMTG may indirectly affect the function of insulin, specifically in obese individuals 
and those with diabetes mellitus [37, 90-94]. In two different studies, it was noted that 
across ethnic groups and in both genders, there is a strong link between being overweight 
and possessing diabetes mellitus [95, 96]. An emphasis is placed on central adiposity, the 
number of years an individual is overweight, as well as the extent to which an individual 
is overweight as factors which contribute to an increased risk of developing diabetes 
mellitus [97]. There is further research being conducted to find additional links of how 
obesity contributes to an increased risk of diabetes, hypertension, dyslipidemia, and the 
metabolic syndrome [98]. 
Additional Risk Factors 
As noted previously, mortality associated with obesity has been attributed to CVD, 
diabetes, kidney disease, and various forms of cancer [99, 100], and obese individuals 
have a greater risk of developing diabetes, dyslipidemia, hypertension, and cardiovascular 
diseases. These can then lead to an increased risk of mortality [9, 101, 102].  In light of 
the growing obesity epidemic, it is important for individuals to utilize successful weight-
loss treatments. 
Individuals who are overweight or obese have a 15 to 48 percent greater risk of 
experiencing a medically treated injury compared to individuals within a normal weight 
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range (BMI 18.5-24.9 kg/m2) [103]. There are decreases in immune function, as well as 
an increased risk of infection [104, 105]. Excess weight has also been associated with 
sleep apnea, which can pose significant side effects. The excess and unnecessary 
abdominal pressure on the diaphragm decreases residual lung volume, which can then lead 
to a reduction in oxygen saturation through the night [97, 106].  
An additional risk factor associated with obesity is osteoarthritis. Ostoearthritis is 
much more prevalent in overweight individuals, and the type of osteoarthritis that is 
associated with significant excess body weight directly correlates to its development in 
the knees and ankles [107]. However, in a study by Bray [97], medical ramifications of 
obesity were evaluated, and it was found that there was also an increase in osteoarthritis 
in non-weight-bearing joints. This finding leads to the conclusion that there are potential 
alterations in cartilage and bone metabolism due to the extra weight, which are 
independent of weight bearing activities. 
 Nonalcoholic fatty liver disease (NAFLD), which encompasses a variety of liver 
abnormalities, has also been associated with obesity. Abnormalities associated with 
NAFLD can include hepatomegaly (swelling of the liver) and elevated liver enzymes. 
Additional abnormalities include liver histology, which would include steatosis (retention 
of lipids in the cell), steatohepatitis (accumulation of fat along with inflammation), 
fibrosis, and cirrhosis [108]. 
Non-Pharmaceutical Treatments of Obesity 
 The rate at which obesity is increasing coincides with the rise in individuals who 
are dieting [109, 110]. More than 54 million individuals in the United States are currently 
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dieting. Though, the epidemic of obesity continues to grow, with no sign of cessation [53, 
55].  
 Weight loss of 5%-15% of body weight may reduce risk factors associated with 
obesity as well as provide positive health benefits [111], and diet and exercise are 
considered useful strategies for weight loss in moderately obese adults [112]. Current 
treatment programs for reducing obesity have not proven successful long-term, and it has 
been noted that individuals who have lost weight will regain it within five years [113, 
114]. In contrast, it is also beneficial to note, that the efforts proposed to manage the 
obesity epidemic by way of public health initiatives and drugs have only further 
underscored their lack of success [85]. Nonetheless, there have been recent studies that 
have found successful forms of weight loss more long-term [115-117].  
Diet Interventions 
Caloric Restricted Diets  
Diet interventions alone are the most prevalent weight loss method for obesity in 
spite of the understanding that a lack of physical activity is a contributing factor to obesity 
[118, 119]. Caloric restricted diets remain as the foundation for obesity reducing 
strategies. Though, a study conducted with men found that weight loss by way of exercise 
correlated with a greater attenuation of total body fat, maintenance of lean tissue, and an 
increase in cardiorespiratory fitness compared to solely diet-based weight loss. Further, 
exercise even when not accompanied by weight loss is correlated with significant 
decreases in abdominal obesity [40, 111, 120]. Studies have been conducted which 
included female subjects, though few have incorporated an exercise protocol that would 
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expect to yield significant weight loss results [121]. Flechtner-Mors and colleagues [122] 
conducted a three month weight loss study with a follow-up of four years, where the 
participants followed the same protocol throughout the time. Sixty females and 15 males 
completed the intervention. The initial group consisted of 79 females and 21 males 
(45.2±10.2 years and 33.6±3.6 kg/m2). Patients were randomly assigned to Group A or 
Group B. Group A consisted of receiving personalized menus of 1200-1500 kcals (19-
20%:48-54%:25-34%, PRO:CHO:FAT) including three meals and two snacks. Group B 
had two of three meals per day replaced with Slim-Fast diet shakes. The third meal was 
600-900 kcals with 30-45 g of PRO. The energy intake of each of the diets was the same 
throughout the study. The first phase was 12 weeks in duration, and the average percent 
weight loss for Group A and Group B were 1.5±0.4% and 7.8±0.5% (mean±SEM) 
respectively. Systolic blood pressure, plasma triacylglycerol, glucose, and insulin 
concentrations had significantly decreased in Group B, though no changes were seen in 
Group A. During the second phase of follow-up for 48 months, subjects received the same 
dietary instructions as during the first phase. At specific times, blood pressure, 
anthropometric measurements, lab work, and side effects were documented. Generalized 
estimating equations were used to calculate weight loss [123-125]. There were no 
differences in percent weight loss between males and females. The first phase was 12 
weeks in duration, and the average percent weight loss for Group A and Group B were -
1.5±0.4% and -7.8±0.5% (mean±SEM) respectively. Systolic blood pressure, plasma 
triacylglycerol, glucose, and insulin concentrations had significantly decreased in Group 
B, though no changes were seen in Group A. Also, at four years, both groups had a 
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significant decrease in weight compared to baseline (p<0.01). The study promoted the 
potential benefit of meal replacement as a means for weight-loss and weight-loss 
maintenance. Additionally, prepackaged meals could help to increase compliance to a diet 
protocol, because food choices are limited, which could then help to maintain a necessary 
caloric intake.  
Heilbronn et al. [126] organized a longitudinal study involving healthy women 
with a BMI >28 kg/m2. All the subjects had normal plasma glucose and lipid profiles. The 
diet component consisted of 1,500 kcals per day and was a low fat diet with only 15% fat. 
Eighty-three, non-smoking, healthy, obese women (48.0±0.9 years, waist circumference 
98.3±1.0cm, BMI 33.8±0.4 kg/m2, waist/hip ratio 0.83±0.01 cm) completed a 12-week 
caloric restricted intervention. Participants were not allowed to consume alcohol during 
the study. Data are represented as mean±SEE. Participants recorded their food intake over 
a three day period, every two weeks. Additionally, every two weeks, participants received 
dietary counseling and weight checks. Participants reported their food intake, with an 
average being 1,362.33±14.34 kcals/day. The average macronutrient breakdown that was 
reported was 61.4±0.3% carbohydrate, 14.2±0.2% fat, with saturated fat 5.9±0.1%, and 
22.8±0.2% protein. At baseline, the subjects had two consecutive appointments at the 
testing site and then returned every four weeks until the completion of the 12 week study. 
Weight was recorded and lab work was performed in a 12-hour fasted state, to measure 
glucose, serum total cholesterol, HDL cholesterol (HDL-C), and triglyceride 
concentrations by use of commercially available kits (Roche Diagnostics). LDL-
cholesterol (LDL-C) was calculated by using a modified version of the Friedewald 
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equation [127]. Subjects were also tested for serum C-reactive protein (CRP) 
concentrations at baseline and after 12 weeks by using an ultrasensitive ELISA (Alpha 
Diagnostica). Waist and hip measurements were obtained at baseline and after 12 weeks 
as well. After the 12 weeks, total cholesterol (-10%), LDL-C (-11%), HDL-C (-6%), and 
triglyceride concentrations (-14%) had significantly decreased. CRP levels were also 
significantly reduced (p<0.001). CRP was also found to be positively correlated with 
weight loss (p = 0.005) and was highly correlated with BMI after weight loss (p=0.001), 
as well as fat mass determined by waist circumference (p=0.001) and hip circumference 
(p=0.001). Triglycerides were the only blood panel measurement highly correlated with 
CRP concentrations (p=0.009), but CRP levels were also correlated with total cholesterol 
changes (p=0.03).  
High Protein Diets 
 Farnsworth et al. [128] conducted a study with 14 men and 43 women which 
evaluated the effects of a high protein and caloric restricted diet. They ranged from ages 
20 to 65, possessed a fasting serum insulin concentration of >12 µIU/L, a BMI ranging 
from 27 to 43 kg/m2. At the start of the study, most participants were sedentary and were 
required to maintain pre-testing activity levels. Participants were randomly allocated to 
either a high protein (HP) diet (30%:40%:30%) PRO:CHO:FAT ratio or a standard 
amount of protein (SP) diet (15%:55%:30%). Both diets had pre-planned menus, and 60% 
of the energy intake was provided for the subjects. The study lasted 16 weeks, and subjects 
were matched according to fasting serum insulin, BMI, age, and sex. The first 12 weeks 
consisted of 1,500 kcal on average, then there were four weeks of maintaining energy 
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balance while having the same macronutrient breakdown. Body weight, blood pressure, 
and venous blood samples were taken after an overnight fast at 0, 4, 8, 12, and 16 weeks. 
At baseline and 16 weeks, a three hour meal tolerance test was given to measure plasma 
glucose, serum insulin, and fatty acid concentrations. Body composition was measured 
using dual energy x-ray absorptiometry. Dietary compliance was measured by a 24-hour 
urine sample to measure the ratio of urea to creatinine. Further measurements included 
markers relating to the breakdown of bone and calcium excretion. There was an overall 
mean weight loss of 7.9±0.5 kg (p<0.0001), but there were not significant differences in 
weight loss between the HP and SP groups. Total fat mass loss was 6.9±0.4 kg after the 
16 week intervention (p<0.0001) but was not different between groups. Men however, lost 
a greater amount of fat mass compared to the women. There was also a significant 
reduction in total lean mass 1.2±0.3 kg (p<0.0001). Women experienced a greater loss of 
lean mass in the SP group than the HP group (p<0.02). Fasting plasma glucose had no 
significant change from baseline and 16 weeks, but fasting serum insulin decreased by 
29±3.4% at 16 weeks (p<0.001). The HOMA index also decreased 27±4% at 16 weeks 
(p<0.001).  
 Layman and colleagues [28] assessed the effects of diet composition and exercise 
on body composition and blood lipids during weight loss over a four month period. They 
hypothesized that an increase in protein and a reduction in carbohydrates along with 
aerobic exercise and resistance training would yield an additive effect on body fat loss and 
the maintenance of fat free mass. It was a randomized study with a two diet groups (high 
protein plus reduced carbohydrates and low protein + high carbohydrates). Both groups 
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also had an exercise intervention consisting of five days per week of walking and two days 
per week of resistance training or a control group that had light walking activity. After the 
16 weeks of intervention, all groups had a significant weight loss, and body weight 
changes were greater in the groups that consumed a higher protein and reduced 
carbohydrate protocol (p<0.05). The PRO + EX group had the greatest relative weight loss 
at 11.2% (p<0.05). The interaction of diet and exercise interventions did not yield 
significant changes in body weight, body composition, hormones, or blood lipids. They 
also saw increased fat losses with a higher protein diet and exercise group (p<0.05). 
Further, the PRO + EX group did not experience significant changes in lean mass (-0.9%, 
p=0.39), and the CHO group experienced the largest decrease in lean mass (-5.4%, 
p<0.001). Individuals in the PRO and PRO + EX groups had a decrease in relative body 
fat by -4.3%. Those who did not participate in a supervised exercise program, had a 
decrease in relative percent body fat by -2.5%.   
 Furthermore, a study by Kersick et al. [31] compared high carbohydrate and high 
protein diets with exercise. Participants were allocated into one of six groups: 1) no diet + 
no exercise control  (CON), 2) no diet + exercise (ND), 3) high carbohydrate, high energy 
diet (HED) + exercise (2,600 kcals; 55:15:30%); 4) very low carbohydrate, high protein 
(VLCHP) + exercise (1,200; 63:7:30%), 5) low carbohydrate, moderate protein (LCMP) 
+ exercise (1,200; 50:20:30%), or 6) high carbohydrate, low protein (HCLP) + exercise 
group (1,200; 55:15:30%). Participants were sedentary, obese females (38.5 ± 8.5 yrs, 
164.2 ± 6.7 cm, 94.2 ± 18.8 kg, 34.9 ± 6.4 kg/m2, 43.8 ± 4.2% body fat). There were 161 
subjects who participated in the 14 week study. Dependent variables included 
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anthropometric measurements, body composition, cardiovascular and muscular fitness, 
serum and whole blood, hormonal changes, and psychosocial parameters. The VLCHP, 
LCMP, and HCLP groups all restricted caloric intake combined with exercise and had 
similar significant reductions in DEXA fat-free mass. There were also similar changes in 
DEXA fat mass in the same groups after both 10 weeks and 14 weeks which led to an 
overall reduction in DEXA percent body fat. Decreases in DEXA fat measurements were 
significantly greater in the VLCHP group after 14 weeks compared to the HED, ND, and 
CON groups (p<0.05). 
Exercise Interventions 
Aerobic Exercise 
Physical activity has been encouraged as a means to reduce the risk of obesity. It 
has also been seen to help reduce the risk of several chronic diseases that are linked to 
obesity, such as cardiovascular disease, diabetes, depression, and certain types of cancer 
[14]. Physical activity has also been attributed as a successful intervention for weight 
control, and weight-loss interventions that include exercise are more effective in helping 
maintain weight loss long-term in overweight individuals compared to interventions that 
focus solely on diet changes [15-18]. 
Greene et al. [129] had 57 physically inactive, overweight, and obese men (n=25) 
and women (n=32) with baseline demographics of: 44±2 yr, 90.5±2.4 kg, 30.5±0.7 kg/m2, 
39.5%±1.2%, and 27.5±0.7 ml/kg/min. Subjects were randomly assigned to either LTM 
(land treadmill) or UTM (underwater treadmill) training. Participants maintained their 
typical dietary habits throughout the study. Exercise training consisted of three sessions 
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per week during the 12 weeks. All subjects had the same caloric expenditure, and the 
intensity of the exercise was decided from the maximal graded exercise test. VO2max was 
increased in both the UTM and LTM group (p<0.0001). Body mass (p<0.001), BMI 
(p<0.0001), waist circumference (p<0.0001), hip circumference (p<0.001), and waist-to-
hip ratio (p<0.05) were all significantly lower in both groups after 12 weeks of training.  
Kraus and colleagues [130] also conducted a study with 111 men and women who 
had mild dyslipidemia. They were randomly assigned to one of three exercise groups for 
eight months or to a control group for only six months. The exercise groups were: 1) high-
amount-high intensity exercise (a caloric equivalent to jogging about 20 miles per week 
for a 90 kg individual at 65%-80% of VO2max), 2) low-amount-high-intensity (a caloric 
equivalent to jogging 12 miles per week at 65%-80% of VO2max), and 3) low-amount-
moderate-intensity (a caloric equivalent to jogging 12 miles at 40%-55% of VO2max). 
The subjects in the high-amount-high-intensity group were required to expend 23 kcals 
per kilogram of body weight each week. Whereas, subjects in the two different low-
amount groups needed to expend 14 kcals per kilogram of body weight each week. All 
groups used cycle ergometers, treadmills, and elliptical trainers as sources of exercise. 
Participants also wore heart rate monitors (Polar Electro) while exercising. Subjects were 
instructed to maintain their body weight through the duration of the study. However, both 
high-amount-high-intensity and low-amount-moderate-intensity groups lost significantly 
more weight than those in the control group. Additionally, the high-amount-high-intensity 
and low-amount-high-intensity groups had significant increases in peak oxygen 
consumption compared to the control group (p<0.001). These findings revealed that the 
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intensity of the exercise was of greater importance than the amount of exercise in regards 
to improving fitness levels.  
Additionally, Kodama and colleagues [131] conducted a meta-analysis of research 
from 1966 to 2005. The studies were randomized controlled studies conducted with adults 
>20 years of age. They all involved aerobic training, HDL-cholesterol measurements at 
baseline and at the end of the study, at least eight weeks of training, and included a non-
exercise control group. The aerobic exercise was defined as rhythmic and repeated 
movements of the same large-muscle groups for at least 15 minutes. There were 21 trials 
that had an estimated energy expenditure greater than 900 kcal per week, and a significant 
(p<0.001) mean difference in HDL cholesterol change (MDHC) was seen in the exercise 
groups and not in the non-exercise controls. Further, in 25 trials where the total weekly 
exercise length was greater than 120 minutes, there was also a significant (p<0.001) 
MDHC seen. Univariate analysis revealed that exercise duration was the greatest predictor 
of MDHC and that the MDHC was not significantly different when exercise bouts were 
only 30-minutes or less in duration.  
It has been noted that a large contributing factor for why individuals stop 
exercising is due to injury [132]. In a longitudinal study done by Janney and Jakicic [133], 
397 sedentary adults with a BMI between 25 and 40 kg/m2 participated in an 18-month 
study which emphasized exercise to either help promote weight loss or prevent further 
weight gain. The effects of exercise and BMI on the frequency of injuries or illnesses 
relating to exercise were observed. It was concluded that overweight and obese adults who 
were prescribed an exercise protocol did not have a greater risk of injury compared to the 
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controls. However, the onset of injury or illness was attributed to body mass index. The 
value of regular aerobic exercise in reducing the risk of CVD has been well accepted, and 
the effects of exercise as both primary and secondary treatment for CVD are well known 
[76, 134-141]. 
Resistance Exercise 
According to the American College of Sports Medicine [142] and the American 
Heart Association [143], healthy adults are recommended to exercise at moderate intensity 
for at least 30-minutes a day on five days of the week or at vigorous intensity for at least 
20 minutes a day on three days of the week. Sarcopenia is the process in which there is a 
wasting of skeletal muscle mass, often correlating with aging [144]. Inadequate protein 
intake and low levels of physical activity are two factors which contribute to sarcopenia, 
or muscle wasting [22-24]. Having an adequate nutrient intake impacts skeletal muscle 
adaptations and hypertrophy in conjunction with resistance training [26]. When skeletal 
muscle contracts, it stimulates the growth or maintenance to prevent or treat sarcopenia 
and osteoporosis that is associated with aging [25]. In a study by Andrews et al. [145], 
individuals between 60-69 years of age were involved in varying intakes of protein 
combined with resistance training for 12 weeks. Participants also consumed a post-
exercise drink with 0.4g/kg lean mass protein. Significant increases in lean mass (1.1±1.5 
kg) were noted, and the variability in daily protein intake was not correlated with changes 
in lean mass (p>0.05).  
Prabhakaran and colleagues [70] looked at resistance training on lipid profile and 
body fat percentage. It was a 14 week study where 30 healthy, sedentary, non-smoking 
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premenopausal women were randomly assigned to either to either a resistance exercise 
training group or a sedentary control group. One week prior to participating, height/weight 
measurements, skinfold measurements, 1-RM, and a blood sample were obtained. 
Subjects also kept a three days diet record. Subjects were instructed to maintain their 
current dietary intake. The resistance exercise consisted of 45-50 minute sessions three 
times per week at 85% 1RM. Those in the control group were not allowed to participate 
in any structured exercise or activities. Exercises included bench press, leg press, leg 
extension, leg curl, and latissimus dorsi pull by way of a circuit training machine. Bicep 
curls, military press, and triceps extensions were performed with free weights. A new 1RM 
was estimated at the end of each week. There was a nine percent decrease in total 
cholesterol (p>0.05) and a 14.3% decrease in total cholesterol to HDL-cholesterol (HDL-
C) ratio (p>0.05). Results also trended toward a decrease in LDL to HDL-cholesterol ratio 
in the resistance trained group versus the control group (p=0.057). Body mass did not 
change significantly in either group, but body fat percentage significantly decreased in the 
resistance training group (p<0.05) but not in the control group. Further, resistance training 
did not significantly affect triglycerides or HDL-C, but there was a significant correlation 
between the percent change in estimated body fat and the percent change of HDL-C 
(p=0.0034). Additionally, there was a trend toward significance in the correlation between 
body fat percent change and the percent change in total cholesterol (p=0.08) for all 
subjects as well as a significant association between body fat percent change and the 
percent change in HDL-C (p=0.05). There were significant increases in estimated 1RM 
(p<0.05) in all eight of the strength exercises. Further, there was a significant correlation 
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between the percent change in total cholesterol and the percent change in total strength for 
all subjects (p=0.0026).   
Aerobic Plus Resistance Exercise 
Park and colleagues [146] conducted a study with 30 apparently healthy, obese 
women, 40 to 45 years of age, who were not taking regular medications. Subjects were 
placed into one of three groups: 1) an aerobic training group (n=10), 2) a combined 
training group (n=10), or 3) a control group (n=10). Height, weight, resting blood pressure, 
and body mass index (BMI) were measured and calculated respectively. Percent body fat 
and lean body mass were also measure by Inbody3.0. All participants performed a 
maximum treadmill test following Bruce protocol guidelines. Indications for stopping the 
test followed the American College of Sports Medicine (2000) [147]. Aerobic training 
consisted of 60 minutes per day, six days per week at 60% to 70% of HRmax for the first 
12 weeks of the study, involving side by side, step touch, lunge, v-step, grapevine, pivot 
turn, cha cha, mambo rock, diamond step, single hamstring walking heel touch, sit-up, and 
push-up. During weeks 13-24, resistance was at 60-70% of HRmax, involving fast 
walking, turn round, heel side, knee-up, scissors double, hop and jump, jumping jack, side 
kick, full turn, and double kick. Resistance training was completed 60 minutes a day at 
60% of 1RM during 1-12 weeks. For weeks 13-24, it was at 70% of 1RM. The combined 
training group had resistance training 3 days per week and aerobic training 3 days a week, 
alternating from resistance training. Relative VO2max was significantly increased in both 
the aerobic and combined training groups (p<0.01). In the control group, there was a 
significant increase in percent body fat after the 24 weeks. Additionally, weight and body 
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fat percentage were significantly reduced in both of the training groups compared with the 
control group. Lean body mass was unchanged in the aerobic trained group. In contrast, 
in the combined training group, lean body mass was increased (p<0.05). In both the 
aerobic training (p<0.05) and the combined training group (p<0.01), subcutaneous fat 
volume was decreased. Additionally, visceral fat volume, as well as visceral fat 
volume/subcutaneous fat volume ratio were decreased in the aerobic and combined 
training group (p<0.01). Total cholesterol, LDL-cholesterol, and triglycerides 
significantly decreased (p<0.01). Additionally, HDL-cholesterol was increased in both 
training groups (p<0.01). 
Diet and Exercise Interventions 
A decrease in body weight in obese individuals of five percent to 15 percent is able 
to reduce risk factors that are associated with obesity [111]. In a meta-analysis conducted 
by Miller et al. [15], subjects in all the acquired studies were randomized into three 
different groups, a diet group (D), an exercise only group (E), and a diet plus exercise 
group (DE). Subjects were 18 to 68 years of age and 26% of the sample populations were 
male and 46% were female. Criteria also required participants to be overweight, which 
was defined either by the original author, as ≥120% of ideal bodyweight, a BMI ≥27 
kg/m2, or body fat ≥30%. The diet intervention consisted of caloric restriction or a 
decreased energy intake, and the exercise group only had aerobic exercise. The aerobic 
exercise protocol consisted of 14-120 min in duration with a frequency of two to seven 
days per week. The main focus of the meta-analysis was to determine the effects of D, E, 
or DE on energy balance leading to changes in body weight and body composition. There 
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was a significant difference between the D and DE groups versus the E group in a decrease 
in body weight, fat, body fat percentage, and BMI. Though, were no significant differences 
observed between groups D and DE. However, the studies that involved exercise alone, 
had subjects who were younger, lower baseline weights, lower baseline BMI values, and 
lower baseline body fat percentages compared to those in the D and DE groups. When 
evaluating body composition changes between the three groups, those in the E group had 
less weight loss, fat loss, a smaller decrease in body fat percentage, a smaller decrease in 
BMI, and a smaller percentage of initial weight loss. In contrast though, at the one year 
follow-up, no differences were observed between the three groups in weight loss 
maintenance. There were seven E studies that had a one year follow-up program, and the 
data showed that those subjects maintained 70% of their initial weight loss compared to 
73% in the D and DE groups.  
A meta-analysis by Curioni and Lourenco [112] compared nine different previous 
studies from both the Unites States and Finland. The sample size of the studies ranged 
from 40 to 127 participants who were between the ages of 21 and 65 years. Three of the 
studies that were compared included only women, one study had only men, and two of the 
studies had both men and women. The length of involvement for the participants ranged 
from 10 to 52 weeks. There were also follow-ups that ranged from 12 to 24 months. 
Participants met (primarily in small groups) once a week in all the studies except for one. 
The baseline weight of the subjects ranged from 83.5 kg to 106 kg. Diets involved any 
form of caloric restriction, and the exercise was any form that was able to be quantified. 
Those individuals who were in a diet and exercise group and an average weight loss of 
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about 20% greater than those in a diet group alone. (p=0.063). After a one year follow-up, 
maintenance of weight loss was also shown to be 20% greater in the diet and exercise 
groups compared to just diet alone (p=0.058).  
Ross et al. [148] conducted a randomized controlled study in Canada with obese 
and insulin resistant women. Women were premenopausal, BMI >27 kg/m2, waist 
circumference >88cm, weight stable (±2 kg) for six months, nonsmokers, consumed an 
average of <2 alcoholic drinks per day, sedentary (no structured physical activity for the 
year prior to the study), and were taking no medications of any kind. Subjects also were 
tested prior to participation for a normal glucose tolerance and plasma lipid profile. 
Women were randomly assigned to one of four groups: 1) diet weight loss, 2) exercise 
weight loss, 3) exercise without weight loss, and 4) control group. Resting energy 
expenditure was obtained at the start of the study and multiplied by 1.5 to determine the 
estimated energy requirements for each individual. Subjects were randomly allocated to 
either a diet weight loss group (reducing isocaloric diet by 500 kcal/day, n=15), exercise 
weight loss (maintained isocaloric diet combined with expending 500 kcal/day, n=17), 
exercise without weight loss (consumed calories to compensate for expending 500 
kcal/day, n=12), or a weight-stable control (n=10) for 10 weeks of intervention. An initial 
four to five weeks of an isocaloric diet was maintained prior to the 10 week phase. The 
percent macronutrient breakdown was 50%-60% carbohydrate, 15%-20% protein, and 
20%-30% fat throughout the 14 weeks. Exercise consisted of daily walking or jogging 
on a treadmill at about 80% of maximal heart rate until 500 kcal were expended. Waist 
circumference changes were greater in the weight loss groups compared to the control 
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(p<0.001) but not significantly different from each other (p>0.05). The average decrease 
in waist circumference in the diet weight loss and exercise weight loss groups were -
4.1±2.4 and -6.5±2.6 cm respectively. Further, there was a significant decrease in total fat 
(p<0.001) in both weight loss groups, and it was greater in the exercise weight loss group 
(-2.6 kg) compared to the diet weight loss group (p<0.001). Average weight decrease was 
-5.2±1.2 in the diet weight loss group and -6.1±1.2 kg in the exercise weight loss group. 
Commercial Weight Loss Interventions 
In conjunction with the staggering rise in the pervasiveness of obesity, efforts have 
increased in order to develop effective methods to prevent weight gain. However, about 
68% of adults in the United States are currently overweight or obese, and it is imperative 
for effective treatment programs to be created for this population [57, 149]. There are a 
growing number of commercial diets and programs on the market which promote effective 
weight loss strategies. Heshka and colleagues [150] proposed that commercial weight loss 
programs are able to yield a level of weight loss that is equal to or surpasses interventions 
from traditional counseling or medicine. However, there are few studies that have 
evaluated commercial weight loss programs in depth. As a result, there is little known 
about the results of that an overweight or obese individual would experience in one of the 
programs. There is little scientific data available for individuals to use to make a valid 
assessment about the current diet services and programs offered, which was noted in a 
study by Wing [149]. 
A qualitative study conducted in Victoria, Australia by Thomas and colleagues 
[151] utilized open-ended interviews with 76 people who were currently obese (BMI of ≥ 
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30 kg/m2). The purpose of the study was to attempt to interact with individuals who were 
obese and had attempted to lose weight, to understand their perspective on dieting, and to 
have a better understanding of what they believe would be beneficial to them in their 
attempt to lose weight. Data were analyzed by using a constant, comparative method to 
develop and validate each category. Data were then interpreted within team meetings as 
well as by allowing the participants the opportunity to give their perspective on the 
findings of the study. Participants strongly favored commercial diets as a means to lose 
weight and participating in physical activity was not highly favored by many. The obese 
individuals were often introduced to the various weight loss strategies by friends and 
family members. It was also noted that those who participated in their weight loss 
intervention with their peers had a greater sense of acceptance and support. The 
individuals who were unable to adhere to the diet protocol believed it was their own fault 
that they were not able to lose weight. Even though participating in the diet interventions 
did not lead to a sustained weight-loss, two thirds of participants felt as though they were 
effective. It was concluded that very few individuals with obesity are provided with long-
term supervision or support with effective ways to lose weight, though many have received 
short-term advice. Understanding the impact that social networks may have in helping 
with weight loss may be of importance when participants are involved in physical activity. 
Curves Research 
 A study by Kerksick et al. [31], previously discussed, was conducted to determine 
the safety and efficacy of following the Curves diet when altering the ratio of carbohydrate 
and protein, along with following the Curves exercise protocol. Kerksick and colleagues 
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[152] then conducted an additional study which evaluated the impact of various 
macronutrients and caloric intakes combined with regular exercise, on metabolic and 
physiological changes related to weight loss. Both studies worked with obese women and 
consisted of low-energy diets in conjunction with popular exercise programs. Participants 
were randomized into one of six groups with various diet and exercise protocols and were 
randomized according to age and body mass. In the first phase of the study (Phase I) 
participants followed one of four diet and exercise protocols based on energy intake, 
carbohydrate, protein, and fat percentages for one week: 1) high energy, high 
carbohydrate, low protein (2,600 kcal; 55:15:30%; HED), 2) low carbohydrate, high 
protein (1,200 kcals; 7:63:30%, VLCHP), 3) low carbohydrate, moderate protein (1,200 
kcals; 20:50:30%; LCMP), or 4) high carbohydrate, low protein (1,200 kcals; 55:15:30%; 
HCLP). The second phase (Phase II) lasted nine weeks, and the caloric intake was set at 
1,600 kcals for the VLCHP and HCLP groups, and their ratios were changed to 
15:55:30%. The HED group breakdown changed to 2,600; 40:30:30%. The last phase 
(Phase III) continued for four weeks, and during this time all participants followed the 
same protocol of 2,600 kcals; 55:15:30%). Participants also weighed in each day. If there 
was a weight gain of three pounds, subjects returned to following Phase I until the weight 
was lost. Testing sessions were conducted at baseline, 1, 10, and 14 weeks. Changes in 
waist circumference were improved in all the groups that had both resistance exercise and 
energy restriction and were significantly different over time and compared to the control 
group. Body mass and percent fat also improved in the groups with resistance exercise 
and caloric restriction. With a significant main effect over time (p<0.001) and a group x 
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time interaction for fat-free mass (p<0.05). Those in the HCLP group were the only ones 
to have a significant decrease in fat-free mass compared to those in the control but not 
compared to the other groups. These findings could further support the positive effects of 
higher protein in maintaining fat-free mass when caloric restriction is present. Diets low 
in carbohydrates may yield greater weight-loss due to a greater sense of satiety from higher 
protein amounts [153], and there is a growing interest in studying diets that are high in 
protein and possess a moderate amount of carbohydrate and fat [154-156]. 
Weight Watchers Research 
Numerous studies have evaluated the efficacy and effectiveness of Weight 
Watchers [150, 157-163] with weight loss as a significant result for the participants in 
short-term and long-term protocols [150, 157-159]. 
 In a study by Dansinger and colleagues [164], four popular commercial diets were 
compared to evaluate differences in weight loss and heart disease risk reduction. The 
Atkins diet, the Zone diet, Weight Watchers, and the Ornish diet were the four commercial 
diets that were assessed. Participants had a BMI ranging from 27 to 42 kg/m2 and had at 
least one of the cardiac risk factors listed: fasting glucose of greater than or equal to 110 
mg/dL, total cholesterol of greater than or equal to 200 mg/dL, low-density lipoprotein 
(LDL) cholesterol of greater than or equal to 130 mg/dL, high-density lipoprotein (HDL) 
cholesterol of 40 mg/dL or less, triglycerides of greater than or equal to 150 mg/dL, 
systolic blood pressure of greater than or equal to 145 mmHg, diastolic blood pressure of 
greater than or equal to 90 mmHg, or were using oral medications to treat hypertension, 
type II diabetes, or dyslipidemia. Results were assessed at baseline and 1, 2, 6, and 12 
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months. All participants were instructed to take a multivitamin each day, participate in 60 
minutes of exercise each week, and to avoid commercial support services. Participants 
followed the diets for two months, and then followed them according to their interest level. 
A three day diet record was analyzed at baseline and 1, 2, 6, and 12 months. Phone calls 
were also made to the participants each month to assess personal perspective of adherence 
to the diet based on a 10 point scale. Body weight, waist circumference, and resting blood 
pressure were measured. Lab work was also conducted after an overnight fast, measuring 
total cholesterol, HDL-C, triglycerides, glucose, insulin, CRP, and creatinine levels. LDL-
C was also measure using the Friedewald formula [127]. Urine sample were also obtained. 
All four of the diets experienced significant weight loss after one year, but data was not 
significant between groups. In all the groups, about 25% of the participants maintained a 
weight loss of more than five percent of their initial body weight, and about 10% lost more 
than 10% of their body weight. Waist circumference was also strongly correlated with 
weight loss.  
 Another study by Morgan and colleagues [165] also compared Weight Watchers 
Pure Points program, which was an energy-controlled low-fat healthy eating diet, to three 
other commercial weight-loss programs and their effects on lipid-based cardiovascular 
risk factors. The three other commercial-diet programs were The Slim-Fast Plan, which 
was a low-fat meal replacement approach, Dr. Atkins’ New Diet Revolution, a low-
carbohydrate diet, and the Rosemary Conley’s ‘Eat Yourself Slim’ Diet and Fitness Plan, 
which was an energy-controlled low-fat healthy eating diet with one weekly group 
exercise class. Subjects ranged in age from 18-65 and had a BMI between 27-40 kg/m2. 
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Weight, blood pressure, and waist circumference were measured every four weeks, and 
fasting blood samples were obtained at baseline, eight weeks, and 24 weeks. There was a 
significant weight loss after the six month intervention in all four diet groups (p<0.001). 
After six months, LDL-cholesterol concentrations decreased in the Weight Watchers, 
Slim-Fast, and Rosemary Conley groups. Plasma triacylglyceride concentrations also 
decreased in the Atkins, Weight Watchers, and Rosemary Conley groups. Further, HDL-
cholesterol decreased significantly in all groups, except the Atkins group. Additionally, 
plasma insulin decreased in all four diet groups. 
 Heshka and colleagues [150] compared self-help diets to commercial diets, and it 
was found that commercial diets did provide greater weight loss compared to the self-help 
diets. The study was a randomized, parallel-group, 2-year trial that was conducted at six 
clinical centers in the United States between January 1998 and January 2001. Men and 
women participated were between 18-65 years and had a BMI from 27-40 kg/m2. 
Participants were also allowed to have health problems where weight reductions was a 
medically accepted therapy. Participants in the self-help group received consultations with 
a dietitian for 20 minutes at baseline and at week 12. Those in the commercial diet group 
had Weight Watchers membership paid for them. The design of the program was to lose 
up to 0.9 kg/wk. In the commercial group, change in weight at one year ranged from -28 
to +12 kg and from -23 to +21 kg after year two. In the self-help group, the range after 
one year was -26 to +15 kg and -26 to +30 after two years. Weight was significantly lower 
than baseline in the commercial group and the total weight loss was greater compared to 
the self-help group. Until week 52, weight loss was significantly lower in the self-help 
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group. When assessing BMI changes after one year, 56% of those in the commercial group 
were one BMI unit less than at baseline, and 52% were after two years. In the self-help 
group, 31% were after one year, and 29% were one BMI unit lower compared to baseline. 
Significant differences were seen in waist circumference decreases at both one and two 
years. Significant differences were also seen between commercial and the self-help group 
in the average amount of fat loss that was maintained through the last 18 months of the 
study.  
Jenny Craig Research  
Rock et al. [166] conducted an initial study assessing the efficacy of the Jenny 
Craig program where 70 female participants followed either the Jenny Craig program or 
the usual care protocol. Those in Jenny Craig attended weekly meetings at a Jenny Craig 
center. They received all their food free of charge and the diet was 1,200-2,000 kcal/day 
of prepackaged meals. Physical activity was encouraged for 30-minutes per day on five or 
more days of the week. The individuals in the usual care control group were given 
consultation meetings at baseline and 16 weeks with a dietitian. Their goal was to have a 
weight loss of 10% over a 6 month period with a 500 to 1,000 kcal/d deficit. Data 
collection of anthropometrics, blood work, questionnaires, and a step test occurred at 
baseline and 6 and 12 months. After 6 months, an average decrease in weight of -7.2 kg, 
in waist circumference of -7.1 cm, and hip circumference of -5.7 cm (p<0.01 for all three 
variables). At 12 months, those in the Jenny Craig program lost an average of 7.3 kg, 9.0 
cm in waist circumference, and 6.7 cm in hip circumference compared with the usual 
group participants who lost only 0.7 kg, 0.2 cm from the waist, and 0.3 am from the hips. 
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Rock and colleagues [167] conducted an additional study where 442 overweight 
and obese women (BMI 25-40 kg/m2, 18-69 years of age) were randomized into two 
weight-loss groups and were monitored over a two year period. The first group 
participated in an in-person center-based program and the second group was telephone-
based one-on-one weight loss counseling. Menus were set and prepackaged food items 
were provided during the initial weight-loss phase, and physical activity was encouraged. 
The meals involved a decrease in caloric intake while still maintaining adequate nutrition. 
The prepackaged prepared food items consisted of a low-fat (20%-30%), reduced caloric 
intake (1,200-2,000 kcal/day) and were free to the participants. The meals also had an 
increase in vegetables and fruits to help decrease the energy density of the meals. As the 
study progressed, participants shifted to a meal plan that consisted mainly of foods that 
were not provided by the commercial program. However, one prepackaged meal was still 
allotted each day during the weight loss maintenance period. All of the prepackaged meals 
and counselors were provided either in person or over the phone by Jenny Craig®. The 
weight loss counseling sessions were with a dietitian, and an energy intake of a 500-1,000 
kcal/d deficit was prescribed in order to obtain a 10% weight loss over a six month period 
[168]. The physical activity component of the program consisted of 30 minutes of physical 
activity on five or more days of the week. Those involved in the center-based program lost 
an average of 10.9% of their initial weight after one year of involvement. Also, weight 
loss between 12 and 24 months was 27% in both of the intervention groups compared to 
17% in the usual care group (p = 0.003). They also maintained 7.9% of their weight loss 
on average, after 24 months of involvement. Total cholesterol to LDL-cholesterol and 
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leptin levels also showed trending improvements. There were improvements in 
cardiopulmonary fitness, which was assessed by a step-test. After the 24 month study, 
62% of the center-based participants and 56% of the telephone-based participants had a 
weight loss of at least 5% versus only 29% of those who received usual care. Additionally, 
more than 37% of the center-based and telephone-based intervention groups versus 16% 
of the usual care had a weight loss of at least 10% of baseline weight, by the end of the 
study.  
Nutrisystem Research 
 A study conducted by Foster et al. [169] included 69 participants who followed a 
Nutrisystem diet. After 12 weeks of intervention, those who followed the Nutrisystem diet 
had a significantly greater reduction in body weight compared to those who were in the 
group that provided diabetes support and education (-7.1% vs. 0.4%). After 24 months of 
intervention, weight loss was maintained in the Nutrisystem group. Little research has 
been conducted which has looked at the efficacy of the Nutrisystem program. Though, 
there is research that evaluates low glycemic index diet protocols, which is a component 
of Nutrisystem meals [170]. Larsen and colleagues [171] evaluated weight loss 
maintenance by comparing groups with either a high or low protein intake as well as a 
high or low glycemic index. Diets that involve a low glycemic index may be an asset for 
improving body weight and body composition [171] and may positively impact certain 
risk factors in overweight individuals [172, 173]. 
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Comparative Studies 
 Analyzing the comparative effectiveness in a study evaluates the impact of 
different options that are available for treating a given condition [174]. Wadden and 
colleagues [175] assessed a number of studies on commercial weight loss programs, 
including Weight Watchers, Jenny Craig, and Nutrisystem. It was determined that 
commercial weight loss programs in general may provide success for overweight and 
obese individuals who are unable to obtain common lifestyle modifications. Nonetheless, 
the cost of the programs may be a limitation for whether or not an individuals would be 
able to participate. In this study, we compared similar commercial weight-loss programs. 
The cost to benefit ratio was assessed. A benefit of running a comparative study is 
potentially being able to disprove common assumptions about a given treatment [174].  
Summary of Weight Loss Benefits 
 The negative risk factors associated with overweight and obese are potentially 
reversible [176]. Weight loss helps to improve blood pressure, lipid levels, as well as 
glucose tolerance among overweight individuals who have hypertension, dyslipidemia, 
and diabetes [177-183]. Additionally, in hypertensive and diabetic patients, weight loss 
has led to a reduction in medication usage [184, 185]. However, there are advantages and 
disadvantages of various diet and exercise interventions in various populations.  Analyzing 
the comparative effectiveness in a study evaluates the impact of different options that are 
available for treating a given condition [174]. The purpose of the present investigation is 
to compare the effectiveness of commercially available weight loss programs that involve 
different diet and exercise interventions on weight, resting energy expenditure, total mass, 
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fat mass, fat-free mass, body fat percentage, triglycerides, total cholesterol, HDL-
cholesterol, LDL-cholesterol, glucose, insulin, leptin, peak aerobic capacity, and isotonic 
muscular strength and endurance in sedentary, overweight women.   
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CHAPTER III 
METHODS* 
 
Participants 
One hundred thirty-three women (47.2±11.3 yrs, 161.9±6.7 cm, 92.8±14.6 kg, 
35.5±5.6 kg/m2, 45.8±4.5% body fat) were randomized into one of five groups. The 
institutional review board (IRB) approved the protocol prior to initiating the study #2010--
0813. Initial screening was obtained via telephone. In order to be eligible to attend a 
familiarization session, subjects were not allowed to have participated in a planned 
exercise program in the three months prior to the study, which included not having 
participated in an organized exercise program for more than 30 minutes a day on at least 
three days of the week. The participants gave a self-reported weight and were not allowed 
to have a weight change of either gaining or losing seven pounds in the three months prior 
to starting the study. Additionally, they were not allowed to participate if they were 
currently pregnant or nursing, if they had a child within the last 12 months, or if they were 
planning on having a child within the upcoming 12 months. Subjects were also not allowed 
to participate if they had any uncontrolled metabolic disorders such as electrolyte 
abnormalities, heart disease, arrhythmias, diabetes, thyroid disease, hypogonadism, a 
history of hypertension, hepatorenal disease, musculoskeletal disease, autoimmune 
                                                 
*
Reprinted with permission from Dalton R, Baetge C, Lockard B, Levers K, Galvan E, Jagim A, Simbo S, 
Byrd M, Jung Y, Oliver J: Analysis of efficacy and cost effectiveness of popular weight loss and fitness 
programs. Journal of the International Society of Sports Nutrition 2013, 10(Suppl 1):P4. 
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disease, or neurological disease. If participants were taking any thyroid, hyperlipidemic, 
hypoglycemic, anti-hypertensive, or androgenic medications, the medications needed to 
have stayed the same within the three months prior to the study. Additionally, within the 
three months prior to testing, if the participants had taken ergogenic levels of nutritional 
supplements that could have affected muscle mass (e.g. creatine, HMB), 
anabolic/catabolic hormone levels (androstenedione, DHEA, etc.), or weight loss (e.g. 
ephedra, thermogenics, etc.), they were not eligible to participate. The participants needed 
to be willing to participate in an exercise program, and they also were required to have a 
body mass index between 27 and 50 kg/m2. Subjects who had a controlled medical 
condition were required to have a physician clearance form (Appendix D) completed and 
signed by their physician prior to participating in the study. Subjects who met the 
eligibility criteria through a phone screening were then allowed to attend a familiarization 
session where they were informed of the study requirements and signed an informed 
consent statement in compliance with the Human Subjects Guidelines of Texas A&M 
University and the American College of Sports Medicine.  
Study Site 
All testing sessions took place in the Exercise and Sport Nutrition Laboratory, in 
the Department of Health and Kinesiology at Texas A&M University in College Station, 
Texas.  
Experimental Design 
The overview of the research design and timeline for all testing sessions is 
displayed in Table 1. After attending a familiarization session, if an individual was still 
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eligible for the study, they were randomly assigned to one of the four diet groups or the 
control group. The subjects participated in a baseline testing session followed by three 
additional testing sessions, each four weeks apart. Resting testing measurements as well 
as fasting lab work were conducted at all four testing sessions. Exercise testing procedures 
were conducted only at baseline and the final testing session. A post-study questionnaire 
was administered at the completion of the study as well (Appendix I). 
Independent and Dependent Variables 
The independent variables in the study included the diet intervention, including 
Curves Complete® 90-day Challenge (CC), Weight Watchers® Points Plus (WW), Jenny 
Craig® At Home (JC) or Nutrisystem® Advance Select™ (NS) as well as the exercise 
protocol of each commercial weight loss program. Dependent variables included weight, 
resting energy expenditure, body composition, resting heart rate, resting blood pressure, 
waist and hip anthropometric measurements, one repetition maximum (1RM), 80% 1RM 
endurance, peak aerobic capacity, fasting serum and whole blood profiles (total 
cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, glucose, insulin, and 
leptin). Estimated dietary energy intake was evaluated by a four-day diet record (Food 
Processor Nutrition Analysis Software Version 10.12.0 ESHA Nutrition Research) 
(Appendix F) and an eating satisfaction survey (Appendix E). The participants’ estimated 
weekly physical activity was monitored by a physical activity log (Appendix G), the 
International Physical Activity Questionnaire, and those in the CC group were also 
provided with a pedometer. Psychosocial evaluations were assessed by the standardized 
quality of life questionnaire (SF-36) and a body image questionnaire (BIQ).  
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Familiarization Session 
Individuals who were interested in the study were screened by phone to determine whether 
they were eligible to attend a familiarization session. During the familiarization session 
the participants completed a personal history (Appendix B) and medical history (Appendix 
C) form and also signed the consent form (Appendix A). They received written and verbal 
explanations of the study protocol and design, testing procedures, including the lab work, 
and equipment that was used during their participation in the 12-week study. The 
participants were given instruction on how to accurately record dietary intake and physical 
activity throughout the 12 weeks. A tour of the lab was also given in order to show each 
component of a testing session. Height and weight of each participant were recorded, and 
the completed forms were reviewed. Participants who had controlled metabolic disorders 
were required to obtain medical clearance from their physician prior to participating in the 
study. They needed to have their physician sign a Physician Clearance Form (Appendix 
D) provided by the lab. After a thorough explanation of the study was provided, if 
participants were still eligible and interested in participating in the study, they were 
scheduled for their baseline testing session and randomized into one of the five groups. 
General Methods and Design 
Pre-Testing Guidelines 
 Prior to each testing session, participants were asked to record four days of their 
dietary intake, which included three weekdays and one weekend day. They also recorded 
their physical activity seven days prior to baseline testing. Participants were asked to not 
make any changes to their regular diet and exercise patterns prior to starting the study and 
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Table 1: Overview of research design and testing schedule. 
 
Familiarization 
and Entry 
(T0) 
 
Baseline  
(T1) 
 
4 weeks 
(T2) 
 
8 weeks 
(T3) 
 
12 weeks 
(T4) 
 
Phone interview  
 
Familiarization 
session  
 
General medical 
exam by a 
physician to 
determine 
qualifications to 
participate in study. 
 
Randomization into 
diet programs or 
control group 
 
 
Psychosocial 
Questionnaires: 
SF-36 QOLa 
BIQb 
 
Review Food Logs 
Eating Satisfaction 
Survey  
 
Review Activity Logs 
 
Fasting Blood 
Samples 
 
Weight 
 
Waist & Hip 
Circumference 
 
Resting HRc & BPd 
 
REEe 
 
DEXAf 
 
GXTg 
 
Isotonic Bench Press 
 
Isotonic Leg Press 
 
 
Psychosocial 
Questionnaires: 
SF-36 QOLa 
BIQb 
 
Review Food Logs 
Eating Satisfaction 
Survey  
 
Review Activity Logs 
 
Fasting Blood 
Samples 
 
Weight 
 
Waist & Hip 
Circumference 
 
Resting HRc & BPd 
 
REEe 
 
DEXAf 
 
 
Psychosocial 
Questionnaires: 
SF-36 QOLa 
BIQb 
 
Review Food Logs 
Eating Satisfaction 
Survey  
 
Review Activity Logs 
 
Fasting Blood 
Samples 
 
Weight 
 
Waist & Hip 
Circumference 
 
Resting HRc & BPd 
 
REEe 
 
DEXAf 
 
 
Psychosocial 
Questionnaires: 
SF-36 QOLa 
BIQb 
 
Review Food Logs 
Eating Satisfaction 
Survey  
 
Review Activity Logs 
 
Fasting Blood 
Samples 
 
Weight 
 
Waist & Hip 
Circumference 
 
Resting HRc & BPd 
 
REEe 
 
DEXAf 
 
GXTg  
 
Isotonic Bench 
Press 
 
Isotonic Leg Press 
 
Post-study 
Questionnaire 
a Quality of Life, b Body Image Questionnaire, c heart rate, d blood pressure, e resting energy expenditure, f dual 
energy x-ray absorptiometry, g graded exercise test 
 
 
to abstain from exercise 48 hours prior to testing (once participating in the study), as well 
as from alcohol and over the counter medications 24 hours prior to testing. Participants 
were also required to have fasted for 12 hours prior to each testing session. Subjects were 
required to wear close-toed shoes and to not wear any metal. Participants reported to the 
Exercise and Sport Nutrition Laboratory (ESNL) the morning of each testing session at an 
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assigned time between 5:00am and 10:00am. Lab personnel confirmed that they brought 
their required diet and exercise log and that they had adhered to the pre-testing guidelines.  
Curves® Complete 90-Day Fitness Challenge Program 
The participants who were randomized into the Curves Complete (CC) group 
followed the protocol outline in Table 2. The macronutrient breakdown of the CC group 
was a ratio 45:30:25 of protein, carbohydrates, and fat respectively. The first week of the 
program consisted of a 1,200 kilocalorie diet, and the remaining 11 weeks were allotted 
1,500 kilocalories. ESNL personnel explained with each subject the Curves diet as well as 
the exercise protocol. Participants were given a “Curves Fitness and Weight Management 
Plan” book [186] and “The Curves Food & Exercise Diary” [187] to help assist in 
following the diet plan. They were also provided with “Curves Essentials 2 Go” 
supplements, which consisted of two calcium tablets, one multi-vitamin tablet, and an 
omega-3 gel-capsule. They were required to exercise on the Curves circuit, which was 
located in the ESNL, four times per week. Each participant had an assigned key which 
was set-up to help track the number of workouts per week and the intensity of each 
workout. There were 13 hydraulic machines that were part of the Curves circuit. Three of 
the workouts consisted of a 30-second alternation between a Curves machine and 
calisthenics exercises, to maintain heart rate (HR). During these 30-minute sessions, 
participants completed two rounds of the circuit. The fourth workout involved alternating 
every minute between a Curves machine and Zumba dancing. There was a certified Zumba 
instructor who provided guidance and instruction on proper Zumba technique. For a 
Zumba workout, the circuit was only completed once.   
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On the remaining three days of the week, when the participants were not exercising on the 
Curves circuit, they were encouraged to walk for at least 30-minutes. In order to help 
encourage exercise on those days, participants in the Curves group were given a pedometer 
(Sportline 370 Multi-Function TraQ Any-Wear Pedometer, Yonkers, NY, USA) to wear 
each day while participating in the study. The pedometer was programed for each subject 
individually, which included include height, weight, age, and step length. They were 
instructed to wear the pedometer on the waistband of their pants from the time they got 
out of bed in the morning until the time they returned to bed at the end of the day. The 
pedometer tracked the number of steps taken each day, and the participants were required 
to record their steps at the end of each day for the entire 12 weeks. The ultimate goal each 
day was to complete 10,000 steps.  
Weight Watchers® Points Plus Program 
 The subjects who were randomized into the Weight Watchers (WW) group 
were enrolled in the Weight Watchers® PointsPlus Program and were required to attend a 
weekly meeting at a Weight Watchers facility. Each food item was given a point value, 
and each participant was allotted a specific total points for each day. The total points were 
based on entry level demographics, such as height, weight, age and gender, which was 
provided at registration of the program. The points system is formulated based on a food’s 
protein, carbohydrate, fat, and fiber content [188]. Participants were required to purchase 
their own food and had the opportunity to buy specific Weight Watchers items from their 
local Weight Watchers facility. A goal of Weight Watchers is for the individual to be able 
to track the points throughout the day and obtain the required nutrients. At the weekly 
50 
 
Table 2: Curves diet protocol.  
Diet 
Period 
Total 
Kcala/
Day 
Group Macronutrient Grams/
Day 
Kcal/ 
Day 
Percentage  
Daily Diet 
(%) 
 
Phase 1 
(1 Week) 
 
1,200 
kcal/d 
 
High Protein 
Diet + Exercise 
 
 
 
  
 
 
PROb  
CHOc 
FAT 
 
135  
90  
33   
 
 
 
540  
360  
300   
 
 
 
45  
30  
25   
 
 
 
Phase 2 
(11 weeks) 
 
1,500 
kcal/d 
 
  
 
 
High Protein 
Diet + Exercise 
 
 
 
  
 
 
PROb  
CHOc 
FAT  
 
  
 
 
169 
113  
42   
 
 
 
675 
450  
375  
 
  
 
 
45  
30 
25   
a kilocalories, b protein, c carbohydrates 
 
 
meetings, the participants were able to ask questions regarding their diet and exercise and 
the meeting facilitator provided feedback to encourage positive changes to further promote 
weight-loss. The participants were encouraged to exercise and more specifically, to 
participate in organized walking sessions, but exercise was not required during the 12 
weeks of participation in the study. 
Jenny Craig® At Home 
 The subjects who were randomized into the Jenny Craig (JC) group were enrolled 
in the Jenny Craig® At Home program, which is an online-based program. Once registered 
by lab personnel, the participants received their meals every two weeks from Jenny Craig 
Inc. (Carlsbad, CA). The meals were assigned as breakfast, lunch, dinner, snacks, and 
desserts. Participants also supplemented their meals with their own fresh vegetables, fruits 
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and dairy products. A main focus of the JC program is portion control and a balanced 
approach to life, which includes meals [189]. Each participant was given a calorie level 
that was designed to help promote a one to two pound weight loss each week or one 
percent of the baseline weight. Menus were personalized to implement the most recent 
Dietary Guidelines for Americans and the Dietary Reference Intakes issued by the Institute 
of Medicine. The daily nutrients breakdown (given a 1,200 kilocalorie diet) were as the 
following: two grams of sodium, two grams of potassium, 100-200 milligrams of 
cholesterol, 20-30 grams of fiber, and 1,000 milligrams of calcium. The nutritional 
composition breakdown consisted of 50%-60% carbohydrates, 20%-30% protein, and 
20%-30% fat. Participants were required to participate in a 10-15 minute weekly phone 
session, and each JC subject had a personal consultant who called them each week at an 
agreed upon time. The consultants were able to answer potential questions about the diet 
and give exercise suggestions to the individual. The JC program includes the one-on-one 
time to help improve self-monitoring, goal-setting, problem-solving and coping skills, 
with a three-part focus of Food, Body, and Mind. Though exercise was not required in the 
JC program, it was highly encouraged. The ultimate goal for exercise was to gradually 
work up to 30 minutes or more of moderate exercise on five or more days of the week. 
Subjects also had access to additional resources through Jenny Craig such as a 
Progress/Weight Tracker, Activity Planner, Online Journal, Message Boards, Chat 
Rooms, and a personal YourStyle® Profile. 
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Nutrisystem® Advance SelectTM Program 
 The women who participated in the Nutrisystem (NS) group were enrolled in the 
Nutrisystem® Advance SelectTM Program. The meal plan for each of the subjects was the 
fresh/frozen option, and the participants received a variety of foods every 28 days which 
included both nonperishable food items as well as those that needed to be stored in the 
freezer. The meals included breakfast, lunch, dinner, two snacks, and an additional snack 
or dessert for each day. The NS program focuses on the Glycemic Index (GI) and 
emphasizes carbohydrates that have a lower GI, due to the fact that they digest more 
slowly, which can help to maintain balanced blood sugar levels [170]. Also due to a slower 
transit time with low GI foods, there is able to be a greater sense of satiety which can 
improve the body’s ability to burn calories more efficiently. Another component of NS 
meals is that they are high in protein, which is also able to help increase a sense of satiety 
for both after and between meals. The program emphasizes increased protein, because it 
helps to maintain muscle mass, which further improves the burning of calories. Nuts were 
one source of protein utilized in NS meals, because they provide a healthy source of fats. 
The meals also contained 1,800 to 2,200 milligrams of sodium each day. Subjects were 
given the option to remove and replace food items according to their likes and dislikes of 
food. However, the meal plans still maintained all the requirements under the 
Nutrisystem® Advance SelectTM Program guidelines. The participants were given the 
option of calling a NS consultant whenever needed in order to answer questions and/or for 
assistance with meal and exercise options. There were online resources available that 
included interactive tracking tools. Participants were able to track their food, fitness, 
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weight, water and other components. Contacting counselors, dietitians, and other NS 
members was also available through the online resources, to help increase success in the 
program. In the NS group, exercise was encouraged, and walking specifically was 
emphasized. The goal was to incorporate 10 minutes of physical activity, three times per 
day.  
Procedures 
Diet Analysis 
Participants recorded three weekdays and one weekend day of their food and fluid 
(excluding water) intake prior to each of the four testing sessions. Dietary information was 
analyzed to determine the average caloric intake and macronutrient intake using Food 
Processor Nutrition Analysis Software Version 10.12.0 (ESHA Nutrition Research, 
Salem, OR). A registered dietitian reviewed all of the analyzed dietary information.  
Participants also completed an Eating Satisfaction Survey (Appendix E). The 
survey questions were categorized into: appetite, hunger, satisfied food, fullness, energy, 
and quality. 
Physical Activity Analysis 
Participants completed a seven day record of their physical activity (Appendix H) 
prior to each of the four testing sessions. The type of activity, the intensity, and the 
duration were included in the recording. The International Physical Activity Questionnaire 
(IPAQ) was also utilized at each of the four testing sessions to assess physical activity as 
well. The questionnaire evaluated the quantity of walking, moderate, vigorous, and total 
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(walking + moderate + vigorous) physical activity as MET-min/wk in the four areas of: 
work, transportation, household activities, and sitting. 
Anthropometric Measurements 
Height and weight measurements were obtained at the familiarization session, and 
participants were also weighed at weeks 0, 4, 8, and 12. Measurements were taken by 
using a Healthometer (Bridgeview, IL, USA) self-calibrating digital scale, which had a 
precision of ±-0.02 kg. Waist and hip measurements in centimeters were also measured 
by using a Gulick II tape measure. The protocol for the measurements followed the 
guidelines given by the American College of Sports Medicine (ACSM) [142].  
Heart Rate and Blood Pressure 
Resting heart rate (RHR) was determined by palpating the radial artery and also 
adhered to standard ACSM [142] procedures. Resting blood pressure was measured in the 
supine position after the participant had rested for five minutes. A mercurial 
sphygmomanometer (American Diagnostic Corporation, model #AD-720, Hauppuage, 
NY, USA) was utilized and measurements followed standard procedures. 
Resting Energy Expenditure 
Resting energy expenditure (REE) was measured using the ParvoMedics TrueMax 
2400 Metabolic Measurement System (ParvoMedics Inc., Sandy, UT). Participants were 
fasted for 12 hours and laid in a supine position on the exam table. Their legs were elevated 
and rested on a padded box, in order to enhance comfort. A clear plastic hood and canopy 
were placed over their head and neck. Tubing connected the hood to the metabolic 
measuring system. Subjects were instructed to remain as still as possible for 20 minutes 
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without falling asleep. Oxygen and carbon dioxide exchange were measured. Metabolic 
measurements were recorded after 10 minutes and averaged from a five minute time 
segment where the principle variables (e.g. VO2 L/min) changed less than five percent 
[191]. The manufacturer reported that the coefficient of variation for the device is ±2% in 
lean, healthy individuals. 
Dual Energy X-Ray Absorptiometry 
Body composition was determined by using the Hologic Discovery W QDR series 
Dual Energy X-ray Absorptiometry (DEXA) system (Watham, MA).  The DEXA 
consisted of a low dose x-ray scan of the entire body (excluding the head) in order to 
determine fat mass, fat-free mass, and body fat percentage. Quality control (QC) 
calibration procedures were performed at the start of each testing session day. The QC 
scan was completed on a spine phantom (Discovery W-CALIBER Model DPA/QDR-1 
anthropometric spine phantom). Participants were informed prior to the scan of any 
potential risks that could occur from being exposed to the small amount of radiation and 
were required to give consent by signing a Radiation Exposure Questionnaire (Appendix 
H) prior to each scan. Subjects were instructed to remove any metal from the body prior 
to laying supine on the scanning table. The arm scanned the participant for approximately 
six minutes. Participants were instructed to close their eyes when the arm scanned over 
their head, and their feet were secured by using sticky tape. Radiation exposure from the 
DEXA scan was approximately 1.5 mR per scan. This amount of radiation is comparative 
to the amount of natural radiation a person would be exposed to in one month of living in 
College Station, Texas. Throughout the study, the approximate dose that was received for 
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each subject was less than 9 mR. Previous research has shown that using DEXA as a 
means of determining body composition is a valid form of measurement [192, 193]. 
Additionally, there have been test-retest reliability studies conducted on fat free/soft tissue 
mass on the DEXA that have found mean coefficients of variation of 0.31-0.45% with a 
mean intra-class correlation of 0.985 [194]. 
Peak Aerobic Capacity 
Participants performed a graded exercise test (GXT), which included a 12-lead 
echocardiogram (ECG), in order to determine peak aerobic capacity (VO2max). 
Cardiopulmonary exercise tests were conducted at baseline and at 12 weeks. Each test was 
staffed by ESNL exercise physiology graduate students in accordance with standard 
procedures given by the American College of Sports Medicine’s (ACSM) Guidelines for 
Exercise Testing and Prescription [142]. The Nasiff Cardio Card electrocardiograph 
(Nasiff Associates, Inc, Central Square, NY, USA) was used to assess heart function 
during each test. Subjects started-out in a supine position on the preparation table, and 
resting blood pressure was determined in order to be certain it was within the required 
range. The participants were prepped for the ECG. Electrode sites were cleansed with a 
sterile alcohol wipe, and the electrodes were placed at 10 sites including: right 
subclavicular fossa (RA), left subclavicular fossa (LA), fourth intercostal space at the right 
sternal border (V1), fourth intercostal space at the left sternal border (V2), half way 
between V2 and V4 (V3), fifth intercostal space at the mid-clavicular line (V4), fifth 
intercostal space at the anterior axillary line (V5), fifth intercostal space at the midaxillary 
line (V6), right abdominal line (RL) and left abdominal (LL) line. The ECG was printed 
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while the participant was in the supine position and was reviewed by lab personnel. Lab 
personnel made certain there were no contraindications which would prevent the 
participants from being involved in the exercise testing. Subjects were asked to step onto 
the treadmill and stood with their hands by their side. An additional ECG reading, blood 
pressure, and heart rate measurement were obtained. A sterile mouth piece was placed in 
the participant’s mouth, and the head gear was adjusted and placed over the head. A nose 
clip was placed on the nose to make sure all gas flow occurred via the mouth. Tubing was 
connected from the mouth piece to the metabolic measuring system. Gas exchange 
measurements were obtained by using a ParvoMedics 2400 TrueMax Metabolic 
Measurement System (ParvoMedics Inc., Sandy, UT, USA). The participants followed the 
Bruce Protocol [195, 196] for the treadmill testing procedures. When the participant was 
ready to start the warm-up portion of the testing, the treadmill was adjusted to a speed of 
2.0 mph and 0% grade. Subjects were asked to walk with their hands by their side 
throughout the testing but were allowed to place the back of their hands against the 
handrails if needed for stability purposes. After the two-minute warm-up stage, the speed 
decreased to 1.7 mph, and the grade increased to 10%. The participants were encouraged 
to continue on the treadmill to the highest stage they were able to reach. The ECG was 
monitored throughout the testing and lab personnel checked for any signs to end testing, 
according to ACSM guidelines [142]. Throughout testing, heart rate (HR), ECG, and gas 
exchange were monitored. Blood pressure (BP) and ratings of perceived exertion (RPE) 
were also obtained in the last 45 seconds of each stage. Once the participants were unable 
to continue testing, they grabbed the handrails, and lab personnel initiated the cool-down 
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period. Peak BP, RPE, ECG, and HR were measured, and the head gear, mouth piece, and 
nose clip were removed. There were three minutes of an active recovery period while the 
participant continued walking on the treadmill, and there was also an additional three 
minutes of passive recovery, while the participant was seated in a chair. HR, BP, ECG, 
and RPE was continued to be monitored during that time. 
Isotonic Strength and Endurance Tests 
Leg press and bench press were performed at baseline and 12 weeks in order to 
determine one repetition maximum (1RM) and 80% of 1RM. Participants’ leg strength 
and endurance were determined by using a standard hip sled/leg press (Nebula Fitness, 
Versailles, OH, USA), and their upper body strength and endurance were determined by 
using an isotonic bench press and the Nebula Fitness (Versailles, OH, USA) Olympic 
Power Station (#1005). When the tests were performed by resistance-trained subjects in 
previous studies conducted in the ESNL, test-retest reliability comparisons have revealed 
low mean coefficients of variation as well as high reliability (1.9% bench press, intraclass 
r=0.94 and 0.7% leg press, intraclass r=0.91) [197]. The location of the seat and foot 
placement on the leg press were determined for each participant and maintained for each 
testing session. The protocol for both leg press and bench press were the same. The testing 
started with a warm-up consisting of two sets of 10 lifts without any added weight. Weight 
was added to the bar and participants lifted it for one repetition. A two-minute rest period 
was given between each set, throughout the entire strength testing. After each rest period, 
weight was added (approximately five to 10 pounds for bench press and approximately 
10-25 pounds for leg press) until the 1RM was obtained. Once 1RM was determined, there 
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was a four-minute rest period prior to the endurance part of the testing. Muscular 
endurance was assessed by having the participants lift the bar with 80% of their 1RM as 
many times as they could while maintaining standard lifting techniques and testing criteria 
[198].  
Blood Collection 
Fasting blood profiles were obtained in order to measure cholesterol, triglycerides, 
HDL-cholesterol, LDL-cholesterol, glucose, liver enzymes, whole blood analysis, insulin, 
and leptin. Participants were fasted for 12 hours and had not exercised 48 hours prior to 
each blood draw. Whole blood and serum samples were collected following standard 
phlebotomy procedures by giving a sterile venipuncture of an antecubital vein. After 
collection, the tubes of blood were centrifuged at 1100 x g for 15-minutes in a standard 
bench top centrifuge (Cole Palmer, Vernon Hills, IL, Model #17250-10). An Abbott Cell 
Dyn 3500 automated hematology analyzer (Abbott Laboratories, Abbott Park, IL, USA) 
was used to analyze the whole blood samples. The samples were analyzed in order to 
obtain complete blood cell counts. Some serum was pipetted from the collection tube and 
placed into micro-centrifuge tubes. They were then frozen at -80o C to be analyzed at a 
later time. A complete metabolic panel was also obtained after analyzing the remaining 
serum samples by Quest Diagnostics (Quest Diagnostics, 5850 Rogerdale Road, Houston, 
TX, USA 77072). An Olympus AAU 5400 Chemistry Immuno Analyzer (Olympus 
America Inc., Center Valley, PA, USA) was utilized for the analyses.  
Fasting insulin levels were assayed in duplicate by using a commercially available 
enzyme linked immunoabsorbent assay (ELISA) kit and a BioTek ELX-808 
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Ultramicroplate reader (BioTek Instruments Inc., Winooski, VT). It was set at an optical 
density of 450 nm against a known standard curve and used standard procedures from 
BioTek Gen5 Analysis software (BioTek Instruments Inc., Winooski, VT). The intra-
assay coefficient of variation has been shown to range from 2.9% to 6.2%, and the inter-
assay coefficient of variation has ranged from 5.4% to 8.6% (ALPCO, Salem, NH). 
Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) was calculated by 
multiplying fasting insulin (µU/mL) and fasting glucose (mg/dL), then dividing by 405 
[199].  
Fasting serum leptin levels were determined in duplicate by using a BioTek ELX-
808 Ultramicroplate reader (BioTek Instruments Inc., Winooski, VT). An optical density 
of 450 nm was also used and common analyzing procedures were followed using BioTek 
Gen5 Analysis software (BioTek Instruments Inc., Winooski, VT). Intra-assay coefficient 
of variation has been shown to range from 3.7% to 5.5%, and the inter-assay coefficient 
of variation of has ranged from 5.8% to 6.8% (ALPCO, Salem, NH).   
Psychosocial Evaluations 
Questionnaires were completed by the participants, including a standardized 
Quality of Life Questionnaire (SF-36) [200, 201], and a Body Image Questionnaire. The 
SF-36 Quality of Life Questionnaire has been used as a psychosocial evaluation and 
results may be impacted by general improvements in health and/or weight loss [202, 203]. 
The questions helped to assess various physical and mental components, including 
physical functioning (the ability to perform vigorous physical activities without being 
limited by health), role physical (the ability to work and perform daily activities), bodily 
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pain (limitations during the day due to pain), general health (evaluation of personal 
health), vitality (perception of energy level), social functioning (the ability to perform 
normal social activities), role emotion (difficulties with work or other daily activities), and 
mental health (the state of feeling peaceful, happy, and calm).  
The Body Image Questionnaire is comprised of three different sections. The first 
is the Rosenburg Self-Esteem Scale (RSE) [204]. The RSE measures self-esteem by using 
a four-point Likert scale. It ranges from one (strongly agree) to four (strongly disagree). 
Total scores range from 10 to 40; the higher the score, the greater the correlation with 
higher self-esteem. The second section is Social Physique Anxiety Scale (SPAS) which 
was developed by Hart and colleagues in 1989 [205]. It consists of 12 questions that use 
a five-point Likert scale. It ranges from one (not at all true) to five (extremely true). Totals 
range from 12 to 60, with an increase in social physique anxiety correlating with an 
increase in score. This portion of the questionnaire is used to evaluate the level of anxiety 
an individual experiences as a result of the degree to which it is perceived that others are 
devaluing her body. Several studies have shown the internal consistency (r=0.90), 
predictive validity, and the construct validity [205-207]. The third section of the 
questionnaire is the Multidimensional Body-Self Relations section (MBSRQ-AS). It 
consists of five sections: Appearance Evaluation, Appearance Orientation, Overweight 
Preoccupation, Self-Classified Weight, and the Body Areas Satisfaction Scale (BASS). 
It’s on a five point scale from one (strongly disagree) to five (strongly agree). At the 
completion of the study, participants were asked to fill-out a post-study questionnaire in 
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order to provide feedback pertaining to their experience as a participant in the weight-loss 
study.  
Cost to Benefit Analysis 
In an attempt to assess costs of the diets used, a random sample of 10 participants’ 
food logs for one week were analyzed to determine the cost of the program and food. Food 
costs were estimated according to the price of purchased foods that were described on a 
given food log. The costs were then averaged and applied to each subject for the duration 
of the study. The cost per day (CC 6.4±1.6, WW 4.9±1.4, JC 2.2±1.1, NS 1.8±1.1, C 
4.7±2.2 $/day) was used to calculate an average 90 day food cost (CC 579±147, WW 
438±130, JC 200±101, NS 162±103, C 422±198 $/90 days). The 90 day food cost was 
then added to the program participation costs (CC 300, WW 120, JC 2,400, NS 900, C 0 
$/90 days) in order to estimate a total cost (CC 879±147, WW 558±130, JC 2,600±101, 
NS 1,062±103, C 422±198 $/90 days) per program [208]. 
Statistical Analysis 
Analysis was conducted on all participants who completed the 12 weeks of the 
study. One-way Analysis of Variance (ANOVA) was used to analyze baseline 
demographic data, and data were normally distributed. Multivariate Analysis of Variance 
(MANOVA) with repeated measures was used to analyze related variables with the IBM 
SPSS for Windows Version 20 software (IBM Corporation, Armonk, NY). If there were 
instances where data was missing, they were replaced by using the last observed value. 
However, with the nutrient data, missing data was replaced with the series mean. Overall 
MANOVA effects were assessed by using Wilks’ Lambda time and diet x time p-levels. 
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Each variable that was analyzed by MANOVA, Greenhouse-Geisser univariate tests of 
within-subjects time and diet x time effects and between-subjects univariate diet effects 
were reported. Non-related variables were analyzed by repeated measures ANOVA with 
univariate time, time x diet, and diet effects reported. Tukey’s least significant difference 
(LSD) post hoc analyses was also utilized in order to determine at which time point and 
between which diets the significance was obtained. Weight, body mass index, 
International Physical Activity Questionnaire, scanned mass, scanned fat mass, scanned 
fat-free mass, scanned percent body fat, resting energy expenditure, nutrient intake, Eating 
Satisfaction Survey, anthropometrics, heart rate, blood pressure, peak aerobic capacity, 
and psychosocial variables are reported as delta changes from baseline. Lipids, hormones, 
and muscular strength changes are presented as percent change from baseline. The first 
testing session (T1) was subtracted from the final testing session (T4) in order to determine 
the delta values: (T4-T1). In order to determine percent change, T1 was subtracted from 
T4, then divided by 100. The total was then multiplied by 100: 100[(T4-T1)/T1]. The delta 
changes and percent changes were calculated and then also analyzed by ANOVA or 
MANOVA with repeated measures in order to evaluate the changes from baseline. Data 
were considered statistically significant when the probability of type I error was less than 
or equal to 0.05. Data were considered to have statistical trends when the p-value was set 
between 0.05 and 0.10.  Data was presented as means ± standard deviation, except group 
means were presented as means ± standard error mean. The sample had sufficient power 
(CC n=29; WW n=29; JC n=27; NS n=28; C n=20) in order to assess statistically 
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significant changes. A sample size of 20 per group was needed for there to be a power of 
0.8 at a 0.05 α-level.  
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CHAPTER IV  
STUDY OUTCOME* 
 
Results 
Baseline Demographics 
No significant differences were seen at baseline between the five groups in age, 
height, weight, body mass index (BMI), or body fat percentage, which was found when 
analyzed by ANOVA. As denoted in Table 3, there were 133 women who completed the 
12 week intervention. Baseline demographics consisted of age 47.2±11.3 yrs, height 
161.9±6.7 cm, weight 86.3±14.1 kg, BMI 35.5±5.6 kg/m2, and body fat percentage 
45.8±4.5%.  
 
 
Table 3: Baseline demographics for all groups. Curves (CC), Weight Watchers (WW), 
Jenny Craig (JC), Nutrisystem (NS), and Control (C). 
 
 
 
 
 
 
                                                 
*Reprinted with permission from Dalton R, Baetge C, Lockard B, Levers K, Galvan E, Jagim A, Simbo S, 
Byrd M, Jung Y, Oliver J: Analysis of efficacy and cost effectiveness of popular weight loss and fitness 
programs. Journal of the International Society of Sports Nutrition 2013, 10(Suppl 1):P4.    
Variable Mean CC WW JC NS C P-value
Age (yrs) 47.2±11.3 46.5±10.1 48.2±10.8 46.0±12.4 45.6±12.4 50.6±10.9 0.57
Height (cm) 161.9±6.7 161.4±6.5 164.4±6.8 160.7±7.0 161.7±5.6 161.1±7.6 0.25
Weight (kg) 92.8±14.6 90.7±13.6 91.1±14.4 91.0±14.6 96.8±15.9 95.0±14.2 0.41
BMI
a
 (kg/m
2
) 35.5±5.6 34.9±5.9 34.2±6.4 35.1±4.5 36.9±5.2 36.5±5.2 0.34
Body Fat (%) 45.8±4.5 45.6±3.7 44.2±4.8 46.6±3.9 46.5±4.6 46.3±5.2 0.22
Significance level w as set at p < 0.05. Mean (n=133), CC (n=29), WW (n=29), JC (n=27), NS (n=28), C (n=20). a 
= Body Mass Index
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Participant Consort 
 There were 356 women who passed the initial phone screening and who then 
attended a familiarization (FAM) session. Of those who signed a consent form and who 
were eligible to participate, 210 were randomized into one of the five groups. Of the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Participant consort.  
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210 who were randomized, 146 individuals withdrew prior to baseline testing, and 77 
participants withdrew after having completed one or more testing sessions, as depicted in 
Figure 1. 
Energy Intake 
 Energy intake was measured at 0, 4, 8, and 12 weeks by a self-reported four day 
diet log. Participants recorded three week day and one weekend day of their dietary intake 
prior to each testing session. A one-way MANOVA was run to analyze total energy intake 
expressed as kilocalories (kcal) per day and kcal per grams per day. An additional 
MANOVA was run to determine macronutrient breakdown and was expressed as grams 
per day, grams per kilogram per day, and percentage of macronutrients of total calories 
consumed. 
Absolute Energy Intake 
 There was an overall time (Wilks’ Lambda p<0.001) and time x diet (Wilks’ 
Lambda p<0.001) effect for absolute energy intake. MANOVA univariate revealed a time 
(p<0.001) and diet (p<0.001) effect for total energy intake when expressed as kcal per day 
and grams per day. Table 4 shows how all groups experienced a decrease in energy intake 
over the 12 weeks. As seen in Figure 2, when analyzed as delta changes from baseline, 
NS had the greatest decrease in absolute energy intake (CC -303±507, p=0.043; WW -
527±849, p<0.001; JC -556±758, p<0.001; NS -630±424, p<0.001; C -316±767 kcal/day, 
p=0.05). When assessing protein intake as delta changes from baseline, CC was the only 
group that had a trend toward an absolute protein increase at week 8 (p=0.093). Protein 
intake significantly decreased by week 12 in the JC group (-14.1±24.2 g/day p=0.031). 
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The NS and C groups experienced a significant decrease in protein intake at week 4 
(p=0.022) and weeks 4 (p=0.014) and 8 (p=0.011) respectively. However, neither were 
significantly less by the end of the 12 weeks. WW had a trend toward a significant decrease 
at week 8 (p=0.055). CC was the only group to have an increase in protein (9.4±27.2 
g/day) at week 12 compared to WW (-9.1±42.5, p=0.045), JC (-14.1±24.2, p=0.013), and 
C (-10.7±35.0, p=0.046), and a trend was seen when compared to NS (-8.0±35.0 g/day, 
p=0.063). When assessing carbohydrate intake, there was a significant decrease in 
absolute carbohydrate in the CC group at week 4 (-56.6±88.7, p=0.006), week 8 (-
58.9±78.3, p=0.002), and week 12 (-62.6±82.4 g/day, p=0.002). WW also experienced a 
decrease in carbohydrate intake at weeks 4 (-49.4±111.2, p=0.008), 8 (-48.6±108.4, 
p=0.005), and 12 (-46.2±115.5 g/day, p=0.011). There was a decrease in carbohydrates 
for NS at weeks 4 (-87.9±87.2, p<0.001), 8 (-88.4±87.4, p<0.001), and 12 (-89.3±76.1 
g/day, p<0.001) as well. The C group had a trend toward a decrease at weeks 4 (p=0.070) 
and 8 p=0.089) but not at week 12. Also at week 12, CC was trending toward a 
significantly greater decrease in carbohydrates than JC (p=0.094). NS had a significantly 
greater decrease in carbohydrate compared to JC at week 12 (-89.3±76.1 vs -16.0±83.2, 
p=0.007), and there was a trend when compared to the C group (-33.1±103.0 g/day, 
p=0.051). CC, WW, JC, and NS all had a significant decrease in fat intake compared to 
baseline at all three time points with NS having the greatest decrease. When expressed as 
delta changes at week 12, CC (-15.8±34.0, p=0.018), WW (-24.4±32.2, p<0.001), JC (-
32.7±28.9, p<0.001), and NS (-39.0±27.1 g/day, p<0.001). NS had a significantly greater 
reduction in absolute fat intake compared to CC (NS -41.4±27.7, CC -20.7±33.9 g/day, 
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Table 4: Changes in absolute dietary intake. Observed between groups at 0, 4, 8, and 12 
weeks for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), 
and Control (C). 
 
 
 
p=0.011). WW, JC, and NS all experienced significantly greater reductions in fat intake 
at week 12 compared to the C as well (WW -25.7±29.1, p=0.049, JC -34.8±28.7, p=0.006, 
NS -41.4±27.7, p=0.001). 
Variable Group Group (SEM) P-level
CC 1,747.5
j
± 515 1,351
‡
± 228 1,397
‡
± 311 1,445
‡i
± 430 1,485 ± 72.8 T = 0.001 
WW 1,871 ± 859 1,331
‡
± 352 1,326
‡
± 340 1,344
‡
± 386 1,468 ± 65.7 D = 0.001 
JC 1,826 ± 721 1,353
‡i
± 318 1,438
‡
± 756 1,270
‡
± 279 1,472 ± 69.7 T x D = 0.628 
NS 1,882 ± 465 1,188
‡
± 186 1,257
‡
± 305 1,252
‡
± 280 1,395 ± 68.3
C 2,122 ± 718 1,681
‡abcd
± 510 1,783
‡abcd
± 582 1,807
‡abcd
± 554 1,848
†
± 78.3
Mean 1,882 ± 674 1,365 ± 371 1,422 ± 508 1,403* ± 427
CC 74.5 ± 17.7 83.1
bcde
± 26.4 84.8
#bcde
± 18.5 83.9
bcd
± 22.3 81.6 ± 74.9 T = 0.007 
WW 81.4 ± 42.3 71.1 ± 22.0 70.8
#
± 21.8 72.3
c
± 21.6 73.9 ± 67.9 D = 0.011
JC 72.7 ± 22.7 65.5 ± 13.9 64.3 ± 13.9 58.6
‡e
± 15.0 65.3 ± 58.9 T x D = 0.051 
NS 77.4 ± 22.6 62.2
‡
± 16.0 68.4 ± 16.0 69.4 ± 20.1 69.4 ± 63.1
C 85.9 ± 29.5 67.1
‡
± 20.9 69.1
‡
± 27.2 75.1 ± 21.6 74.3
†
± 67.2
Mean 78.2 ± 28.7 69.7 ± 21.1 71.3 ± 20.5 71.5* ± 21.5
CC 186.5 ± 80.0 129.9
‡ce
± 33.4 127.7
‡ce
± 38.6 123.9
‡ce
± 50.9 142.0 ± 125.0 T = 0.001 
WW 190.8 ± 120.1 141.3
‡cde
± 41.5 142.2
‡cde
± 44.1 144.5
‡cde
± 51.2 154.7 ± 139.4 D = 0.001 
JC 188.0 ± 60.5 177.2
d
± 52.1 175.0
d
± 44.3 172.0
d
± 51.8 178.1 ± 161.8 T x D = 0.100 
NS 197.4 ± 79.1 109.5
‡e
± 47.1 109.1
‡e
± 47.6 108.1
‡e
± 40.1 131.0 ± 115.1
C 223.8 ± 91.6 184.1
#
± 48.7 189.3
#
± 60.7 190.7 ± 69.9 197.0
†
± 178.7
Mean 196.2 ± 88.8 146.7 ± 52.3 146.8 ± 54.6 146.0* ± 59.6
CC 74.3 ± 30.0 50.2
‡cd
± 18.9 53.6
‡cd
± 19.2 58.6
‡cd
± 23.8 59.2 ± 3.1 T = 0.001 
WW 72.4 ± 31.0 47
‡cd
± 18.9 46.7
‡cd
± 15.7 48.0
‡c
± 17.2 53.5 ± 2.8 D = 0.001
JC 69.1 ± 25.8 35.3
‡
± 11.3 34.3
‡
± 15.7 36.4
‡
± 17.6 43.8 ± 3.0 T x D = 0.007 
NS 76.8 ± 26.4 31.5
‡
± 9.2 35.4
‡
± 14.0 37.8
‡
± 14.0 45.4 ± 2.9
C 81.4 ± 32.3 68.0
#abcd
± 26.2 72.1
abcd
± 27.5 75.4
abcd
± 26.6 74.2
†
± 3.4
Mean 74.5 ± 29.0 45.3 ± 21.1 47.2 ± 22.4 49.9* ± 23.9
Week 12Baseline Week 4
Values are represented as means±standard deviation except group means are ±standard error mean. n = 117; CC (n=22), WW (n=27), JC 
(n=24), NS (n=25), and C (n=19).T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect from baseline p<0.05 
(univariate). † = signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). All letter superscripts 
represent signif icance or trends tow ard signif icance from post hoc LSD. a = signif icantly different than CC (p < 0.05).  b = signif icantly different 
than WW (p < 0.05).  c = signif icantly different than JC (p < 0.05). d = signif icantly different than NS (p < 0.05). e = signif icantly different than C 
(p < 0.05). # = a trend tow ard signif icance from baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard siginif icance compared to CC 
(p > 0.05 and p < 0.1).  g = a trend tow ard siginif icance compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard siginif icance compared to 
JC (p > 0.05 and p < 0.1).  i = a trend tow ard siginif icance compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance compared to 
C (p > 0.05 and p < 0.1).  
Week 8
Energy Intake 
(kcal/day) 
Protein 
Intake 
(grams/day)
CHO Intake 
(grams/day)
Fat Intake 
(grams/day)
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Figure 2: Changes from baseline in absolute energy intake over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
delta change means±SD. n=117. 
 
 
Relative Energy Intake 
There was an overall time (Wilks’ Lambda p<0.001) and time x diet (Wilks’ 
Lambda p<0.001) effect when expressed as kilocalories per kilogram per day and grams 
per kilogram per day. Similar findings were seen in total energy intake throughout the 12 
weeks when based on kilograms of body weight and is depicted in Table 5. CC, WW, JC, 
NS, and C all experienced a significant time effect at weeks 4 (CC p=0.013, WW p=0.001, 
JC p=0.002, NS p<0.001, C p=0.007) and 8 (CC p=0.023, WW p<0.001, JC p=0.007, NS 
p<0.001, C p=0.009), and all but the CC group had a significant change from baseline at 
week 12 (CC -2.5±6.7, p=0.122; WW -4.6±8.7, p=0.002, JC -5.4±8.6, p=0.001; NS -
5.6±4.4, p<0.001, -3.7±9.1, p=0.038), as well. When looking at protein intake represented 
as grams/kg/day, there was a significant time effect for the CC group at weeks 8 (p=0.026) 
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and 12 (0.2±0.3 g/kg/day, p=0.039), and for the C group at weeks 4 (p=0.011) and 8 
(p=0.008) and a trend at week 12 (p=0.085). CC was the only group that had an increase 
protein intake at week 12 and was significantly different than WW (p=0.050), JC 
(p=0.017), and C (p=0.008) and a trend toward being significantly greater than NS 
(p=0.071), seen in Figure 3. When looking at carbohydrates relative to body weight, there  
 
 
Table 5: Changes in relative dietary intake. Observed between diet groups at 0, 4, 8, and 
12 weeks for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem 
(NS), and Control (C)  
 
 
 
Variable Group Group (SEM) P-level
CC 19.8 ± 6.8 15.6
‡j
± 3.2 16.6
‡
± 5.1 17.2
d
± 5.6 17.3 ± 0.9 T = 0.001 
WW 20.6 ± 8.0 15.5
‡j
± 4.6 15.6
‡j
± 4.4 16.0
‡
± 5.0 16.9 ± 0.8 D = 0.023
JC 20.8 ± 8.7 15.8
‡
± 3.6 17.1
‡i
± 9.3 15.4
‡
± 3.8 17.3 ± 0.9 T x D = 0.877
NS 19.8 ± 4.2 13.1
‡abce
± 3.5 14.2
‡e
± 3.8 14.2
‡
± 3.4 15.3 ± 0.8
C 22.9 ± 9.1 18.0
‡
± 6.3 18.9
‡
± 5.8 19.2
‡bcd
± 6.3 19.7
†
± 1.0
Mean 20.7 ± 7.4 15.5 ± 4.5 16.3 ± 6.1 16.2* ± 5.0
CC 0.84 ± 0.21 0.95
cdeg
± 0.27 0.99
‡bcde
± 0.20 0.99
‡cdeg
± 0.25 0.94 ± 0.04 T = 0.082 
WW 0.91 ± 0.43 0.83
d
± 0.28 0.84 ± 0.28 0.86
c
± 0.29 0.86 ± 0.04  D = 0.011
JC 0.82 ± 0.25 0.76 ± 0.15 0.77 ± 0.21 0.72 ± 0.23 0.77 ± 0.04 T x D = 0.036   
NS 0.82 ± 0.23 0.69
#
± 0.22 0.77 ± 0.19 0.79 ± 0.23 0.77 ± 0.04
C 0.93 ± 0.40 0.72
‡
± 0.24 0.73
‡
± 0.27 0.79
#
± 0.22 0.80
†
± 0.04
Mean 0.86 ± 0.31 0.79 ± 0.25 0.82 ± 0.25 0.83 ± 0.26
CC 2.28 ± 1.11 1.64
‡cde
± 0.50 1.65
‡cei
± 0.67 1.60
‡ce
± 0.70 1.66 ± 0.11 T = 0.001
WW 2.27 ± 1.29 1.77
‡cde
± 0.55 1.81
‡cde
± 0.62 1.86
#cd
± 0.71 1.78 ± 0.10 D = 0.001 
JC 2.33 ± 0.92 2.21
d
± 0.53 2.25
d
± 0.60 2.26
d
± 0.73 2.10 ± 0.10 T x D = 0.207 
NS 2.22 ± 0.85 1.30
‡e
± 0.58 1.31
‡e
± 0.56 1.31
‡e
± 0.50 1.43 ± 0.10
C 2.61 ± 1.29 2.14
#
± 0.74 2.17
#
± 0.73 2.18
#
± 0.87 2.11
†
± 0.12
Mean 2.33 ± 1.09 1.79 ± 0.66 1.8 ± 0.71 1.82* ± 0.77
CC 0.91 ± 0.39 0.62
‡cde
± 0.22 0.69
‡cdj
± 0.29 0.75
‡cdg
± 0.29 0.69 ± 0.04 T = 0.001  
WW 0.85 ± 0.27 0.59
‡cde
± 0.26 0.60
‡cde
± 0.22 0.61
‡cde
± 0.23 0.62 ± 0.03 D = 0.001
JC 0.84 ± 0.31 0.45
‡e
± 0.16 0.45
‡e
± 0.22 0.48
‡e
± 0.24 0.51 ± 0.04 T x D = 0.026 
NS 0.86 ± 0.25 0.38
‡e
± 0.13 0.43
‡e
± 0.18 0.46
‡e
± 0.17 0.50 ± 0.03
C 0.95 ± 0.41 0.78
‡
± 0.33 0.82 ± 0.28 0.86 ± 0.30 0.79
†
± 0.04
Mean 0.88 ± 0.32 0.55 ± 0.26 0.58 ± 0.27 0.62* ± 0.28
Protein Intake 
(grams/kg/d)
Carbohydrate 
Intake 
(grams/kg/d)
Fat Intake  
(grams/kg/d)
Values are+B12:S35 represented as means±standard deviation except group means are ±standard error mean. n = 117; CC (n=22), WW 
(n=27), JC (n=24), NS (n=25), and C (n=19).T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect from 
baseline p<0.05 (univariate). † = signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). 
All letter superscripts represent signif icance or trends tow ard signif icance from post hoc LSD. a = signif icantly different than CC (p < 
0.05).  b = signif icantly different than WW (p < 0.05).  c = signif icantly different than JC (p < 0.05). d = signif icantly different than NS (p < 
0.05). e = signif icantly different than C (p < 0.05). # = a trend tow ard signif icance from baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a 
trend tow ard siginif icance compared to CC (p > 0.05 and p < 0.1).  g = a trend tow ard siginif icance compared to WW (p > 0.05 and p < 
0.1).  h = a trend tow ard siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a trend tow ard siginif icance compared to NS (p > 0.05 
and p < 0.1).  j = a trend tow ard siginif icance compared to C (p > 0.05 and p < 0.1).  
Baseline Week 4 Week 8 Week 12
Energy Intake 
(kcals/kg/day)
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was a significant time effect for CC and NS, with a decrease in carbohydrate intake at 
weeks 4 (CC p=0.008; NS p<0.001), 8 (CC p=0.005; NS p<0.001), and 12 (CC -0.6±0.9, 
p=0.005; NS -0.8±0.8 g/kg/day, p<0.001), shown in Figure 4. WW also experienced a 
significant decrease at weeks 4 (p=0.022) and 8 (p=0.022) and a trend at week 12 was 
noted (p=0.059). The C group had a trend toward a significant decrease in carbohydrate 
 
 
 
Figure 3: Changes from baseline in relative protein intake over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
delta change means±SD. n=117.  
 
 
intake at weeks 4 (p=0.069), 8 (p=0.069), and 12 (-0.4±1.2, p=0.092). CC trended toward 
having a significantly greater decrease than JC (p=0.072) in carbohydrate intake at week 
12. All diet groups had a significant decrease (p<0.001) in fat intake, and the average 
decrease for all the groups was -0.2±0.3 g/kg/day, depicted in Figure 5. 
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Figure 4: Changes from baseline in relative carbohydrate intake over 12 weeks. Curves 
(CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). 
Values are delta change means±SD. n=117.  
 
 
 
 
Figure 5: Changes from baseline in relative fat intake over 12 weeks for Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values 
are delta change means±SD. n=117. 
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Percent Energy Intake 
Diets were also assessed as percentage of macronutrients in kilocalories to total 
kilocalorie intake. There was also an overall significant time (Wilks’ Lambda p<0.001) 
effect and time x diet (Wilks’ Lambda p<0.001) effect. Table 6 shows that CC, WW, and 
NS all had a significant increase in percent protein at weeks 4 (CC p<0.001,WW p=0.013, 
and NS p<0.001), 8 (CC p<0.001, WW p=0.006, NS p<0.001), and 12 (CC p<0.001, WW 
 
 
Table 6: Changes in percent dietary intake. Observed between diet groups at 0, 4, 8, and 
12 weeks for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem 
(NS), and Control (C)  
 
 
 
Variable Group Group (SEM) P-level
CC 18.6 ± 5.1 25.6
‡bce
± 7.0 26.1
‡bce
± 6.2 25.7
‡ceg
± 6.6 24.0 ± 0.8 T = 0.001 
WW 19.3 ± 4.5 22.5
‡de
± 4.8 22.7
‡de
± 6.4 22.7
‡cde
± 5.1 21.8 ± 0.7 D = 0.001
JC 17.9 ± 3.9 20.5
#de
± 3.6 20.4
#de
± 2.8 19.3
d
± 4.8 19.5 ± 0.7 T x D = 0.001 
NS 18.0 ± 5.2 26.2
‡e
± 5.0 27.6
‡e
± 6.5 26.9
‡e
± 5.3 24.7 ± 0.7
C 18.0 ± 4.0 16.8 ± 3.6 16.6 ± 3.5 17.8 ± 3.7 17.3
†
± 0.8
Mean 18.4 ± 4.6 22.5 ± 5.9 22.9 ± 6.6 22.7* ± 6.2
CC 42.8 ± 9.3 40.2
bcei
± 9.0 38.2
‡bce
± 7.1 36.1
‡bcei
± 8.1 39.3 ± 1.1 T = 0.095  
WW 42.3 ± 9.2 44.7
c
± 8.0 44.6
c
± 7.4 44.5
ci
± 8.6 44.0 ± 1.0 D = 0.001
JC 45.6 ± 8.4 54.7
‡de
± 6.0 55.3
‡de
± 9.9 54.8
‡de
± 9.4 52.6 ± 1.1 T x D = 0.001 
NS 43.5 ± 10.6 43.9 ± 7.2 41.2 ± 9.7 40.4 ± 8.3 42.3 ± 1.1
C 45.2 ± 5.6 46.1 ± 4.5 45.3 ± 5.3 43.5 ± 7.1 45.0
†
± 1.2
Mean 43.8 ± 8.8 46.0 ± 8.6 45.0 ± 9.9 44.0 ± 10.3
CC 38.6 ± 7.3 34.1
‡cd
± 9.7 35.7
cd
± 7.2 38.2
bcd
± 7.4 36.7 ± 1.0 T = 0.001  
WW 38.4 ± 7.4 32.8
‡ce
± 7.8 32.7
‡ce
± 4.9 32.8
‡ce
± 6.8 34.2 ± 0.9 D = 0.001
JC 36.5 ± 6.9 24.8
‡de
± 5.9 24.3
‡de
± 7.9 25.9
‡de
± 7.9 27.9 ± 1.0 T x D = 0.001 
NS 38.5 ± 7.3 29.9
‡e
± 5.3 31.0
‡e
± 7.3 32.7
‡e
± 8.7 33.0 ± 0.9
C 36.7 ± 7.0 37.1 ± 4.9 38.1 ± 5.5 38.7 ± 5.2 37.7
†
± 1.0
Mean 37.8 ± 7.1 31.5 ± 8.0 32.1 ± 7.7 33.3* ± 8.6
Baseline Week 4 Week 8
Values are represented as means±standard deviation except group means are ±standard error mean. n = 117; CC (n=22), WW 
(n=27), JC (n=24), NS (n=25), and C (n=19).T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect 
from baseline p<0.05 (univariate). † = signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 
(post hoc LSD). All letter superscripts represent signif icance or trends tow ard signif icance from post hoc LSD. a = signif icantly 
different than CC (p < 0.05).  b = signif icantly different than WW (p < 0.05).  c = signif icantly different than JC (p < 0.05). d = 
signif icantly different than NS (p < 0.05). e = signif icantly different than C (p < 0.05). # = a trend tow ard signif icance from baseline 
p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard siginif icance compared to CC (p > 0.05 and p < 0.1).  g = a trend tow ard 
siginif icance compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a 
trend tow ard siginif icance compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance compared to C (p > 0.05 and p < 
0.1).  
Week 12
Protein Intake 
(% total kcal)
CHO Intake  
(% total kcal)
Fat Intake     
(% total kcal)
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p=0.003, NS p<0.001). CC (7.1±7.6%) had a greater increase in percent protein intake at 
week 12 compared to WW (3.5±4.5, p=0.032), JC (1.56.3, p=0.001), and C (-0.3±3.6%, 
p<0.001). However, NS had the greatest increase in percent intake of protein at week 12 
(8.9±6.3%). When looking at the percentage of carbohydrates of total kilocalories, CC had 
a significantly less percentage compared to baseline at weeks 8 (p=0.045) and 12 
(p=0.006). Whereas, JC had a significantly greater percentage compared to baseline at 
weeks 4, 8, and 12 (p<0.001 at each time point). CC had a greater decrease in percent 
carbohydrates at weeks 12 compared to WW (2.2±11.5, p=0.007) and JC (9.2±12.9, 
p<0.001) and was the greatest decrease out of all the groups (CC -6.7±10.9%, p=0.006). 
When assessing percentage of fat in total kilocalories, CC had a decrease in percent fat at 
week 4 (p=0.026), but it was not significant at weeks 8 and 12. WW, JC, and NS had a 
significant decrease in percent fat at weeks 4 (WW p=0.002, JC p<0.001, NS p<0.001), 8 
(WW p=0.002, JC p<0.001, NS p<0.001), and 12 (WW p=0.003, JC p<0.001, NS 
p=0.004). Percent fat intake was significantly less in CC by week 12 when compared to 
JC (p=0.001). JC had the greatest decrease in percent fat at week 12 (-10.6±10.1%).  
Eating Satisfaction Survey 
The Eating Satisfaction Survey was assessed at 0, 4, 8, and 12 weeks of 
intervention. An overall time (Wilks’ Lambda p<0.001) effect was observed, though an 
overall time x diet interaction (Wilks’ Lambda p=0.119) effect was not significant. As 
depicted in Table 7, for the variable of appetite, JC (-0.96±1.87, p=0.005) and C (-
1.05±1.28, p=0.008) had a significant decrease from baseline at week 12. In the category 
of hunger, C had a significant decrease at week 12 (-1.05±2.19, p=0.031). The C group 
76 
 
also had a significant decrease from baseline at week 12 for the area of satisfied food (-
0.90±2.25, p=0.039). For the variable of fullness, JC was significantly lower at week 12 
(-1.04±2.39, p=0.004). In the category of energy, CC, WW, JC, and NS all had a time 
effect at weeks 4 (CC p<0.001; WW p<0.001; JC p<0.001; NS p<0.001), 8 (CC p<0.001; 
WW p<0.001; JC p<0.001; NS p=0.001), and 12 (CC 1.63±1.84, p<0.001; WW 
1.44±1.82, p<0.001; JC 0.85±2.25, p=0.024; NS 1.18±1.83, p=0.002). CC had a 
significant increase in the area of energy compared to C (0.45±1.90, p=0.041), and WW 
had a trend toward a significant increase compared with C (p=0.078) at week 12.  
Additionally, in the area of quality, CC, WW, JC, and NS had a time effect at weeks 4  
(CC p<0.001; WW p<0.001; JC p<0.001; NS p<0.001), 8 (CC p<0.001; WW p<0.001; JC 
p<0.001; NS p<0.001), and 12 (CC 1.81±2.02, p<0.001; WW 1.83±1.94, p<0.001; JC 
2.26±2.18, p<0.001; NS 1.75±2.05, p<0.001). CC, WW, JC, and NS showed significant 
increases when compared to the C group (CC p=0.002; WW p=0.001; JC p<0.001; NS 
p=0.002). Therefore, we accept Ho1 since statistically significant differences were 
observed among groups in macronutrient intake.  
Physical Activity 
 Physical activity was assessed at 0, 4, 8, and 12 weeks by a seven day self-reported 
physical activity log and by the International Physical Activity Questionnaire (IPAQ). 
Analysis by MANOVA revealed an overall trend toward significance for time (Wilks’ 
Lambda p=0.061) and no overall time x diet (Wilks’ Lambda p=0.247) effect for physical 
activity. When looking at delta changes from baseline, CC had a trend toward a significant 
increase in low physical activity (MET 3.3) at week 12 (p=0.077). The C group had a  
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Table 7: Changes in eating satisfaction survey. Observed between groups at 0, 4, 8, and 
12 weeks for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem 
(NS), and Control (C). 
 
 
 
Variable Group Group (SEM) P-level
CC 5.40 ± 1.30 5.00 ± 1.40 5.10 ± 1.30 4.90 ± 1.30 5.11 ± 0.20 T = 0.001 
WW 5.20
cj
± 1.40 5.10 ± 1.30 5.20 ± 1.80 4.90 ± 1.50 5.11 ± 0.19 D = 0.511
JC 6.00 ± 1.50 5.40
#
± 1.60 5.40
#
± 1.10 5.00
‡
± 1.70 5.47 ± 0.20 T x D = 0.899  
NS 5.60 ± 1.40 5.20 ± 1.60 5.50 ± 1.70 5.30 ± 1.70 5.40 ± 0.20
C 6.00 ± 1.30 5.20
#
± 1.30 5.70 ± 0.90 5.00
‡
± 1.00 5.45 ± 0.23
Mean 5.60 ± 1.40 5.20 ± 1.40 5.40 ± 1.40 5.00* ± 1.50
CC 4.70
e
± 1.30 4.30 ± 1.60 4.50 ± 1.20 4.30 ± 1.50 4.45 ± 0.22 T = 0.001 
WW 4.90
j
± 1.80 4.60 ± 1.50 4.60 ± 1.80 4.90 ± 1.50 4.73 ± 0.21 D = 0.222 
JC 5.50 ± 1.70 4.70
#
± 1.60 4.80
#
± 1.20 4.90 ± 1.60 4.99 ± 0.22 T x D = 0.814 
NS 5.00 ± 2.00 4.10
‡j
± 1.50 4.80 ± 1.70 4.50 ± 1.60 4.60 ± 0.21
C 5.80 ± 1.90 5.00
#
± 1.40 5.00
#
± 1.10 4.70
‡
± 1.70 5.11 ± 0.25
Mean 5.10 ± 1.80 4.50 ± 1.60 4.70 ± 1.40 4.70* ± 1.50
CC 6.00 ± 1.40 6.40 ± 1.40 6.20 ± 1.60 5.90 ± 1.40 6.11 ± 0.20 T = 0.022  
WW 6.50 ± 1.20 6.60 ± 1.20 6.60 ± 1.10 6.40
e
± 1.30 6.50 ± 0.19 D = 0.303
JC 6.60 ± 1.70 6.60 ± 1.60 6.10 ± 1.30 6.00
#
± 1.60 6.34 ± 0.20 T x D = 0.824 
NS 6.00 ± 1.50 6.50 ± 1.60 6.00 ± 1.70 6.00 ± 1.50 6.14 ± 0.19
C 6.30 ± 2.10 6.10 ± 1.70 6.00 ± 1.20 5.40
‡
± 1.70 5.91 ± 0.23
Mean 6.30 ± 1.50 6.40 ± 1.50 6.20 ± 1.40 6.00* ± 1.50
CC 6.30 ± 1.40 6.30 ± 1.20 6.50 ± 1.30 6.10 ± 1.10 6.30 ± 0.17 T = 0.003  
WW 6.60 ± 1.10 6.30 ± 1.30 6.30 ± 1.20 6.00 ± 0.90 6.31 ± 0.17 D = 0.986
JC 6.70 ± 1.50 6.50 ± 1.60 6.10 ± 1.50 5.60
‡
± 1.80 6.23 ± 0.17 T x D = 0.828 
NS 6.60 ± 1.60 6.50 ± 1.40 6.10 ± 1.40 6.10 ± 1.20 6.34 ± 0.17
C 6.50 ± 1.70 6.50 ± 1.80 6.00 ± 1.60 6.00 ± 1.20 6.21 ± 0.20
Mean 6.50 ± 1.40 6.40 ± 1.40 6.20 ± 1.40 6.00* ± 1.30
CC 4.80 ± 1.50 6.60
‡g
± 1.60 6.40
‡
± 1.60 6.40
‡
± 1.40 6.06 ± 0.21 T = 0.001 
WW 4.60 ± 1.70 5.90
‡
± 1.30 6.30
‡
± 1.00 6.00
‡
± 1.10 5.71 ± 0.20 D = 0.001 
JC 5.00 ± 1.70 6.30
‡
± 1.30 6.30
‡
± 1.30 5.80
‡
± 1.80 5.84 ± 0.21 T x D = 0.229 
NS 4.90 ± 1.50 6.30
‡
± 1.40 6.00
‡
± 1.60 6.1
‡
± 1.40 5.81 ± 0.20
C 4.40 ± 1.60 4.80
abcd
± 1.80 5.00
abcd
± 1.50 4.80
abcd
± 1.40 4.71† ± 0.24
Mean 4.70 ± 1.60 6.00 ± 1.60 6.10 ± 1.50 5.90* ± 1.50
CC 4.20 ± 1.70 6.40
‡c
± 1.40 6.10
‡
± 1.60 6.00
‡
± 1.60 5.64 ± 0.21 T = 0.001
WW 4.60 ± 1.80 6.60
‡
± 1.00 6.20
‡
± 1.10 6.40
‡
± 1.30 6.00 ± 0.20  D = 0.001 
JC 4.00 ± 1.60 7.10
‡
± 1.30 6.60
‡
± 1.80 6.30
‡
± 1.80 6.00 ± 0.21 T x D = 0.001 
NS 4.50 ± 1.50 6.90
‡
± 1.40 6.40
‡
± 1.50 6.20
‡
± 1.40 6.00 ± 0.20
C 4.80 ± 2.20 4.70
abcd
± 1.30 4.90
abcd
± 1.30 4.6
abcd
± 1.30 4.73
†
± 0.24
Mean 4.40 ± 1.70 6.40 ± 1.50 6.10 ± 1.60 6.00* ± 1.60
Values are represented as means±standard deviation except group means are ±standard error mean. n = 131; CC (n=27), WW (n=29), JC 
(n=27), NS (n=28), and C (n=20).T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect from baseline p<0.05 
(univariate). † = signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). All letter 
superscripts represent signif icance or trends tow ard signif icance from post hoc LSD. a = signif icantly different than CC (p < 0.05).  b = 
signif icantly different than WW (p < 0.05).  c = signif icantly different than JC (p < 0.05). d = signif icantly different than NS (p < 0.05). e = 
signif icantly different than C (p < 0.05). # = a trend tow ard signif icance from baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard 
siginif icance compared to CC (p > 0.05 and p < 0.1).  g = a trend tow ard siginif icance compared to WW (p > 0.05 and p < 0.1).  h = a trend 
tow ard siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a trend tow ard siginif icance compared to NS (p > 0.05 and p < 0.1).  j = a 
trend tow ard siginif icance compared to C (p > 0.05 and p < 0.1).  
Week 12
Appetite
Hunger
Satisfied food
Fullness
Energy
Quality
Baseline Week 4 Week 8
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downward trend at week 4 (p=0.053) and had a significant decrease in low physical 
activity at week 8 (p=0.008). CC had a greater increase in low physical activity (993±3,355 
MET-min/wk) when compared with JC (-589±2,797, p=0.047) and C (-948±3,962 MET-
min/wk, p=0.030) at week 12. Analysis of moderate physical activity revealed an upward 
trend at week 4 (p=0.070) and a significant increase in the CC group at week 8 
(2,198±5,277 MET-min/wk, p=0.001). JC also had an upward trend at week 4 (p=0.067), 
a significant decrease in moderate physical activity at weeks 4 (p=0.032) and 8 (p=0.006). 
Further, at week 8, CC had significantly greater increases compared to all other groups 
and NS had a significant decrease at week 8 (p=0.042) for moderate physical activity. The 
CC group had the greatest increase at week 8 compared to all other groups (CC 
2,198±5,277; WW -240±1,572, p=0.006; JC -518±2,477, p=0.003; NS -1,272±2,250, 
p<0.001; C -2,205±3,492 MET-min/wk, p<0.001). WW also experienced a significant 
increase compared with the C group (p=0.048) at week 8. When assessing vigorous 
physical activity CC showed an upward trend toward significance (p=0.069) at week 4. 
NS also had a significant increase at week 4 (p=0.039). As shown in Figure 6, CC had a 
significant increase in total physical activity (low + moderate + vigorous) at weeks 4 
(4,127±11,151, p=0.018) and week 8 (3,800±8,668 MET-min/wk, p=0.012). NS also had 
an increase at week 4 (3,630±12,515, p=0.033), and the C group experienced a significant 
decrease at week 8 (p=0.038). When assessing physical activity relating to transportation, 
the CC group had an upward trend at week 12 (p=0.054). The C group had a significant 
decrease at weeks 4 (p=0.033), 8 (p=0.010), and 12 (p=0.038). When looking at physical 
activity relating to household activities, CC had an upward trend at week 4 (p=0.064) and 
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Table 8: Changes in international physical activity questionnaire. Observed between 
groups at 0, 4, 8, and 12 weeks for Curves (CC), Weight Watchers (WW), Jenny Craig 
(JC), Nutrisystem (NS), and Control (C). 
 
 
 
 
 
Variable Group P-level
CC 577ce ± 783 946c ± 459 1,325 ± 2,273 1,570# ± 3,454 1,105 ± 313 T = 0.447
WW 1,037ce ± 1,702 1,081c ± 1,804 1,183 ± 1,858 873 ± 1,143 1,044 ± 296 D = 0.026
JC 2,469i ± 2,819 2,610d ± 3,450 1,943d ± 2,319 1,880 ± 2,281 2,226 ± 313 T x D = 0.150
NS 1,288e ± 1,341 1,386 ± 1,844 816 ± 715 1,619 ± 2,779 1,277 ± 307
C 2,943 ± 4,093 1,733# ± 2,166 1,204‡ ± 1,333 1,995 ± 2,781 1,991† ± 387
Mean 1,553 ± 2,374 1,523 ± 2,222 1,306 ± 1,839 1,541 ± 2,554
CC 1,267 ± 1,382 2,374# ± 3,612 3,464‡bcd ± 5,376 2,283 ± 2,654 2,347 ± 463 T = 0.279
WW 1,681 ± 1,545 1,931 ± 2,245 1,441 ± 1,346 1,173e ± 1,497 1,557 ± 438 D = 0.303
JC 1,984 ± 2,892 3,104# ± 3,766 1,466 ± 1,527 2,588 ± 3,374 2,286 ± 463 T x D = 0.027
NS 2,413 ± 2,322 2,987 ± 4,012 1,142‡ ± 1,151 1,689j ± 1,453 2,058 ± 454
C 4,165abci ± 6,317 2,543‡ ± 3,767 1,960‡ ± 3,399 3,764 ± 8,704 3,108 ± 572
Mean 2,154 ± 3,112 2,578 ± 3,469 1,873 ± 3,033 2,162 ± 3,887
CC 1,038 ± 3,945 3,689# ± 9,311 1,894 ± 5,068 1,457j ± 3,036 2,020 ± 578 T = 0.068
WW 200 ± 772 1,193 ± 3,304 1,065 ± 3,686 642 ± 2,292 775 ± 547 D = 0.500
JC 1,452 ± 5,296 1,523 ± 3,970 2,971i ± 9,121 1,240 ± 4,114 1,796 ± 578 T x D = 0.794
NS 347 ± 784 3,305‡ ± 11,752 516 ± 2,292 923 ± 1,392 1,273 ± 567
C 938 ± 3,210 1,840 ± 4,571 913 ± 3,483 75 ± 310 941 ± 714
Mean 767 ± 3,258 2,325 ± 7,473 1,495 ± 5,336 920 ± 2,660
CC 2,882e ± 4,573 7,009‡ ± 10,442 6,682‡d ± 9,190 5,310 ± 8,185 5,471 ± 1,083 T = 0.117
WW 2,919e ± 2,435 4,205 ± 4,360 3,689 ± 5,376 2,689 ± 4,062 3,375 ± 1,025 D = 0.351
JC 5,678 ± 9,861 6,972 ± 9,457 6,192i ± 10,402 5,551 ± 8,064 6,098 ± 1,083 T x D = 0.380
NS 4,048j ± 3,256 7,876‡ ± 14,212 2,474 ± 3,354 4,231 ± 4,542 4,608 ± 1,062
C 8,046 ± 10,639 6,116 ± 7,932 4,166‡ ± 7,459 5,834 ± ##### 6,040 ± 1,339
Mean 4,426 ± 6,721 6,374 ± 9,819 4,635 ± 7,586 4,590 ± 7,218
C 593 ± 1,342 323d ± 707 1,219 ± 2,619 1,229 ± 3,411 841 ± 563 T = 0.455
WW 862 ± 1,686 1,297 ± 2,478 1,051 ± 2,526 637e ± 1,377 962 ± 533 D = 0.233
JC 2,917 ± 9,996 3,241 ± 8,242 1,519 ± 2,221 1,339 ± 2,501 2,254 ± 563 T x D = 0.540
NS 1,532 ± 1,871 2,261 ± 4,273 424e ± 642 1,309 ± 2,175 1,381 ± 553
C 2,443 ± 4,966 2,240 ± 4,204 2,202 ± 5,450 2,454 ± 5,192 2,335 ± 697
Mean 1,593 ± 5,086 1,835 ± 4,724 1,205 ± 2,834 1,298 ± 2,965
CC 199ce ± 386 453 ± 575 722 ± 2,553 785# ± 1,933 540 ± 156 T = 0.427
WW 361eh ± 871 365c ± 758 178c ± 290 274c ± 470 294 ± 148 D = 0.057
JC 951d ± 1,373 814d ± 1,350 741 ± 974 899i ± 1,312 851 ± 156 T x D = 0.164
NS 254e ± 367 356 ± 646 265 ± 389 343 ± 592 304 ± 153
C 1,339 ± 2,857 580‡ ± 848 212‡ ± 380 558‡ ± 923 672 ± 193
Mean 560 ± 1,354 504 ± 880 432 ± 1,281 564 ± 1,182
CC 985e ± 1,361 1,959# ± 3,561 2,602‡bcde ± 3,582 1,713 ± 2,063 1,815 ± 291 T = 0.527
WW 1,175e ± 890 1,435 ± 1,453 1,027 ± 889 726hj ± 581 1,091 ± 275 D = 0.232
JC 1,144e ± 1,252 1,530 ± 1,929 948 ± 1,015 1,792 ± 2,729 1,354 ± 291 T x D = 0.044
NS 1,706 ± 2,127 1,481 ± 2,085 736# ± 713 1,267 ± 1,191 1,297 ± 285
C 2,824 ± 5,369 1,844 ± 2,662 1,188‡ ± 1,821 1,981 ± 3,914 1,959 ± 360
Mean 1,468 ± 2,427 1,630 ± 2,378 1,297 ± 1,995 1,441 ± 2,218
CC 1,104 ± 3,954 4,274‡ ± 9,338 2,138 ± 5,028 1,583 ± 2,447 2,275 ± 523 T = 0.101
WW 521 ± 1,010 1,108 ± 2,915 1,433 ± 3,722 1,051 ± 2,420 1,028 ± 495 D = 0.415
JC 962 ± 1,157 1,681 ± 2,248 3,218# ± 9,415 1,683 ± 4,282 1,886 ± 523 T x D = 0.596
NS 557 ± 1,006 3,580 ± 11,648 1,049 ± 2,570 1,313 ± 1,649 1,625 ± 513
C 1,439 ± 3,567 1,452
‡
± 4,082 565 ± 689 842 ± 2,118 1,074 ± 646
Mean 867 ± 2,369 2,466 ± 7,265 1,750 ± 5,325 1,321 ± 2,732
Low PAk                
(MET-min/wk)
Moderate PA      
(MET-min/wk)
Vigorous PA          
(MET-min/wk)
Baseline Week 4 Week 8 Week 12 Group (SEM)
Transportation PA 
(MET-min/wk)
House PA               
(MET-min/wk)
Recreation PA       
(MET-min/wk)
Job PA                     
(MET-min/wk)
Total PA                  
(MET-min/wk)
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Table 8: Continued 
 
 
a significant increase at week 8 (1,618±3,921 MET-min/wk, p=0.002). NS had a 
downward trend though at week 8 (p=0.057), and C had a significant decrease at week 8 
(p=0.011) in household related physical activity. CC had a greater increase compared with 
all other groups (CC 1,618±3,921; WW -147±1,150, p=0.014, JC -195±1,277, p=0.014; 
NS -969±2,257, p<0.001; C -1,636±3,785 MET-min/wk p<0.001) at week 8 in the area of 
household related physical activity. CC and NS also had significant increases in physical 
activity relating to recreational activities at week 4 (CC 3,170±10,322, p=0.031; NS 
3,023±11,544 MET-min/wk, p=0.036), and JC experienced an upward trend at week 8 
(p=0.055). In the area of sitting physical activity, WW had a downward trend at week 4 
(p=0.052) and a significant decrease at weeks 8 (p=0.015) and 12 (p=0.045). The C group 
also had a significant decrease at weeks 4 (p=0.013) and 8 (p=0.023) as well as a 
downward trend at week 12 (p=0.059).  
Physical activity was also assessed in the CC group by recording number of steps 
per day via a pedometer. The average number of steps from baseline to 12 weeks for the 
CC group was 8,907±2,366 steps. All participants were sedentary at baseline, which was 
Variable Group P-level
CC 1,258j ± 589 1,045 ± 352 1,127i ± 657 1,063 ± 666 1,124 ± 94 T = 0.002
WW 1,351 ± 713 1,061# ± 526 1,003‡d ± 432 1,042‡ ± 521 1,114 ± 89 D = 0.272
JC 1,321j ± 660 1,229 ± 1,115 1,227 ± 634 1,263 ± 559 1,260 ± 94 T x D = 0.605
NS 1,341 ± 614 1,142 ± 582 1,434 ± 753 1,281 ± 476 1,300 ± 92
C 1,701 ± 1,067 1,214‡ ± 648 1,277 ± 640 1,321# ± 772 1,378 ± 116
Mean 1,371 ± 719 1,131 ± 685 1,206 ± 636 1,182 ± 593
Values are represented as means±standard deviation except group means are ±standard error mean. n = 125; CC (n=26), WW (n=29), JC (n=26), NS (n=27), 
and C (n=17).T = time effect. D = diet effect.  T x D = time x diet effect. * = significant time effect from baseline p<0.05 (univariate). † = significant diet effect 
p<0.05 (univariate). ‡ = significant time effect from baseline p<0.05 (post hoc LSD). All letter superscripts represent significance or trends toward significance 
from post hoc LSD. a = significantly different than CC (p < 0.05).  b = significantly different than WW (p < 0.05).  c = significantly different than JC (p < 0.05). d = 
significantly different than NS (p < 0.05). e = significantly different than C (p < 0.05). # = a trend toward significance from baseline p > 0.05 and p < 0.1 (post hoc 
LSD). f = a trend toward siginificance compared to CC (p > 0.05 and p < 0.1).  g = a trend toward siginificance compared to WW (p > 0.05 and p < 0.1).  h = a 
trend toward siginificance compared to JC (p > 0.05 and p < 0.1).  i = a trend toward siginificance compared to NS (p > 0.05 and p < 0.1).  j = a trend toward 
siginificance compared to C (p > 0.05 and p < 0.1), k = physical activity.
Sit PA                    
(MET-min/wk)
Baseline Week 4 Week 8 Week 12 Group (SEM)
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defined as not participating in a planned exercise program three months prior to the study 
and to not have exercised for more than 30 minutes a day on three or more days of the 
week. There were increases in physical activity in the CC group which were monitored by 
a required 75% compliance to the exercise protocol vs a recommended walking program 
in WW, JC, and NS. Due to changes seen in a variety of areas of physical activity, we 
accept Ho2 since statistically significant differences were observed among groups in 
physical activity levels.   
 
 
Figure 6: Changes from baseline in total physical activity over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values 
are delta change means±SD. n=125. 
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Body Composition 
Total weight, body mass index (BMI), and resting energy expenditure (REE) were 
assessed by ANOVA at 0, 4, 8, and 12 weeks. There was a significant overall time (Wilks’ 
Lambda p<0.001) and time x diet (Wilks’ Lambda p<0.001) effect for total weight. Table 
9 shows that CC, WW, JC, and NS all had a significant decrease in total weight at weeks 
4, 8, and 12 (CC -4.3±4.3, WW -4.4±3.5, JC -5.3±3.8, NS -5.2±4.5 kg, p<0.001 for all 
groups at all three time points). At week 12, CC, WW, JC, and NS had a significantly 
greater decrease in weight compared to C (0.1±3.1 kg; p<0.001 for all groups), which is 
depicted in Figure 7. 
There was also an overall time (Wilks’ Lambda p<0.001) effect and time x diet 
(Wilks’ Lambda p=0.044) effect for BMI. Post hoc LSD analysis revealed a significant 
time effect from baseline for CC, WW, JC, NS, and C at weeks 4, 8, and 12 (CC -4.0±1.7, 
WW -4.4±3.3, JC -4.4±1.6, NS -4.3±1.6, C -2.4±1.1 kg/m2; p<0.001 for all groups at each 
of the three time points). At week 12, though, CC (p=0.008), WW (p=0.001), JC 
(p=0.001), and NS (p=0.001) had a significantly lower BMI compared to the C group. 
Resting energy expenditure (REE) was assessed as total kilocalories per day as 
well as total kilocalories per kilogram per day. When looking at REE represented as 
kcal/day, there was a significant time (Wilks’ Lambda p<0.001) effect though no time x 
diet (Wilks’ Lambda p=0.287) effect. CC and WW experienced a significant decrease in 
REE from baseline at weeks 4 (CC p=0.005, WW p<0.001,), 8 (CC p=0.048, WW 
p<0.0010) and 12 (CC -101.7±170.4, p=0.004; WW -108.0±159.4 kcal/day, p<0.002), JC 
and NS had a significant decrease at week 4 (JC p=0.020, NS p=0.025) and a trend at week 
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8 (JC p=0.060, NS p=0.081). Also at week 12, CC (p=0.011) and WW (p=0.008) were 
significantly lower than C.  
 
Table 9: Changes in weight, body mass index, and resting energy expenditure. Observed 
between groups at 0, 4, 8, and 12 weeks for Curves (CC), Weight Watchers (WW), 
Jenny Craig (JC), Nutrisystem (NS), and Control (C)  
 
 
 
When assessed as kcal/kg/day, there was an overall time (Wilks’ Lambda p=0.006) 
effect but no time x diet (Wilks’ Lambda p=0.425) effect. CC had a trend toward a 
significant decrease at week 4 (p=0.091) but not at weeks 8 or 12. However, WW still had 
a significantly lower REE at weeks 4 (p=0.011) and 8 (p=0.029). JC also had a trend 
Variable Group Group (SEM) P-level
CC 90.7 ± 13.6 88.4
‡
± 14.0 87.2
‡j
± 13.9 86.4
‡
± 14.1 88.2 ± 2.7 T = 0.001
WW 91.1 ± 14.4 88.6
‡
± 14.7 87.5
‡j
± 14.8 86.8
‡j
± 14.3 88.5 ± 2.7 D = 0.263
JC 91.0 ± 14.6 88.1
‡
± 14.2 86.8
‡j
± 14.5 85.7
‡e
± 14.5 87.9 ± 2.8 T X D = 0.001
NS 96.8 ± 15.9 93.7
‡
± 16.1 92.5
‡
± 16.4 91.7
‡
± 16.6 93.7 ± 2.8
C 95.0 ± 14.2 94.9 ± 13.4 94.8
‡
± 13.3 95.1 ± 13.4 95.0 ± 3.3
Mean 92.8 ± 14.6 90.5 ± 14.7 89.4 ± 14.8 88.8* ± 14.9
CC 34.9 ± 5.9 31.7
‡
± 5.8 31.3
‡j
± 5.7 30.9
‡e
± 5.8 32.2 ± 1.0 T = 0.001
WW 34.2
i
± 6.4 30.5
‡de
± 5.2 30.1
‡de
± 5.2 29.8
‡de
± 5.1 31.1 ± 1.0 D = 0.126
JC 35.1 ± 4.5 31.5
‡j
± 4.1 31.1
‡e
± 4.2 30.7
‡e
± 4.2 32.1 ± 1.0 T X D = 0.001
NS 36.9 ± 5.4 33.3
‡
± 5.4 32.8
‡
± 5.5 32.6
‡
± 5.7 33.9 ± 1.0
C 36.6 ± 5.2 34.1
‡
± 4.9 34.2
‡
± 5.0 34.2
‡
± 5.1 34.8 ± 1.2
Mean 35.5 ± 5.6 32.1 ± 5.2 31.7 ± 5.3 31.5* ± 5.3
CC 1,501.0 ± 222.3 1,418.0
‡
± 244.4 1,435.7
‡g
± 203.3 1,399.2
‡
± 242.3 1,438.5 ± 37.0 T = 0.001
WW 1,470.9 ± 218.1 1,357.5
‡
± 249.8 1,340.6
‡i
± 210.7 1,362.9
‡
± 217.0 1,383.0 ± 37.0 D = 0.640
JC 1,412.7 ± 243.7 1,341.3
‡
± 209.3 1,348.5
#i
± 221.6 1,385.4 ± 217.7 1,372.0 ± 38.3 T X D = 0.001
NS 1,500.4 ± 220.2 1,432.8
‡
± 191.8 1,442.0
# 
± 180.4 1,457.7 ± 256.6 1,458.2 ± 37.6
C 1,416.9 ± 224.7 1,396.6 ± 190.4 1,433.5 ± 206.4 1,455.6 ± 245.7 1,425.6 ± 44.5
Mean 1,463.7 ± 225.7 1,389.1 ± 220.4 1,398.2 ± 206.8 1,409.3* ± 235.3
CC 16.63
ehi
± 1.69  16.08
#e
± 1.62 16.58
beh
± 1.55 16.26 ± 1.65 16.39 ± 0.29 T = 0.008
WW 16.27
e
± 1.97 15.43
‡
± 2.30 15.45
‡
± 1.85 15.82 ± 1.91 15.74 ± 0.29 D = 0.365
JC 15.64 ± 2.11 15.32 ± 1.55 15.65 ± 1.93 16.33
#j
± 2.05 15.73 ± 0.30 T X D = 0.081
NS 15.69 ± 2.28 15.48 ± 1.77 15.85 ± 2.05 16.05 ± 2.11 15.77 ± 0.29
C 14.99 ± 1.74 14.81 ± 1.63 15.22 ± 1.88 15.35 ± 1.93 15.09 ± 0.35
Mean 15.91 ± 2.03 15.47 ± 1.82 15.79 ± 1.88 16.00* ± 1.93
Baseline Week 8
Values are represented as means±standard deviation except group means are ±standard error mean.  n = 133; CC (n=29), WW (n=29), JC (n=27), NS 
(n=28), and C (n=20). T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect from baseline p<0.05 (univariate). † = signif icant 
diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). All letter superscripts represent signif icance or trends 
tow ard signif icance from post hoc LSD. a = signif icantly different than CC (p < 0.05).  b = signif icantly different than WW (p < 0.05).  c = signif icantly 
different than JC (p < 0.05). d = signif icantly different than NS (p < 0.05). e = signif icantly different than C (p < 0.05). # = a trend tow ard signif icance from 
baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard siginif icance compared to CC (p > 0.05 and p < 0.1).  g = a trend tow ard siginif icance 
compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a trend tow ard siginif icance 
compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance compared to C (p > 0.05 and p < 0.1).  
Week 12Week 4
Total Weight (kg)
BMI (kg/m2)
REE (kcals/d)
REE (kcals/kg/d)
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toward a significant increase in REE at week 12 (p=0.077). Also at week 12, WW had a 
significantly lower REE compared to JC (p=0.036), and CC expressed a trend toward 
being significantly lower than JC (p=0.051). All groups maintained relative REE, and the 
average change in REE for the groups at week 12 were CC -0.37±1.85, p=0.322; WW -
0.45±1.80, p=0.228; JC 0.69±2.13, p=0.077; NS 0.36±2.20, p=0.341; C 0.36±2.08 
kcal/kg/day, p=0.424, shown in Figure 8. 
 
 
 
Figure 7: Changes from baseline in total weight over 12 weeks. Curves (CC), Weight 
Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are delta 
change means±SD. n=133.  
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Figure 8: Changes from baseline in resting energy expenditure over 12 weeks. Curves 
(CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). 
Values are delta change means±SD. n=133.  
 
 
Dual Energy X-Ray Absorptiometry Measurements 
Total scanned mass, fat mass, fat-free mass, and body fat percentage are presented 
in Table 10. MANOVA analysis of the body composition data revealed an overall time 
(Wilks’ Lambda p<0.001) and time by diet (Wilks’ Lambda p<0.001) effect. As seen in 
Table 8, when analyzed by MANOVA univariate there was a significant time (p<0.001)  
and time x diet (p<0.001) effect for total scanned mass (-3.8±4.1 kg), fat mass (-2.5±3.2 
kg), fat-free mass (-1.3±2.4 kg), and body fat percentage (-1.1±2.6%). CC, WW, JC, and 
NS experienced a significant decrease in total scanned mass at weeks 4, 8, and 12 (WW -
4.0±4.4, NS -4.8± 4.0 kg; p<0.001 for all groups at each time point) and fat mass at weeks  
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Table 10: Changes in body composition. Observed between groups at 0, 4, 8, and 12 
weeks for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), 
and Control (C).  
 
 
 
4, 8, and 12 (CC -3.8±4.0, WW -2.2±2.6, JC -3.5±3.3, NS -2.3±2.5 kg, p<0.001 for all 
groups at each time point except week 4 for WW p=0.025). At the end of the 12 weeks, 
CC (-4.0±4.4, p<0.001) and JC (-5.3±3.7 kg, p<0.001) had a significantly greater decrease 
in total mass compared to the C group (0.1±4.1 kg), seen in Figure 9. WW, JC, and NS 
Variable Group Group (SEM) P-level
CC 84.2 ± 13.1 82.2
‡
± 13.5 81.0
‡j
± 13.4 80.2
‡e
± 13.5 81.9 ± 2.6 T = 0.001
WW 84.5 ± 14.2 82.2
‡
± 14.3 81.2
‡j
± 14.3 80.5
‡j
± 13.9 82.1 ± 2.6 D = 0.263
JC 84.8 ± 14.0 81.7
‡
± 13.5 80.6
‡j
± 13.9 79.5
‡e
± 14.0 81.7 ± 2.7 T X D = 0.001
NS 90.1 ± 15.3 87.2
‡
± 15.7 86.0
‡
± 16.0 85.3
‡
± 16.2 87.1 ± 2.7
C 88.4 ± 13.6 88.3 ± 12.9 88.5 ± 12.9 88.5 ± 12.8 88.4 ± 3.1
Mean 86.3 ± 14.1 84.1 ± 14.1 83.1 ± 14.3 82.5* ± 14.4
CC 38.6 ± 8.0 36.6
‡ij
± 8.7 35.2
‡de
± 8.4 34.8
‡de
± 8.9 36.3 ± 1.7 T = 0.001
WW 37.6
d
± 9.0 36.8
‡
± 9.6 35.8
‡ei
± 9.1 35.4
‡ei
± 9.4 36.4 ± 1.7 D = 0.126
JC 39.6 ± 7.7 37.8
‡
± 7.7 36.4
‡j
± 7.9 36.1
‡j
± 7.7 37.4 ± 1.7 T X D = 0.001
NS 42.3 ± 10 40.8
‡
± 11 40.3
‡
± 11.0 40.0
‡
± 11 40.8 ± 1.7
C 41.1 ± 9.1 41.1 ± 8.2 41.3 ± 8.0 41.1 ± 8.3 41.1 ± 2.0
Mean 39.7 ± 8.8 38.4 ± 9.2 37.6 ± 9.2 37.2* ± 9.3
CC 45.6 ± 6.5 45.6 ± 6.4 45.8 ± 6.8 45.4 ± 6.3 45.6 ± 1.3 T = 0.001
WW 46.9 ± 7.0 45.4
‡
± 6.8 45.4
‡
± 7.2 45.1
‡
± 6.6 45.7 ± 1.3 D = 0.640
JC 45.2 ± 7.8 43.9
‡
± 7.0 44.3
‡
± 7.3 43.4
‡j
± 7.6 44.2 ± 1.3 T X D = 0.001
NS 47.8 ± 6.7 46.4
‡
± 6.7 45.7
‡
± 7.0 45.3
‡
± 6.9 46.3 ± 1.3
C 47.3 ± 7.7 47.2 ± 7.3 47.2 ± 7.5 47.5 ± 7.2 47.3 ± 1.5
Mean 46.5 ± 7.1 45.6 ± 6.8 45.6 ± 7.1 45.2* ± 6.9
CC 45.6 ± 3.7 44.1
‡i
± 4.7 43.1
‡de
± 4.9 42.9
‡deh
± 5.4 43.9 ± 0.9 T = 0.001
WW 44.1
cij
± 4.8 44.3 ± 5.4 43.8
ij
± 5.5 43.5
dj
± 5.7 43.9 ± 0.9 D = 0.117
JC 46.6 ± 3.9 46.0 ± 4.0 44.9
‡
± 4.2 45.2
‡
± 4.3 45.7 ± 0.9 T X D = 0.001
NS 46.5 ± 4.6 46.2 ± 5.1 46.3 ± 5.7 46.3 ± 5.2 46.3 ± 0.9
C 46.3 ± 5.2 46.4 ± 4.5 46.6 ± 4.5 46.3 ± 4.5 46.4 ± 1.0
Mean 45.8 ± 4.5 45.3 ± 4.8 44.8 ± 5.2 44.7* ± 5.2
Week 8 Week 12Baseline
Values are represented as means±standard deviation except group means are ±standard error mean. n = 133; CC (n=29), 
WW (n=29), JC (n=27), NS (n=28), and C (n=20). T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time 
effect from baseline p<0.05 (univariate). † = signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline 
p<0.05 (post hoc LSD). All letter superscripts represent signif icance or trends tow ard signif icance from post hoc LSD. a = 
signif icantly different than CC (p < 0.05).  b = signif icantly different than WW (p < 0.05).  c = signif icantly different than JC (p < 
0.05). d = signif icantly different than NS (p < 0.05). e = signif icantly different than C (p < 0.05). # = a trend tow ard signif icance 
from baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard siginif icance compared to CC (p > 0.05 and p < 0.1).  g = 
a trend tow ard siginif icance compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard siginif icance compared to JC (p > 
0.05 and p < 0.1).  i = a trend tow ard siginif icance compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance 
compared to C (p > 0.05 and p < 0.1).  
Week 4
Total Mass 
(kg) 
Fat Mass 
(kg)
Fat Free 
Mass (kg) 
Body Fat 
(%)
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had a significant loss in fat-free mass at weeks 4, 8, and 12 (WW -1.8±2.3, JC -1.8±2.1, 
NS -2.4±2.2 kg, p<0.001 at each time point for WW, JC, and NS, except JC at week 8 
p=0.007), presented in Figure 11. Further, in Figure 12, CC had a significant decrease in 
body fat percentage at weeks 4 (p<0.001), 8 (p<0.001), and 12 (p<0.001), and JC also did 
at weeks 8 (p<0.001) and 12 (-1.4±2.4%, p=0.004). Even though JC had a significant 
decrease in body fat percentage, at week 12, CC had a significantly greater decrease in 
body fat percentage compared to WW (p=0.001), JC (p=0.038), NS  
 
 
 
Figure 9: Changes from baseline in total scanned mass over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
delta change means±SD. n=133.  
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(p<0.001), and C (p<0.001). JC had a trend toward significance compared to NS at weeks 
8 (p=0.074) and 12 (p=0.071). CC had the greatest decrease in fat-mass (-3.8±4.0 kg, 
p<0.001), shown in Figure 10 and body fat percentage (-2.7±3.4%, p<0.001), while 
maintaining fat-free mass (-0.2±2.0 kg, p=0.631) at week 12. Therefore, we can accept 
Ho3 since statistically significant differences were observed among groups in body 
composition related variables. 
 
 
  
Figure 10: Changes from baseline in fat mass over 12 weeks. Curves (CC), Weight 
Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are delta 
change means±SD. n=133.  
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Figure 11: Changes from baseline in fat free mass over 12 weeks. Curves (CC), Weight 
Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are delta 
change means±SD. n=133.  
 
 
 
 
Figure 12: Changes from baseline in percent body fat over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
delta change means±SD. n=133.  
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Table 11: Changes in anthropometric measurements. Observed between groups at 0, 4, 
8, and 12 weeks for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), 
Nutrisystem (NS), and Control (C).  
 
 
 
Anthropometric Measurements 
 Waist and hip measurements as well as waist to hip ratio were assessed by 
MANOVA at 0, 4, 8, and 12 weeks. There was an overall time (Wilks’ Lambda p<0.001) 
effect and time x diet (Wilks’ Lambda p<0.004) effect. As seen in Table 11, post hoc 
analysis revealed a significant decrease in waist circumference for WW and JC at weeks 
4 (WW p<0.001  JC p=0.003) , 8 (WW p<0.001 JC p=0.002), and 12 (WW -4.3±6.4, 
p<0.001; JC -3.7±3.8 cm p=0.001). CC and NS revealed a trend at week 4 (CC p=0.066, 
NS p=0.060) but were both significant at weeks 8 (CC p=0.001 NS p=0.009) and week 12 
Variable Group P-level
CC 94.3
i
± 12 92.8
#j
± 12 91.4
‡ei
± 11 91.5
‡e
± 11.8 92.5 ± 2.00 T = 0.001
WW 96.6 ± 12 93.4
‡j
± 11.0 93
‡j
± 11 92.4
‡e
± 9.8 93.8 ± 2.00 D = 0.211
JC 96.8 ± 11.7 94.2
‡
± 11 93.9
‡
± 10 93.1
‡e
± 10.5 94.5 ± 3.10 T X D = 0.007
NS 99.4 ± 10.0 97.8
#
± 12 97.1
‡
± 11.6 96.2
‡
± 11.8 97.6 ± 3.00
C 97.6 ± 10 99.3
#
± 12 98.5 ± 10 99.5 ± 11.2 98.7 ± 2.40
Mean 96.9 ± 11 95.2 ± 12 94.5 ± 11 94.2* ± 11.2
CC 119.5
i
± 11.0 117.4
‡i
± 12 116.2
‡j
± 11 115.4
‡e
± 10.4 117.1 ± 2.10 T = 0.001
WW 118.4d ± 11.7 116.3
‡dj
± 11 116.5
‡j
± 13 115.4
‡ei
± 11.7 116.6 ± 2.10 D = 0.131
JC 120.0 ± 11 117.8
‡
± 8.9 117.7
‡
± 9.9 114.8
‡ei
± 9.3 117.6 ± 2.20 T X D = 0.008
NS 124.8 ± 14.0 122.6
‡
± 15 121.1
‡
± 14.4 120.5
‡
± 15.2 122.3 ± 2.20
C 122.9 ± 9.7 122.5 ± 8.9 122.8 ± 11.0 123.7 ± 9.9 123.0 ± 2.50
Mean 121.0 ± 12 119.1 ± 12 118.6 ± 12 117.6* ± 11.9
CC 0.79
g
± 0.06 0.79 ± 0.07 0.79 ± 0.10 0.79 ± 0.10 0.79 ± 0.01 T = 0.755
WW 0.82 ± 0.06 0.80
#
± 0.07 0.80
‡
± 0.10 0.80
‡
± 0.10 0.81 ± 0.01 D = 0.815
JC 0.81 ± 0.06 0.80 ± 0.06 0.80 ± 0.10 0.81 ± 0.10 0.80 ± 0.01 T X D = 0.325
NS 0.80 ± 0.06 0.80 ± 0.06 0.80 ± 0.10 0.80 ± 0.10 0.80 ± 0.01
C 0.80 ± 0.06 0.81
#
± 0.07 0.80 ± 0.10 0.80 ± 0.10 0.80 ± 0.01
Mean 0.80 ± 0.06 0.80 ± 0.07 0.80 ± 0.10 0.80 ± 0.10
Baseline Week 8
Values are represented as means±standard deviation except group means are ±standard error mean.  n = 133; CC (n=29), WW (n=29), JC 
(n=27), NS (n=28), and C (n=20). T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect from baseline p<0.05 
(univariate). † = signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). All letter 
superscripts represent signif icance or trends tow ard signif icance from post hoc LSD. a = signif icantly different than CC (p < 0.05).  b = 
signif icantly different than WW (p < 0.05).  c = signif icantly different than JC (p < 0.05). d = signif icantly different than NS (p < 0.05). e = 
signif icantly different than C (p < 0.05). # = a trend tow ard signif icance from baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend 
tow ard siginif icance compared to CC (p > 0.05 and p < 0.1).  g = a trend tow ard siginif icance compared to WW (p > 0.05 and p < 0.1).  h = a 
trend tow ard siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a trend tow ard siginif icance compared to NS (p > 0.05 and p < 0.1).  j = 
a trend tow ard siginif icance compared to C (p > 0.05 and p < 0.1).  
Week 12Week 4 Group (SEM)
Waist 
Circumference 
(cm) 
Hip 
Circumference 
(cm)  
Waist/Hip Ratio 
(cm)
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(CC -2.8±5.0, p=0.008; NS -3.2±6.2 cm, p=0.003). The C group had a trend toward a 
significant decrease at week 4 (p=0.096). By week 12, CC (p=0.004), WW (p<0.001), and 
JC (p=0.001) and NS (p=0.002) had a significantly greater decrease in waist circumference 
compared to the C group, seen in Figure 13.  
When assessing hip circumference, there was a significant decrease from baseline 
for CC, WW, JC, and NS at weeks 4 (CC p=0.019, WW p=0.027; JC p=0.023; NS 
p=0.015), 8 (CC p<0.001 WW p<0.009; JC p=0.003; NS p<0.001), and 12 (CC -4.1±4.9, 
p<0.001; WW -3.0±2.8, p<0.001; JC -5.1±4.4, p<0.001; NS -4.3±4.2 cm, p<0.001). At 
week 12, CC (p<0.001), WW (p=0.002), JC (p<0.001), and NS (p<0.001) also had a  
 
 
 
Figure 13: Changes from baseline in waist circumference over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
delta change means±SD. n=133.  
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significantly greater decrease in hip circumference compared to the C group, shown in 
Figure 14. JC also had a significantly lower hip circumference compared to WW at week 
12 (p=0.046). WW had a significant decrease in waist to hip ratio at weeks 8 (p=0.009) 
and 12 (p=0.048), and it was lower than C at week 12 (p=0.035). 
Markers of Health 
Resting Heart Rate and Resting Blood Pressure 
 Resting heart rate and resting blood pressure were also measured and analyzed by 
MANOVA at 0, 4, 8, and 12 weeks of intervention. There was an overall time (Wilks’ 
Lambda p<0.001) effect seen. Table 12 shows how CC showed a trend toward significance 
at week 4 (p=0.054) and had a significant decrease in resting heart rate at weeks 8 
 
 
 
Figure 14: Changes from baseline in hip circumference over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
delta change means±SD. n=133.  
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Table 12: Changes in resting heart rate and resting blood pressure. Observed between 
groups at 0, 4, 8, and 12 weeks for Curves (CC), Weight Watchers (WW), Jenny Craig 
(JC), Nutrisystem (NS), and Control (C)  
 
 
 
(p=0.001) and 12 (-5.5±10.0 bpm, p=0.004). JC also had a decrease in resting heart rate at 
weeks 4 (p=0.002), 8 (p=0.006), and 12 (-3.8±10.9 bpm, p=0.047). NS had a trend toward 
a significant decrease in heart rate at week 4 (p=0.051) and was significantly lower at 
week 12 (-3.8±9.1 bpm, p=0.043). Also at week 12, CC expressed a trend toward being 
significantly lower than WW (p=0.077) and was significantly lower than the C group 
(p=0.069), shown in Figure 15. Resting systolic blood pressure was also significantly 
lower for CC and NS at weeks 4 (CC p=0.011; NS p=0.005), 8 (CC p=0.038; NS p=0.002), 
and 12 (CC -7.6±14.2, p=0.002; NS -9.1±13.7 bpm, p<0.001). At week 12, CC was 
trending toward significantly lower compared to JC (p=0.067) and was significantly lower 
Variable Group Group (SEM) P-level
CC 70.3 ± 9.7 66.8
#
± 7.6 63.6
‡b
± 8.6 64.8
‡g
± 9.2 66.3 ± 1.1 T = 0.001
WW 69.7 ± 6.4 70.5
cd
± 8.6 67.9
i
± 8.1 68.8
d
± 7.2 69.2 ± 1.0 D = 0.059
JC 70.4 ± 9.6 64.4
‡
± 9.2 64.8
‡
± 7.0 66.6
‡
± 8.8 66.6 ± 1.1 T X D = 0.308
NS 67.5 ± 7.6 63.9
#j
± 7.2 64.3 ± 8.1 63.7
‡
± 6.9 64.9 ± 1.1
C 67.4 ± 9.0 68.2 ± 10.7 66.6 ± 7.7 67.3 ± 6.7 67.4 ± 1.3
Mean 69.2 ± 8.5 66.7 ± 8.8 65.4 ± 8.0 66.1* ± 8.0
CC 127.5 ± 16.2 121.8
‡
± 9.3 122.3
‡
± 9.2 119.9
‡
± 10.8 123 ± 2.0 T = 0.005
WW 125.6 ± 10.4 122.7 ± 10.8 123.3 ± 11.7 122.9 ± 11.4 124 ± 2.0 D = 0.023
JC 124.2
i
± 11 122.2 ± 10.4 123.6 ± 10.7 123.0 ± 10.5 123 ± 2.1 T X D = 0.110
NS 131.1 ± 19 124.8
‡
± 17.1 123.4
‡
± 11.7 122.0
‡
± 12.8 125 ± 2.0
C 130.5 ± 11 133.5
abcd
± 18.3 133.7
abcd
± 16.3 132.4
abcd
± 17.7 132.5
†
± 2.5
Mean 127.6 ± 14 124.4 ± 13.7 124.7 ± 12.2 123.5* ± 12.9
CC 78.3
e
± 6.9 75.2
#i
± 6.3 74.3
‡e
± 6.1 74.7
‡ce
± 7.0 75.6 ± 1.2 T = 0.035
WW 76.9
e
± 8.3 77.2 ± 7.2 77.6 ± 8.4 77.6
j
± 8.8 77.3 ± 1.2 D = 0.010
JC 79.1
j
± 9.5 77.1 ± 8.3 77.0 ± 10.1 79.3 ± 9.0 78.1 ± 1.2 T X D = 0.766
NS 80.8 ± 11 78.9 ± 8.2 77.7
#
± 8.1 78.2 ± 7.2 78.9 ± 1.2
C 83.8 ± 9.3 83.1
abcd
± 8.7 80.9 ± 8.9 82.2 ± 10.7 82.5
†
± 1.5
Mean 79.5 ± 9.1 78.0 ± 8.0 77.3 ± 8.5 78.1* ± 8.7
Baseline Week 8
Values are represented as means±standard deviation except group means are ±standard error mean. n = 131; CC (n=28), WW (n=29), JC (n=27), NS 
(n=28), and C (n=19).T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect from baseline p<0.05 (univariate). † = signif icant 
diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). All letter superscripts represent signif icance or trends 
tow ard signif icance from post hoc LSD. a = signif icantly different than CC (p < 0.05).  b = signif icantly different than WW (p < 0.05).  c = signif icantly 
different than JC (p < 0.05). d = signif icantly different than NS (p < 0.05). e = signif icantly different than C (p < 0.05). # = a trend tow ard signif icance from 
baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard siginif icance compared to CC (p > 0.05 and p < 0.1).  g = a trend tow ard siginif icance 
compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a trend tow ard siginif icance 
compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance compared to C (p > 0.05 and p < 0.1).  
Week 12Week 4
Resting Heart Rate 
(beats/min)
Resting Systolic 
(mm/Hg)
Resting Diastolic 
(mm/Hg)
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than C (p=0.014), depicted in Figure 16. NS showed a trend toward being significantly 
lower than WW (p=0.059) and was significantly lower than JC (p=0.024) and the C group 
(p=0.004) at week 12 as well. Depicted in Figure 17, CC experienced a trend toward a 
decrease in resting diastolic blood pressure at week 4 (p=0.070) and had a significant 
decrease at weeks 8 (p=0.023) and 12 (p=0.045). NS showed a trend downward at week 8 
(p=0.077) but was not significant at week 12. CC expressed a trend toward having a 
significantly greater decrease in diastolic blood pressure compared to WW (p=0.087) at 
week 12. Therefore, we accept Ho4 since statistically significant differences were 
observed among groups in variables relating to markers of health. 
 
 
 
Figure 15: Changes from baseline in resting heart rate over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
delta change means±SD. n=131.  
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Figure 16: Changes from baseline in resting systolic blood pressure over 12 weeks. 
Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control 
(C). Values are delta change means±SD. n=131.  
 
 
 
Figure 17: Changes from baseline in resting diastolic blood pressure over 12 weeks. 
Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control 
(C). Values are delta change means±SD. n=131.  
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Blood Lipid Panel 
A fasting lipid panel was measured at 0, 4, 8, and 12 weeks of the study 
intervention and analyzed by MANOVA. There was an overall time (Wilks’ Lambda 
p<0.001) effect seen. Changes are expressed as percent change from baseline. Table 13 
depicts the changes in lipids through the 12 weeks. JC experienced a significant increase 
in triglycerides at week 12 with a percent change of 15.1±42.6%, p=0.016. As seen in 
Figure 18, NS had a trend toward a significant increase as well as weeks 8 (p=0.058) and 
12 (p=0.064). Additionally, at week 12 CC (-6.7±26.4%) had a greater percent decrease 
in triglycerides compared to JC (15.1±42.6, p=0.012) snd NS (11.1±29.1, p=0.037), and 
WW (-2.7±31.2%) also had a significantly greater decrease compared to JC (p=0.038) as 
well. When looking at total cholesterol, CC had a significant decrease at week 4 (p=0.009), 
showed a downward trend at week 8 (p=0.078), but was not significant at week 12 (-
3.6±10.0, p=0.119). WW had a significant decrease at week 4 (p=0.010) as did JC 
(p=0.003). NS also showed a significant decrease at weeks 4 (p=0.033) and 8 (p=0.047) 
and a trend at week 12 (-3.8±15.5%, p=0.095). No significant differences were observed 
between groups at week 12 in changes in total cholesterol. Percent changes in HDL-
cholesterol (HDL-C) were significantly lower in JC at week 4 (p<0.001) and 8 (p=0.011) 
and expressed a trend downward at week 12 (-5.0±16.3%, p=0.069), as seen in Figure 19. 
NS also had a significant decrease in percent change at week 4 (p=0.006) and 8 (p=0.008). 
Changes in HDL-C were significantly different at week 12 between CC and JC (p=0.049), 
with CC having the greatest increase of all the groups (2.5±15.1%). CC also showed a  
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Table 13: Changes in fasting blood lipids. Observed between groups at 0, 4, 8, and 12 
weeks for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), 
and Control (C)  
 
 
 
 
trend toward significance when compared to NS (p=0.082) and the C group (p=0.068). 
LDL-cholesterol (LDL-C) percent changes were significantly lower in CC at week 4 
(p=0.029) and expressed a trend at week 8 (p=0.062). Though the changes were not 
Variable Group Group (SEM) P-level
CC 127.8 ± 64.6 122.9 ± 60.7 118.4 ± 68.2 115.0
#i
± 58.7 121.0 ± 9.1 T = 0.076
WW 130.0 ± 60.9 109.5
‡
± 44.7 118.9 ± 37.7 116.6
#i
± 44.4 118.8 ± 8.9 D = 0.724
JC 132.9 ± 60.0 125.8 ± 50.5 133.3 ± 54.9 140.4 ± 57.3 133.1 ± 9.4 T X D = 0.296
NS 128.0 ± 51.5 126.5 ± 50.8 136.9 ± 64.4 134.3 ± 45.6 131.5 ± 9.1
C 140.0 ± 58.4 128.0 ± 43.2 122.4
#
± 40.2 133.3 ± 44.0 130.9 ± 11
Mean 131.1 ± 58.5 122.0 ± 50.4 126.0 ± 54.8 137.3 ± 50.9
CC 191.4 ± 30.8 178.8
‡
± 28.0 183.1
#
± 32.9 184.2
#
± 33.0 184.4 ± 5.5 T = 0.001
WW 187.5 ± 35.5 174.5
‡e
± 28.4 180.6 ± 31.6 186.9 ± 33.0 182.4 ± 5.4 D = 0.802
JC 189.1 ± 29.3 174.2
‡e
± 29.0 181.2
#
± 27.6 183.7 ± 28.0 182.1 ± 5.7 T X D = 0.316
NS 189.7 ± 39.9 177.7
‡j
± 31.3 178.5
‡
± 29.8 179.0
‡
± 29.2 181.2 ± 5.5
C 192.9 ± 33.1 192.4
bd
± 32.5 190.6 ± 31.9 188.2 ± 35.6 191.0 ± 6.5
Mean 190.0 ± 33.6 178.8 ± 29.9 182.3 ± 30.6 184.2* ± 31.4
CC 54.8 ± 13.2 52.4
#dh
± 11.5 54.8
dh
± 15.6 55.8
dhj
± 14.3 54.4 ± 2.1 T = 0.001
WW 54.1 ± 13.3 50.9
‡
± 12.0 51.4
‡
± 11.6 53.9
i
± 14.1 52.6 ± 2.1 D = 0.266
JC 53.5 ± 12.3 46.8
‡
± 7.7 49.1
‡
± 8.4 49.7
‡
± 7.8 49.8 ± 2.2 T X D = 0.009
NS 51.0 ± 14.0 46.7
‡
± 9.9 46.8
‡
± 10.6 48.2
‡
± 11.6 48.2 ± 2.1
C 51.4 ± 10.5 51.8 ± 11.9 49.6 ± 10.5 49.2 ± 12.2 50.5 ± 2.5
Mean 53.1 ± 12.7 49.6 ± 10.8 50.4 ± 11.9 51.5* ± 12.5
CC 111.1 ± 22.7 101.7
‡j
± 21.8 103.1
#j
± 25.2 105.4 ± 22.7 105.3 ± 4.8 T = 0.001
WW 107.3 ± 31.8 101.8
j
± 24.7 105.5 ± 29.1 109.3 ± 27.7 106.0 ± 4.7 D = 0.555
JC 108.9 ± 25.4 100.8
#j
± 26.4 105.4 ± 24.8 106.0 ± 27.0 105.3 ± 5.0 T X D = 0.597
NS 113.0 ± 32.1 105.6
#
± 26.2 104.4
‡
± 21.9 104.0
‡
± 28.1 106.8 ± 4.8
C 122.3 ± 50.7 115.0 ± 32.6 116.6 ± 26.6 112.4
‡
± 30.7 116.6 ± 5.7
Mean 112.0 ± 32.6 104.4 ± 26.2 106.4 ± 25.6 107.1* ± 26.9
CC 3.65 ± 0.85 3.55
i
± 0.88 3.53
ij
± 0.97 3.45
#i
± 0.78 3.54 ± 0.16 T = 0.336
WW 3.62 ± 0.90 3.56
i
± 0.80 3.66 ± 0.86 3.59 ± 0.80 3.61 ± 0.16 D = 0.380
JC 3.64 ± 0.73 3.78 ± 0.73 3.77 ± 0.78 3.77 ± 0.79 3.74 ± 0.17 T X D = 0.734
NS 3.90 ± 0.92 3.95 ± 0.91 3.96 ± 0.88 3.87 ± 0.92 3.92 ± 0.16
C 3.90 ± 1.00 3.88 ± 1.05 4.00 ± 1.04 3.82 ± 1.46 3.90 ± 0.19
Mean 3.73 ± 0.88 3.73 ± 0.88 3.77 ± 0.91 3.69 ± 0.95
Total 
Cholesterol 
(mg/dL)
HDL-C (mg/dL)
LDL-C (mg/dL)
TC/HDL-C
Values are represented as means±standard deviation except group means are ±standard error mean. n = 131; CC (n=28), WW (n=29), JC 
(n=26), NS (n=28), and C (n=20).T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect from baseline p<0.05 
(univariate). † = signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). All letter superscripts 
represent signif icance or trends tow ard signif icance from post hoc LSD. a = signif icantly different than CC (p < 0.05).  b = signif icantly different 
than WW (p < 0.05).  c = signif icantly different than JC (p < 0.05). d = signif icantly different than NS (p < 0.05). e = signif icantly different than C 
(p < 0.05). # = a trend tow ard signif icance from baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard siginif icance compared to CC 
(p > 0.05 and p < 0.1).  g = a trend tow ard siginif icance compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard siginif icance compared to 
JC (p > 0.05 and p < 0.1).  i = a trend tow ard siginif icance compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance compared to 
C (p > 0.05 and p < 0.1).  
Baseline Week 12Week 4 Week 8
Triglycerides 
(mg/dL)
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Figure 18: Changes from baseline in triglycerides over 12 weeks. Curves (CC), Weight 
Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are percent 
change means ± SD. n=131.  
 
 
 
 
Figure 19: Changes from baseline in HDL-cholesterol over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
percent change means ± SD. n=131.  
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Figure 20: Changes from baseline in LDL-cholesterol over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
percent change means ± SD. n=131.  
 
 
 
Figure 21: Changes from baseline in total cholesterol:HDL-cholesterol over 12 weeks. 
Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control 
(C). Values are percent change means ± SD. n=131.  
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significant at week 12 for the CC group (-4.7±11.5%, p=0.370). WW however, had an 
increase in LDL-C percent change from baseline at week 12 (10.3±51.2%, p=0.047). CC 
(p=0.043) and NS (p=0.028) had significantly greater decreases in LDL-C compared to 
WW, with NS having the greatest decrease (-6.1±21.0%, p=0.250), shown in Figure 20. 
When assessing total cholesterol to HDL-C ratio, CC showed a trend toward a significant 
decrease (-4.9±11.3%, p=0.053) at week 12. Whereas, JC showed a trend toward a 
significant increase (4.9±16.1%, p=0.061) at week 12. Figure 21 depicts how the ratio of 
total cholesterol to HDL-C significantly decreased in CC compared to JC (p=0.007) and 
the C group (3.7±11.9%, p=0.029) and expressed a trend when compared to WW 
(1.5±13.6%, p=0.072). Therefore, due to the changes seen in the lipid levels, we accept 
Ho6 since statistically significant differences were observed among groups in blood lipid 
panels. 
Hormone Levels 
Glucose, insulin, glucose/insulin ratio, and calculated HOMA were analyzed at 
weeks 0, 4, 8, and 12 by MANOVA. There was an overall time (Wilks’ Lambda p=0.016) 
but no time x diet (Wilks’ Lambda p=0.121) effect.  Change from baseline is presented as 
percent change. When looking at percent change from baseline in glucose levels, no 
significant changes were seen in any of the groups at any time point (p=0.132), depicted 
in Table 14. Additionally, there was not a significant group effect (p=0.642). Though not 
significant, CC had the greatest decrease in glucose at week 12 (-3.8±14.9%, p=0.240). 
When analyzing insulin levels, Figure 22 shows that NS was the only group that had a  
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Table 14: Changes in hormones. Observed between groups at 0, 4, 8, and 12 weeks for 
Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control 
(C) 
 
 
 
significant increase (32.4±106.4, p=0.045) at week 12, though C had a significant increase 
at week 4 (p=0.015) and 8 (p=0.019). At week 12, CC (-28.1±31.1, p=0.021), WW (-
Variable Group Group (SEM) P-level
CC 98.6 ± 23.5 94.7 ± 15.5 99.4 ± 19 92.3
#
± 12 96.3 ± 3.2 T = 0.040 
WW 93.3 ± 12.9 92.2 ± 8.4 92.1 ± 10.9 90.8
i
± 9.8 92.1 ± 2.6 D = 0.516 
JC 97.8 ± 11.6 92.8
‡
± 7.6 94.7 ± 10.1 96.4 ± 13.2 95.4 ± 2.3 T x D = 0.403 
NS 100.9 ± 12.3 95.5
‡
± 8.9 98.6 ± 9.0 98.4 ± 9.8 98.3 ± 2.6
C 96.2 ± 10.9 97.9 ± 12.5 99.0 ± 7.9 96.1 ± 10.9 97.3 ± 2.8
Mean 97.4 ± 13.9 94.4 ± 10.2 96.4 ± 11.3 95.1 ± 11.3
CC 13.7 ± 9.0 9.3
#
± 4.6 8.6
#
± 4.9 8.9
#
± 5.9 10.1 ± 2.6 T = 0.064 
WW 14.4 ± 7.2 14.2 ± 12.9 16.8
fh
± 19.6 11.7 ± 11.5 14.3 ± 2.1 D = 0.600
JC 13.0 ± 6.2 11.0 ± 7.6 9.6 ± 5.0 9.7
#i
± 4.8 10.8 ± 1.8 T x D = 0.288 
NS 15.7 ± 12.5 13.2 ± 14.5 12.7 ± 9.8 13.8 ± 7.2 13.8 ± 2.1
C 11.5 ± 8.4 12.8 ± 6.7 14.1 ± 9.9 11.5 ± 4.9 12.5 ± 2.3
Mean 13.7 ± 8.7 12.2 ± 10.1 12.4 ± 11.3 11.2 ± 7.3
CC 10.8 ± 7.1 14.3 ± 11.1 16.4
#
± 10.4 15.9
#
± 12.9 14.3 ± 2.6 T =0.302 
WW 9.0 ± 6.8 11.6 ± 8.0 13.8
#
± 17.2 12.9
#
± 8.8 11.8 ± 2.1 D = 0.895
JC 9.1 ± 4.4 17.5
‡
± 22.6 12.9 ± 7.3 13.4
‡
± 8.9 13.2 ± 1.9 T x D = 0.219 
NS 12.3 ± 11.9 13.5 ± 9.1 12.0 ± 8.4 9.7 ± 6.4 11.9 ± 2.1
C 13.5 ± 11.6 9.8 ± 5.3 9.6 ± 4.6 12.4 ± 11.7 11.3 ± 2.3
Mean 10.8 ± 8.6 13.6 ± 13.7 12.8 ± 10.3 12.6 ± 9.5
CC 3.68 ± 3.24 2.29
‡
± 1.40 2.21
‡
± 1.54 2.10
‡i
± 1.53 2.57 ± 0.64 T = 0.007 
WW 3.42 ± 2.01 3.24 ± 2.77 3.84
h
± 4.18 2.62 ± 2.42 3.28 ± 0.53 D = 0.719
JC 3.23 ± 1.85 2.57 ± 1.90 2.26
#
± 1.30 2.35
#i
± 1.46 2.60 ± 0.46 T x D = 0.170 
NS 4.02 ± 3.45 3.12
#
± 3.41 3.15 ± 2.63 3.31 ± 1.61 3.40 ± 0.51
C 2.70 ± 2.00 3.02 ± 1.45 3.47 ± 2.62 2.70 ± 1.12 2.97 ± 0.57
Mean 3.41 ± 2.50 2.87 ± 2.35 2.98 ± 2.66 2.64 ± 1.69
CC 53.9 ± 19.1 38.4
‡
± 15.8 34.7
‡e
± 12.0 37.3
‡e
± 19.0 41.1 ± 6.7 T = 0.238 
WW 52.7 ± 30.2 38.0
‡
± 21.1 41.2
‡j
± 26.0 41.0
‡j
± 22.9 43.2 ± 5.6 D = 0.009
JC 52.8 ± 24.3 36.5
‡
± 25.2 42.9
‡
± 33.5 43.5
#j
± 32.0 43.9 ± 5.2 T x D = 0.001 
NS 52.8 ± 23.6 42.6
‡
± 25.8 44.0 ± 27.7 49.0 ± 33.1 47.1 ± 5.8
C 55.9 ± 18.7 64.8
abcd
± 22.8 58.5 ± 26.3 60.4 ± 39.0 59.9
†
± 6.4
Mean 53.5 ± 23.5 43.1 ± 24.4 44.1 ± 27.3 46.0 ± 28.5
Baseline Week 4 Week 8 Week 12
Values are represented as means±standard deviation except group means are ±standard error mean. n = 74, except leptin n = 78; CC 
(n=22), WW (n=27), JC (n=24), NS (n=25), and C (n=19).T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time 
effect from baseline p<0.05 (univariate). † = signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 
(post hoc LSD). All letter superscripts represent signif icance or trends tow ard signif icance from post hoc LSD. a = signif icantly 
different than CC (p < 0.05).  b = signif icantly different than WW (p < 0.05).  c = signif icantly different than JC (p < 0.05). d = 
signif icantly different than NS (p < 0.05). e = signif icantly different than C (p < 0.05). # = a trend tow ard signif icance from baseline p > 
0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard siginif icance compared to CC (p > 0.05 and p < 0.1).  g = a trend tow ard 
siginif icance compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a 
trend tow ard siginif icance compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance compared to C (p > 0.05 and p < 
0.1), k = Homeostatic Model Assesment.  
Glucose 
(mg/dL)
Insulin (µIU/ml)
Glucose/Insulin 
Ratio
Leptin (ng/ml)
HOMA
k 
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19.2±50.9, p=0.027), and JC (-19.0±38.4%, p=0.018) had a greater change in insulin 
levels when compared to NS. CC (p=0.073) and JC (p=0.084) also had a trend toward a 
significant change compared to the C group at week 12. CC showed a significant increase 
in glucose to insulin ratio at week 8 (p=0.004) and 12 (57.8±72.9%, p=0.012), seen in 
Figure 23. WW and JC also did at week 4 (WW p=0.024; JC p=0.003), week 8 (WW 
p=0.014; JC p=0.005), and week 12 (WW 53.1±61.6, p=0.005; JC 52.7±80.2%, p=0.001). 
NS expressed a trend toward a significant increase at week 4 (p=0.087), a significant 
increase at week 8 (p=0.036), but the change at week 12 was not significant (13.7±69.1%, 
p=0.441). There was not a significant MANOVA univariate interaction (p=0.456), though 
CC (p=0.073), WW (p=0.069), and JC (p=0.055) expressed trends toward a significant 
increase compared to C at week 12. No significant changes from baseline were observed 
in calculated HOMA at week 12, when presented as percent change from baseline, in any 
of the diet groups, seen in Figure 24. Though, the C group had a significant increase at 
week 4 (p=0.012) and 8 (p=0.030). A significant interaction was also seen when analyzed 
by MANOVA univariate (p=0.031). CC (-31.1±32.6, p=0.020), WW (-21.4±48.3, 
p=0.028), and JC (-17.7±45.1%, p=0.028) had a significant decrease in HOMA levels 
when compared to NS (30.7±106.4%) at week 12. Trends were also seen in CC (p=0.059), 
WW (p=0.087), and JC (p=0.096) when compared to the C group at week 12.   
Leptin was also assessed at weeks 0, 4, 8, and 12 by ANOVA. An overall time 
(Wilks’ Lambda p=0.001) and time x diet (Wilks’ Lambda p=0.047) effect was seen. 
Figure 25 shows no significant changes in leptin levels were observed at week 12, though 
CC expressed trends toward a significant decrease at week 4 (p=0.061) and 8 (p=0.076) 
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and had the greatest decrease of all the groups at week 12 (-21.1±21.4%, p=0.151). WW 
had a significant decrease at week 4 (p=0.007) and a trend downward at week 8 (p=0.089). 
JC also had significant decreases at week 4 (p<0.001) and 8 (p=0.030). NS and C both had 
a significant increase at week 4 (NS p=0.030; C p=0.046). Due to changes seen in hormone 
levels, we are therefore able to accept Ho7 since statistically significant differences were 
observed among groups in hormone levels. 
 
 
 
 
Figure 22: Changes from baseline in insulin levels over 12 weeks. Curves (CC), Weight 
Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are percent 
change means ± SD. n=74.  
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Figure 23: Changes from baseline in glucose to insulin ratio over 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
percent change means ± standard deviation. n=74. 
 
 
 
 
 
Figure 24: Changes from baseline in calculated HOMA levels over 12 weeks. Curves 
(CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). 
Values are percent change means ± SD. n=74. 
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Figure 25: Changes from baseline in leptin levels over 12 weeks. Curves (CC), Weight 
Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are percent 
change means±SD. n=78.  
 
 
Markers of Fitness 
Peak Aerobic Capacity 
 Peak aerobic capacity was measured at baseline and 12 weeks by ANOVA and 
represented as liters per minute, milliliters per kilogram per minute, and maximum time 
to exhaustion. When represented as L/min, there was an overall time x diet (Wilks’ 
Lambda p<0.007) effect. As depicted in Table 15, CC (0.11±0.17, p=0.001) and WW 
(0.06±0.22, p=0.050) had an increase in absolute peak aerobic capacity. CC also had a 
greater absolute peak aerobic capacity at week 12 compared to JC (p=0.022), NS 
(p=0.002), and C (p=0.004). WW had a greater increase compared to NS (p=0.032) and C 
(p=0.004) as well.  
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Table 15: Changes in peak aerobic capacity. Observed between groups at 0 and 12 weeks 
for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and 
Control (C).  
 
 
 
 
There was also an overall time (Wilks’ Lambda p<0.001) and time x diet (Wilks’ 
Lambda p<0.015) effect for peak aerobic capacity when relative to body weight. Figure 
26 shows that CC (2.5±2.9, p<0.001), WW (1.1±4.7, p=0.044), and JC (1.4±2.1, p=0.017) 
all had an increase at week 12 compared to baseline. CC expressed a trend toward 
significance when compared to WW (p=0.068) and had a significantly greater increase 
Variable Group P-level
CC 1.8 ± 0.23 1.94
‡e
± 0.2 1.9 ± 0.06 T = 0.218
WW 1.8 ± 0.37 1.84
‡
± 0.4 1.8 ± 0.06 D = 0.672
JC 1.8 ± 0.40 1.83 ± 0.3 1.8 ± 0.07 T X D = 0.007
NS 1.9 ± 0.42 1.84 ± 0.4 1.9 ± 0.06
C 1.8 ± 0.30 1.72 ± 0.3 1.7 ± 0.08
Mean 1.8 ± 0.35 1.85 ± 0.4
CC 20.5 ± 3.2 23.0
‡de
± 3.4 22 ± 0.7 T = 0.001
WW 20.3 ± 4.6 21.4
‡e
± 4.4 21 ± 0.7 D = 0.076
JC 20.4 ± 3.8 21.8
‡e
± 3.1 21 ± 0.8 T X D = 0.015
NS 19.8 ± 5.1 20.6
j
± 5.7 20 ± 0.7
C 18.7 ± 3.1 18.2 ± 3.3 19 ± 0.9
Mean 20.0 ± 4.1 21.2* ± 4.4
CC 7.6
e
± 0.9 8.4
‡deg
± 0.8 8.0 ± 0.2 T = 0.001
WW 7.2 ± 1.3 7.8
‡e
± 1.3 7.5 ± 0.2 D = 0.024
JC 7.2 ± 1.2 7.9
‡e
± 1.2 7.6 ± 0.2 T X D = 0.020
NS 7.2 ± 1.7 7.6
j
± 1.7 7.4 ± 0.2
C 6.7 ± 1.4 6.8 ± 1.4 6.7
†
± 0.3
Mean 7.2 ± 1.3 7.8* ± 1.4
Baseline 12 Weeks Group (SEM)
Values are represented as means±standard deviation except group means are ±standard error 
mean. n = 128; CC (n=28), WW (n=28), JC (n=26), NS (n=28), and C (n=18). T = time effect. D = diet 
effect.  T x D = time x diet effect. * = signif icant time effect from baseline p<0.05 (univariate). † = 
signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc 
LSD). All letter superscripts represent signif icance or trends tow ard signif icance from post hoc 
LSD. a = signif icantly different than CC (p < 0.05).  b = signif icantly different than WW (p < 0.05). c 
= signif icantly different than JC (p < 0.05). d = signif icantly different than NS (p < 0.05). e = 
signif icantly different than C (p < 0.05). # = a trend tow ard signif icance from baseline p > 0.05 and 
p < 0.1 (post hoc LSD). f = a trend tow ard siginif icance compared to CC (p > 0.05 and p < 0.1).  g = 
a trend tow ard siginif icance compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard 
siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a trend tow ard siginif icance compared to 
NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance compared to C (p > 0.05 and p < 0.1).  
VO2 max (L/min)
VO2 max 
(ml/kg/min)
Time to 
Exhaustion (min) 
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compared to NS (p=0.024) and C (p=0.001). There was also a trend toward a significant 
increase when comparing WW to the C group (p=0.068), and JC had a greater increase in 
relative peak aerobic capacity compared to the C group (p=0.037) as well. 
When analyzing maximum time to exhaustion, there was a time (Wilks’ Lambda 
p<0.001) and time x diet (Wilks’ Lambda p<0.020) effect. CC (p<0.001), WW (p<0.001), 
JC (p<0.001), and NS (p=0.005) had an increase in time to exhaustion seen at week 12. 
CC (0.8±0.8) had a greater increase in time to exhaustion compared to NS (0.4±0.5 min, 
p=0.032) and C (0.1±0.6 min, p=0.003) at week 12. WW (0.6±0.8 min, p=0.049) and JC 
(0.7±0.9 min, p=0.010) also had greater increase in time to exhaustion compared to the C 
group at week 12.  
 
 
 
Figure 26: Changes from baseline in peak aerobic capacity after 12 weeks. Curves (CC), 
Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). Values are 
delta change means±SD. n=128. When analyzed by Tukey’s LSD post hoc: * significantly 
different from baseline (p<0.05), d significantly different than NS (p<0.05), e significantly 
different than C (p<0.05). 
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Isotonic Strength and Endurance 
Isotonic lower and upper body strength and endurance were measured at baseline 
and after 12 weeks of diet and exercise intervention. Muscular strength was analyzed by 
MANOVA, and muscular endurance was analyzed by MANOVA as well. For isotonic 
lower and upper body strength assessment, there was an overall time (Wilks’ Lambda 
p=0.015) and time by diet (Wilks’ Lambda p=0.003) effect. Changes in lower and upper 
body strength are expressed as percent change from baseline. As denoted in Table 16, CC 
(15.0±21.9%, p=0.001) and C (13.8±22.7%, p=0.010) had an increase in one repetition 
maximum (1RM) for isotonic lower body strength seen at week 12. CC showed a trend 
toward significance compared to WW (p=0.064) and NS (p=0.068) and experienced a 
significantly greater increase compared to JC (p=0.044) at week 12, seen in Figure 27. For 
upper body strength test, CC (8.7±12.5, p=0.001) had a significant increase at week 12. 
WW (4.9±14.8, p=0.065) and JC (5.4±14.0%, p=0.063) showed a trend toward a 
significant increase. CC had a greater increase when compared to NS (p=0.005) and C 
(p=0.023). NS additionally had a significant decrease in upper body 1RM compared to 
WW (p=0.026) and JC (p=0.024), shown in Figure 28.  
There was not a significant time (Wilks’ Lambda p=0.390) or time x diet (Wilks’ 
Lambda p=0.591) effect for muscular endurance. CC was the only group that had a 
significant increase in lower body muscular endurance (22.8±75.1%, p=0.040) at week 
12. Due to changes in peak aerobic capacity, as well as lower and upper body strength and 
endurance, we can accept Ho5 since statistically significant differences were observed 
among groups in variables relating to markers of fitness. 
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Table 16: Changes in lower and upper body strength and endurance. Observed between 
groups at 0, 4, 8, and 12 weeks for Curves (CC), Weight Watchers (WW), Jenny Craig 
(JC), Nutrisystem (NS), and Control (C). 
 
 
Variable Group P-level
CC 169.7
d
± 51.6 192.9
‡
± 67.8 181.3 ± 10.9 T = 0.007
WW 169.8
d
± 43.0 174.9
i
± 50.6 172.4 ± 10.7 D = 0.259
JC 182.2 ± 66.8 179.3 ± 61.9 180.7 ± 11.8 T X D = 0.091
NS 204.7 ± 63.2 207.7 ± 63.6 206.2 ± 11.1
C 178.5 ± 66.1 198.9
‡
± 77.9 188.7 ± 13.6
Mean 180.9 ± 58.4 190.2* ± 64.0
CC 31.1 ± 6.1 33.5
‡
± 6.3 32.3 ± 1.5 T = 0.069
WW 31.5 ± 7.5 32.9
#
± 8.5 32.2 ± 1.4 D = 0.966
JC 30.6 ± 8.6 32.0
#
± 8.6 31.3 ± 1.6 T X D = 0.004
NS 33.6 ± 8.1 32.2
#
± 8.4 32.9 ± 1.5
C 32.1 ± 8.9 31.6 ± 9.4 31.8 ± 1.8
Mean 31.8 ± 7.7 32.5 ± 8.1
CC 14.1 ± 7.5 15.5
b
± 9.7 14.8 ± 1.2 T = 0.530
WW 12.6 ± 5.0 10.5
d
± 3.7 11.5 ± 1.4 D = 0.306
JC 14.8 ± 8.5 14.1 ± 9.3 14.5 ± 1.4 T X D = 0.322
NS 14.3 ± 5.3 15.3 ± 9.3 14.8 ± 1.3
C 13.5 ± 4.6 11.9 ± 2.8 12.7 ± 1.5
Mean 13.9 ± 6.4 13.6 ± 8.0
CC 8.4
j
± 3.5 7.8 ± 3.9 8.1 ± 0.6 T = 0.220
WW 8.0 ± 2.8 8.0
j
± 2.6 8.3 ± 0.6 D = 0.218
JC 8.4
j
± 2.7 7.8 ± 3.3 8.1 ± 0.6 T X D = 0.753
NS 8.3
j
± 5.7 7.0 ± 2.3 7.6 ± 0.6
C 6.2 ± 3.4 6.3 ± 2.1 6.3 ± 0.7
Mean 7.9 ± 3.9 7.4 ± 3.0
Baseline
Values are represented as means±standard deviation except group means are ±standard error mean. n 
= 126; CC (n=28), WW (n=29), JC (n=24), NS (n=27), and C (n=18).T = time effect. D = diet effect.  T x D 
= time x diet effect. * = signif icant time effect from baseline p<0.05 (univariate). † = signif icant diet effect 
p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). All letter superscripts 
represent signif icance or trends tow ard signif icance from post hoc LSD. a = signif icantly different than 
CC (p < 0.05).  b = signif icantly different than WW (p < 0.05).  c = signif icantly different than JC (p < 
0.05). d = signif icantly different than NS (p < 0.05). e = signif icantly different than C (p < 0.05). # = a 
trend tow ard signif icance from baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard 
siginif icance compared to CC (p > 0.05 and p < 0.1).  g = a trend tow ard siginif icance compared to WW 
(p > 0.05 and p < 0.1).  h = a trend tow ard siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a 
trend tow ard siginif icance compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance 
compared to C (p > 0.05 and p < 0.1).  
12 Weeks Group (SEM)
Leg Press 1RM (kg)
Bench Press 1RM 
(kg)
Leg Press 
Endurance
Bench Press 
Endurance
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Figure 27: Changes from baseline in lower body strength 1RM after 12 weeks. Curves 
(CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). 
Values are delta change means±SD. n=126. When analyzed by Tukey’s LSD post hoc: * 
significantly different from baseline (p<0.05), c significantly different than JC (p<0.05). 
 
 
 
 
Figure 28: Changes from baseline in upper body strength 1RM after 12 weeks. Curves 
(CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), and Control (C). 
Values are delta change means±SD. n=126. Analyzed by Tukey’s LSD post hoc: * 
significantly different from baseline (p<0.05), d significantly different than NS (p < 0.05), 
e significantly different than C (p < 0.05). 
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Psychosocial Evaluations 
SF-36 Quality of Life Inventory 
The SF-36 Quality of Life Questionnaire was assessed by MANOVA at 0, 4, 8, 
and 12 weeks of intervention. An overall time (Wilks’ Lambda p<0.001) and time x diet 
(Wilks’ Lambda p=0.001) effect was seen. As seen in Table 17, in the category of physical 
functioning, CC and WW had a significant increase from baseline at weeks 4 (CC 
p=0.001; WW p=0.012), 8 (CC p<0.001; WW p=0.002), and 12 (CC 13.3±18.3, p=0.003; 
WW 8.9±10.5, p=0.041). JC also did at weeks 8 (p<0.001) and 12 (18.3±41.0, p<0.001). 
The C group had a significant increase at week 4 (p=0.23) and showed a trend at week 8 
(p=0.075). In the area of role physical, CC had a significant increase at week 8 (p=0.029) 
and 12 (24.1±68.8, p=0.003), and WW and NS also did at week 4 (WW p=0.027; NS 
p=0.001), 8 (WW p=0.011; NS p=0.003), and 12 (WW 46.4±84.4, p=0.003; NS 
24.1±68.8, p=0.043). JC had significant increases at week 4 (p=0.018) and 8 (p=0.044). 
In the area of bodily pain, JC had a significant increase at week 4 (p=0.018), 8 (p=0.014), 
and a trend upward at week 12 (p=0.087). NS had upward trends at week 4 (p=0.058) and 
8 (p=0.069) as well. For general health, CC and JC had a significant increase at weeks 4 
(CC p=0.001; JC p=0.015), 8 (CC p<0.001; JC p=0.001), and 12 (CC 11.9±13.5, p<0.001; 
JC 5.2±10.7, p=0.036). For the area of mental health, CC and WW had a time effect at 
weeks 4 (CC WW p=0.001), 8 (CC p=0.049; WW p<0.001), and 12 (CC 6.1±10.2, 
p=0.005; WW 5.4±9.8, p=0.011). JC also did at weeks 4 (p=0.038) and 8 (p=0.007). When 
looking at role emotional, there was a significant increase for WW at weeks 4 (p=0.014), 
8 (p=0.037), and 12 (26.2±70.5, p=0.047) and for JC at week 4 (p=0.010) and a trend at 
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Table 17: Changes in quality of life inventory. Observed between groups at 0, 4, 8, and 
12 weeks for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem (NS), 
and Control (C) 
 
 
 
 
 
 
Variable Group Group (SEM) P-level
CC 76.9 ± 20 87.2
‡hj
± 17.8 90.7
‡de
± 17 90.2
‡e
± 17.1 86.3 ± 3.3 T = 0.001  
WW 78.4 ± 15.6 86.1
‡
± 12.7 86.6
‡e
± 13 87.3
‡e
± 13.2 84.6 ± 3.2 D = 0.142
JC 75.4 ± 18 78.3 ± 18.1 88.7
‡ei
± 9.6 93.7
‡ei
± 37.1 84.0 ± 3.3 T x D = 0.005 
NS 80.0
j
± 20.1 82.3 ± 18.6 80.9 ± 22 82.3 ± 22.5 81.4 ± 3.2
C 69.2 ± 24.9 77.8
‡
± 19.4 75.0
#
± 22 72.5 ± 25.7 73.6 ± 4.0
Mean 76.5 ± 19.5 82.7 ± 17.4 85.0 ± 18 86.1* ± 24.9
CC 340.7 ± 75.4 361.1 ± 58.1 375.0
‡
± 48 388.0
‡cd
± 25.4 366.2 ± 10.7 T = 0.001  
WW 326.8 ± 83.6 358.9
‡
± 57.8 366.1
‡
± 53 373.2
‡i
± 49.5 356.3 ± 10.5 D = 0.038
JC 325.9 ± 83.1 361.1
‡
± 56.0 357.4
‡
± 63 350.0 ± 66.1 348.6 ± 10.7 T x D = 0.023 
NS 312.1 ± 90.0 362.5
‡
± 63.6 358.9
‡
± 59 343.8
‡
± 78.4 344.3 ± 10.5
C 327.8 ± 90.7 312.5
abcd
± 88.8 313.9
abcd
± 98 300.0
abcd
± 84.0 313.5
†
± 13.1
Mean 326.5 ± 83.5 354.1 ± 65.2 357.2 ± 65 354.7* ± 67.6
CC 76.0 ± 13.6 77.7
e
± 13.9 79.6
e
± 15.7 78.7 ± 13.0 78.0 ± 2.2 T = 0.028 
WW 74.5 ± 12.2 75.5 ± 13.2 77.8 ± 10.4 73.7 ± 16.6 75.4 ± 2.1  D = 0.046
JC 72.5 ± 17.1 79.8
‡e
± 11.7 80.3
‡e
± 9.5 78.4
#
± 11.9 7.7 ± 2.2 T x D = 0.714 
NS 70.3 ± 18.4 76.0
#j
± 15.1 75.9
#
± 16.3 75.7 ± 16.9 74.5 ± 2.1
C 71.2 ± 14.9 68.5 ± 18.5 71.6 ± 11.7 71.4 ± 16.2 70.7
†
± 2.6
Mean 73.0 ± 15.3 76.0 ± 14.5 77.4 ± 13.2 75.9* ± 15.0
CC 67.9 ± 12.7 76.0
‡e
± 8.7 78.0
‡ei
± 10.2 79.7
‡de
± 9.5 75.4 ± 2.5 T = 0.001  
WW 71.9 ± 14.8 74.7
j
± 13.6 75.2 ± 14.4 74.9
j
± 14.9 74.2 ± 2.4 D = 0.087
JC 73.2 ± 14.6 78.8
‡ei
± 12.1 80.7
‡de
± 12.9 78.4
‡de
± 12.9 77.8 ± 2.5 T x D = 0.053 
NS 69.5 ± 17.1 72.4 ± 15.3 71.8 ± 16.2 70.7 ± 17.0 71.1 ± 2.4
C 66.8 ± 18.4 67.7 ± 17.7 69.4 ± 15.9 67.2 ± 17.3 67.8 ± 3.0
Mean 70.1 ± 15.4 74.3 ± 13.7 75.4 ± 14.3 74.6* ± 14.9
CC 61.1 ± 8.9 65.6
‡e
± 9.1 65.2
‡
± 8.9 67.3
‡de
± 8.3 64.8 ± 1.7 T = 0.001  
WW 58.4 ± 10.6 64.6
‡e
± 8.8 66.0
‡i
± 6.6 63.9
‡
± 11.6 63.2 ± 1.6 D = 0.073
JC 59.7 ± 11.1 63.6
‡e
± 10.1 65.2
‡
± 7.5 62.8 ± 10.5 62.8 ± 1.7 T x D = 0.213 
NS 59.7 ± 13.2 61.4 ± 10.6 61.7 ± 11 60.9 ± 15.2 60.9 ± 1.6
C 56.4 ± 12 57.6 ± 10.8 56.0
abcd
± 11 60.0 ± 9.7 57.5 ± 2.1
Mean 59.3 ± 11.1 62.9 ± 10 63.3 ± 9.6 63.2* ± 11.5
CC 374.1
i
± 46.5 369.1 ± 57.7 369.1 ± 72 382.7
i
± 41.7 373.8 ± 10.7 T = 0.008  
WW 347.6 ± 81.9 379.8
‡j
± 52.4 375.0
‡
± 46 373.8
‡
± 44.8 369.0 ± 10.5 D = 0.352
JC 342.0 ± 75.4 376.5
‡j
± 48.8 365.4
#
± 61.0 356.8 ± 76.1 360.2 ± 10.7 T x D = 0.504 
NS 336.9 ± 83.8 354.8 ± 65.6 346.4 ± 79 352.4 ± 85.3 347.6 ± 10.5
C 340.7 ± 82.9 346.3 ± 77.7 350.0 ± 71 359.3 ± 71 349.1 ± 13.1
Mean 348.7 ± 75.1 366.7 ± 60.2 362.0 ± 66 365.4* ± 65.8
CC 47.7 ± 9.2 50.5 ± 10.7 51.9
‡
± 7.5 49.5 ± 6.5 49.9 ± 0.9 T = 0.412
WW 50.0
e
± 4.8 48.7 ± 7.1 49.1 ± 7.6 51.3
d
± 5.0 49.8 ± 0.8 D = 0.276 
JC 50.5
e
± 8.1 52.8
d
± 15.6 49.5 ± 5.4 49.8 ± 6.5 50.6 ± 0.9 T x D = 0.300 
NS 48.7 ± 5.2 46.2 ± 11.1 50.0 ± 3.4 47.8 ± 8.4 48.1 ± 0.8
C 45.8 ± 6.1 50.7 ± 10.9 50.0
#
± 8.6 48.6 ± 4.0 48.8 ± 1.0
Mean 48.7 ± 7.0 49.6 ± 11.5 50.1 ± 6.6 49.5 ± 6.4
Baseline Week 4 Week 8 Week 12
Physical 
Function
Role Physical
Role Emotional
Mental Health
Social Function
Bodily Pain
General Health
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Table 17: Continued 
 
 
week 8 (p=0.078). When analyzed by MANOVA univariate, there was not a significant 
time (p=0.412) or diet (p=0.275) effect for the variable social function. The average 
change of all the groups was 0.72±9.1. For the variable vitality, a time effect was seen for 
CC, WW, and NS at weeks 4 (CC p=0.003; WW p=0.006; NS p=0.030), 8 (CC p<0.001; 
WW p=0.001; NS p=0.001), and 12 (CC 11.5±13.2, p<0.001; WW 7.7±13.2, p=0.002; NS 
5.7±11.6, p=0.022). JC also had a significant increase in the area of vitality at week 4 
(p=0.050) and 8 (p=0.001), though it was not significant at week 12 (3.9±15.8, p=0.123). 
Body Image Questionnaire 
The Body-Image Questionnaire was analyzed by MANOVA at 0, 4, 8, and 12 
weeks of intervention. An overall time (Wilks’ Lambda p<0.001) effect was seen. Table 
18 shows that CC, WW, JC, and C all had a significant increase from baseline for 
appearance evaluation at weeks 4 (CC p=0.009; WW p=0.024; JC p=0.044), 8 (CC  
 
Variable Group Group (SEM) P-level
CC 52.4 ± 10.5 58.9
‡e
± 8.5 63.5
‡ei
± 10.0 63.9
‡ce
± 9.8 59.7 ± 1.9 T = 0.001  
WW 51.1 ± 13.6 57.0
‡j
± 11.2 59.5
‡j
± 10.3 58.8
‡j
± 13.1 56.6 ± 1.8 D = 0.087
JC 52.4 ± 12.2 56.7
‡j
± 10.4 60.7
‡e
± 7.3 56.3 ± 15.1 56.5 ± 1.8 T x D = 0.280 
NS 53.9 ± 13.9 58.6
‡e
± 12.5 58.6
‡j
± 14.4 59.6
‡j
± 16.0 57.7 ± 1.8
C 49.4 ± 11.0 50.8 ± 10.3 53.1 ± 11.6 51.9 ± 11.4 51.3 ± 2.3
Mean 52.0 ± 12.3 56.8 ± 10.8 59.4 ± 11.2 58.6* ± 13.7
Week 8 Week 12Baseline Week 4
Values are represented as means±standard deviation except group means are ±standard error mean. n = 128; CC (n=27), WW (n=28), JC (n=27), 
NS (n=28), and C (n=18).T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect from baseline p<0.05 (univariate). † = 
signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). All letter superscripts represent 
signif icance or trends tow ard signif icance from post hoc LSD. a = signif icantly different than CC (p < 0.05).  b = signif icantly different than WW (p 
< 0.05).  c = signif icantly different than JC (p < 0.05). d = signif icantly different than NS (p < 0.05). e = signif icantly different than C (p < 0.05). # = a 
trend tow ard signif icance from baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard signif icance compared to CC (p > 0.05 and p < 
0.1).  g = a trend tow ard signif icance compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard signif icance compared to JC (p > 0.05 and p < 
0.1).  i = a trend tow ard signif icance compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard signif icance compared to C (p > 0.05 and p < 0.1).  
Vitality
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Table 18: Changes in body image questionnaire. Observed between groups at 0, 4, 8, 
and 12 weeks for Curves (CC), Weight Watchers (WW), Jenny Craig (JC), Nutrisystem 
(NS), and Control (C). 
 
 
Variable Group Group (SEM) P-level
CC 2.49 ± 0.70 2.78
‡d
± 0.66 2.87
‡d
± 0.72 2.84
‡d
± 0.73 2.75 ± 0.11 T = 0.001 
WW 2.28 ± 0.73 2.52
‡i
± 0.80 2.65
‡i
± 0.88 2.59
‡h
± 0.76 2.51 ± 0.11 D = 0.061
JC 2.25 ± 0.74 2.48
‡i
± 0.70 2.62
‡
± 0.67 2.95
‡d
± 0.75 2.57 ± 0.12 T x D =0.075 
NS 2.21 ± 0.65 2.16 ± 0.74 2.33 ± 0.74 2.38 ± 0.72 2.27 ± 0.11
C 2.22 ± 0.51 2.54
‡i
± 0.52 2.53
‡
± 0.49 2.6.0
‡
± 0.59 2.47 ± 0.14
Mean 2.30 ± 0.68 2.50 ± 0.72 2.60 ± 0.74 2.68* ± 0.74
CC 3.57 ± 0.46 3.55 ± 0.54 3.51 ± 0.53 3.44 ± 0.60 3.52 ± 0.09 T = 0.113 
WW 3.58 ± 0.53 3.47 ± 0.62 3.4
‡h
± 0.55 3.45 ± 0.54 3.47 ± 0.09 D = 0.481
JC 3.76
e
± 0.60 3.53
‡
± 0.76 3.67
j
± 0.67 3.63 ± 0.61 3.65 ± 0.09 T x D = 0.527 
NS 3.63
j
± 0.47 3.4
‡
± 0.83 3.61 ± 0.45 3.52 ± 0.53 3.54 ± 0.09
C 3.36 ± 0.57 3.40 ± 0.60 3.36 ± 0.65 3.46 ± 0.58 3.39 ± 0.11
Mean 3.59 ± 0.53 3.47 ± 0.67 3.52 ± 0.57 3.50 ± 0.56
CC 2.56 ± 0.51 2.86
‡dh
± 0.54 2.92
‡deh
± 0.59 3.10
‡bdeh
± 0.60 2.86 ± 0.09 T = 0.003  
WW 2.59 ± 0.45 2.61 ± 0.73 2.81
#j
± 0.65 2.72 ± 0.81 2.68 ± 0.09 D = 0.030
JC 2.46 ± 0.49 2.51 ± 0.86 2.63 ± 0.60 2.79
‡j
± 0.48 2.60 ± 0.09 T x D = 0.296 
NS 2.50 ± 0.65 2.45 ± 0.65 2.55 ± 0.52 2.58 ± 0.56 2.52 ± 0.09
C 2.46 ± 0.40 2.54 ± 0.80 2.50 ± 0.68 2.45 ± 0.65 2.49
†
± 0.10
Mean 2.52 ± 0.51 2.60 ± 0.72 2.70 ± 0.62 2.75* ± 0.65
CC 2.89 ± 0.75 3.43
‡
± 0.86 3.31
‡
± 0.70 3.19
‡c
± 0.94 3.21 ± 0.12 T = 0.001  
WW 2.82 ± 0.66 3.04 ± 0.97 3.06
#cd
± 0.80 3.00
ci
± 0.87 2.98 ± 0.12 D =0.081
JC 2.94
j
± 0.57 3.33
‡
± 1.08 3.63
‡e
± 0.80 3.64
‡e
± 0.62 3.39 ± 0.12 T x D =0.452 
NS 3.00
e
± 0.68 3.27 ± 1.01 3.49
‡j
± 0.70 3.34
‡
± 0.57 3.28 ± 0.12
C 2.58 ± 1.02 3.09
‡
± 1.05 3.06
‡
± 1.10 3.14
‡
± 0.99 3.00 ± 0.14
Mean 2.86 ± 0.73 3.24 ± 0.99 3.32 ± 0.80 3.26* ± 0.83
CC 4.33 ± 0.74 4.24 ± 0.54 4.24 ± 0.56 4.00
‡d
± 0.55 4.20 ± 0.10 T = 0.004 
WW 4.34 ± 0.52 4.07 ± 1.02 4.28 ± 0.47 4.07
#i
± 0.95 4.19 ± 0.10 D =  0.606 
JC 4.46 ± 0.44 3.94
‡
± 1.27 4.17
‡
± 0.50 4.22 ± 0.64 4.20 ± 0.10 T x D = 0.743 
NS 4.55 ± 0.44 4.27 ± 1.01 4.30
#
± 0.79 4.43 ± 0.50 4.39 ± 0.10
C 4.48 ± 0.73 4.23 ± 1.24 4.15
#
± 1.08 4.08
‡
± 1.20 4.23 ± 0.12
Mean 4.43 ± 0.58 4.15 ± 1.02 4.23 ± 0.68 4.16* ± 0.79
CC 31.07 ± 5.45 30.76 ± 4.16 31.38 ± 5.21 33.03
b
± 5.17 31.56 ± 0.86 T = 0.091
WW 29.41
d
± 5.83 28.59 ± 7.71 29.69
c
± 4.17 29.62 ± 7.33 29.33 ± 0.86 D = 0.248 
JC 31.78 ± 5.23 29.37 ± 10.00 32.93
j
± 4.80 31.96 ± 5.20 31.51 ± 0.89 T x D = 0.886 
NS 32.54 ± 5.57 30.36 ± 8.43 31.54 ± 5.80 32.32 ± 5.92 31.69 ± 0.88
C 31.05 ± 4.93 30.25 ± 8.56 29.85 ± 9.96 30.25 ± 9.22 30.35 ± 1.04
Mean 31.16 ± 5.47 29.84 ± 7.86 31.13 ± 6.05 31.50 ± 6.60
CC 23.83 ± 2.58 23.45 ± 1.90 23.55
e
± 2.65 23.31 ± 2.47 23.53 ± 0.38 T = 0.118 
WW 23.69 ± 2.41 22.62 ± 4.72 24.21
e
± 2.37 22.52
#ci
± 4.69 23.26 ± 0.38  D = 0.045
JC 24.48
e
± 2.08 22.33
‡
± 6.78 24.41
e
± 1.78 24.67
e
± 1.80 23.97 ± 0.40 T x D = 0.616 
NS 24.11
j
± 2.57 23.07 ± 5.14 23.54
j
± 2.32 24.07
e
± 2.05 23.70 ± 0.39
C 22.75 ± 2.17 22.30 ± 5.53 21.80 ± 5.65 21.80 ± 5.59 22.16
†
± 0.46
Mean 23.83 ± 2.41 22.79 ± 4.95 23.60 ± 3.12 23.35 ± 3.60
Values are represented as means±standard deviation except group means are ±standard error mean. n = 133; CC (n=29), WW (n=29), JC (n=27), NS 
(n=28), and C (n=20).T = time effect. D = diet effect.  T x D = time x diet effect. * = signif icant time effect from baseline p<0.05 (univariate). † = 
signif icant diet effect p<0.05 (univariate). ‡ = signif icant time effect from baseline p<0.05 (post hoc LSD). All letter superscripts represent signif icance 
or trends tow ard signif icance from post hoc LSD. a = signif icantly different than CC (p < 0.05).  b = signif icantly different than WW (p < 0.05).  c = 
signif icantly different than JC (p < 0.05). d = signif icantly different than NS (p < 0.05). e = signif icantly different than C (p < 0.05). # = a trend tow ard 
signif icance from baseline p > 0.05 and p < 0.1 (post hoc LSD). f = a trend tow ard siginif icance compared to CC (p > 0.05 and p < 0.1).  g = a trend 
tow ard siginif icance compared to WW (p > 0.05 and p < 0.1).  h = a trend tow ard siginif icance compared to JC (p > 0.05 and p < 0.1).  i = a trend 
tow ard siginif icance compared to NS (p > 0.05 and p < 0.1).  j = a trend tow ard siginif icance compared to C (p > 0.05 and p < 0.1).  
Week 12
Appearance 
Evaluation 
Appearance 
Orientation 
Body Area 
Satisfaction 
Overweight 
Preoccupation 
Self-Classified Weight 
Social Physique 
Anxiety 
Rosenberg Self-
Esteem 
Baseline Week 4 Week 8
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p=0.001; WW p=0.001; JC p=0.002), and 12 (CC 0.35±0.82, p=0.007; WW 0.31±0.55, 
p=0.016; JC 0.70±0.86, p<0.001). JC had a significantly greater increase compared with 
WW (p=0.033) and NS (p=0.005) and showed a trend when compared to CC (p=0.055) at 
week 12. When assessing appearance orientation by MANOVA univariate, there was not 
an overall significant time (p=0.113) or diet (p=0448) effect. In the category of body area 
satisfaction, CC had a time effect at weeks 4 (p=0.032), 8 (p=0.001), and 12 (0.54±0.56, 
p<0.001). JC also had a significant increase at week 12 (0.33±0.48, p=0.012). Also at 
week 12, CC had a greater increase in score compared to WW (0.13±0.87, p=0.024), NS 
(0.08, 0.82, p=0.013), and the C group (-0.01±0.52, p=0.007). In the area of overweight 
preoccupation, there was an increase in score for CC, JC, and C at weeks 4 (CC p=0.004; 
JC p=0.043; C p=0.022), 8 (CC p=0.002; JC p<0.001; C p=0.003), and 12 (CC 0.30±0.78, 
p=0.043; JC 0.69±0.62, p<0.001; C 0.56±1.13, p=0.002). NS also had an increased score 
at week 8 (p<0.001) and 12 (0.34±0.53, p=0.026). By week 12, JC had a significantly 
greater increase in scoring compared to WW (p=0.014) and a trend was seen when 
compared with CC (p=0.067) for overweight preoccupation. For self-classified weight, 
CC (-0.33±0.70, p=0.031) and C (-0.40, 1.37, p=0.029) had a significant decrease at week 
12. By week 12, WW also showed a downward trend (p=0.069). JC had a decrease at week 
4 (p=0.005) and week 8 (p=0.046), though not significant at week 12 (p=0.126). 
MANOVA univariate analysis showed no diet (p=0.755) or time x diet (p=0.743) effect 
for self-classified weight. In the category of social physique anxiety, when analyzed by 
MANOVA univariate, there was only a trend toward a significant time (p=0.091) effect 
and no time x diet (p=0.886) effect. For the variable of Rosenberg self-esteem, no overall 
116 
 
MANOVA univariate time (p=0.118) effect or time x diet (p=0.616) effect was observed. 
Due to changes seen in the SF-36 Quality of Life Questionnaire and the Body Image 
Questionnaire we are able to accept Ho8 since statistically significant differences were 
observed among groups in variables relating to psychological evaluations. 
Cost to Benefit Assessment 
Analysis was run on food logs of 10 participants to assess the cost to benefit ratio 
of each group. Participants in the CC and WW groups experienced greater losses in weight 
(CC -0.013±0.01; WW -0.016±0.01; JC -0.005±0.003; NS -0.011±0.01; C 0.001±0.016 
lbs/$, p<0.001), waist circumference (CC -0.0017±0.003; WW -0.0027±0.004; JC -
0.0006±0.001; NS -0.0012±0.002; C 0.0018±0.006 inches/$; p<0.001), hip circumference 
(CC -0.0022±0.002; WW -0.0020±0.002; JC -0.0008±0.001; NS -0.0016±0.002; C 
0.0008±0.003 inches/$; p<0.001), fat mass (CC -4.8±4.5; WW -4.0±4.9; JC -1.3±1.3; NS 
-2.2±2.3; C -0.08±0.04.8 g/$, p<0.001), and body fat percentage (CC -0.0033±0.004; WW 
-0.0014±0.004; JC -0.0005±0.0009; NS -0.0002±0.0016 %/$; C -0.0001±0.004.8, 
p<0.005) per dollar spent compared to those in JC, NS, and C. The WW group also had a 
greater decrease in fat-free mass (CC -0.72±2.8; WW -2.87±3.7; JC -0.69±0.8; NS -
2.3±2.1; C 0.33±5.4 g/$, p<0.005) per dollar spent compared to CC, JC, NS, and C. 
Further, all diet groups experienced an improved peak aerobic capacity (CC 
0.0034±0.003; WW 0.0006±0.010; JC 0.0002±0.002; NS 0.0007±0.001; C -0.0052±0.013 
ml/kg/min/$, p<0.005) per dollar spent when compared to the control. 
 
 
117 
 
CHAPTER V 
SUMMARY AND CONCLUSIONS* 
 
Summary 
Results of the current study support findings from previous studies that weight-
loss programs that incorporate resistance exercise combined with higher protein and lower 
carbohydrate and fat yield greater improvements in body composition. There is a greater 
maintenance of fat-free mass and a greater decrease in fat mass and body fat percentage 
as well as improving various markers of health and fitness [28, 31, 152, 209, 210]. 
Analysis of energy intake revealed no significant differences in energy intake at baseline, 
and no significant differences were seen between diet groups in average energy intake 
throughout the study.  All groups had a decrease in energy intake, with an average intake 
of 1,403±427 kcal/day. Further, all diet groups experienced a decrease in weight (-4.0±4.2 
kg, p<0.001), body mass index (-4.0±2.1 kg/m2, p<0.001), waist circumference (-2.7±5.9 
cm, p<0.001), hip circumference (-3.4±4.4 cm, p<0.001), fat mass (-2.5±3.2 kg, p<0.001), 
body fat percentage (-1.1±2.6%, p<0.001), resting heart rate (-3.0±9.8 bpm, p<0.001), and 
resting systolic blood pressure (-4.1±13.2 mmHg, p=0.005), and an improved glucose to 
insulin ratio (36.4±72.1%, p=0.001). All diet groups also maintained relative resting 
energy expenditure (0.09±2.03 kcal/kg/day, p=0.008). Though all diet groups lost weight 
and had improvements in anthropometrics and various markers of health, CC had greater 
                                                 
* Reprinted with permission from Dalton R, Baetge C, Lockard B, Levers K, Galvan E, Jagim A, Simbo S, 
Byrd M, Jung Y, Oliver J: Analysis of efficacy and cost effectiveness of popular weight loss and fitness 
programs. Journal of the International Society of Sports Nutrition 2013, 10(Suppl 1):P4.    
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improvements in body composition, blood pressure, peak aerobic capacity, muscular 
strength, and hormone ratios and trended toward improvements in blood lipid ratios. These 
findings are similar to previous findings that following a comparative diet protocol 
combined with structured resistance training yields greater results [31, 152] than other 
weight-loss approaches. The CC diet and exercise protocol was generally more effective 
compared to other commercial weight-loss programs that had caloric restriction but where 
exercise was solely encouraged. The other commercial diets were able to provide 
improvements in weight-loss and waist and hip circumference as well as maintaining REE, 
though the CC group was able to have the same and even greater improvements while still 
maintaining fat-free mass and having the greatest decrease in fat mass and body fat 
percentage. 
The findings in the present study revealed that CC was the only group with a 
significant increase in relative protein intake (0.15±0.30 g/kg/day, p=0.039) combined 
with a decrease in relative carbohydrate intake (-0.63±0.95, p=0.005). Though, all diet 
groups experienced a decrease in fat intake, with an average decrease of -0.24±0.34 
g/kg/day, p<0.001. Additional studies that compared Weight Watchers with other 
commercial diet groups did not report nutritional intake [150, 160]. Further, studies that 
have evaluated the Jenny Craig [166, 167] and Nutrisystem [169] programs have not 
included a dietary breakdown of energy intake. Participants in the present study did a fairly 
good job achieving energy intake and macronutrient intake while following these diets 
compared to results in previously reported studies [31, 164, 165]. It is also important to 
note though, that even though the CC group was assigned a 45:25:30 PRO:CHO:FAT 
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ratio, participants were only able to obtain about 25.7±6.6% protein in their diet on 
average, which is similar to previous findings, as well [31, 152, 209, 210]. 
Weight-loss programs that include exercise, specifically resistance exercise, may 
contribute to greater improvements in body composition [28, 146]. In that regard, CC had 
a significant increase in total physical activity (3,801±8,668 MET-min/wk, p=0.012) 
through the first eight weeks and had the greatest increase after 12 weeks, though not 
significant (2,429±8,901 MET-min/wk, p=0.163). CC also experienced the greatest 
decrease in fat mass (-3.8±4.0 kg, p<0.001) and body fat % (-2.7±3.4%, p<0.001) and was 
the only group that maintained fat-free mass (-0.19±2.00 kg, p=0.631). Previous studies 
that have been conducted on the effectiveness of Weight Watchers, Jenny Craig, and 
Nutrisystem have placed a large focus on weight loss versus including other components 
of body composition. Our current analysis had similar findings in weight loss for the 
participants in WW compared to previous results [150, 158, 164]. However, Jenny Craig 
studies have been more long-term of 12 and 24 months [166, 167], and our NS participants 
did not experience as great a weight loss compared to a previous study conducted by Foster 
et al. [169]. 
The current study also found that all of the groups, except for WW, had a decrease 
in resting heart rate with an average decrease of -3.0±9.8 bpm (p<0.001). CC though, was 
the only group to have a decrease in both systolic blood pressure (-7.6±14.2 mmHg, 
p=0.002) and diastolic blood pressure (-3.6±7.3 mmHg, p=0.045). A decrease in blood 
pressure was also found by Kersick and colleagues [31] in groups with comparable total 
energy intake and macronutrient intake combined with resistance exercise. Heart rate and 
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blood pressure changes in the WW group of the current study though were not significant 
and actually opposed previous findings by Dansinger et al. [164]. When assessing blood 
lipids, a trend toward a decrease in total cholesterol to HDL-cholesterol ratio (-4.9±11.3%, 
p=0.053) was also seen in the CC group, and CC additionally, had the greatest increase in 
glucose to insulin ratio (57.8±72.9%, p=0.012). Some differing results were observed in 
changes in blood lipids between the current analysis and the study by Kerksick et al. [31] 
after 14 weeks of a comparable diet and exercise protocol. However, a notable similarity 
was that decreases in leptin levels in the four diet groups of the current study were the 
greatest after the first four weeks of intervention. These results compared to their findings 
which revealed a significant decrease after two weeks of intervention, where caloric 
restriction was the greatest. A study conducted by Morgan et al. [165] found that 
triacylglycerides, LDL-C, and HDL-C all significantly decreased in the Weight Watchers 
group after 2 months (p<0.001 for all variables). Further, Dansinger and colleagues [164] 
found that the subjects in Weight Watchers had a decrease of -17.9 mg/dL in total 
cholesterol (p<0.01), -14.7 mg/dL for LDL-cholesterol (p<0.01), and -2.2 µIU/mL 
(though not significant) for insulin after 2 months. In contrast, the only significant finding 
in lipids or hormones in the WW group of the current study at week 8 was a significant 
increase in LDL-cholesterol (1.6±23.0%, p=0.045) and a significant increase in glucose 
to insulin ratio (44.7±100.0%, p=0.014). Other more long-term studies conducted with 
WW [160] and JC [166] found additional improvements in insulin levels. Interestingly, a 
focus of NS meals is the glycemic index (GI) and the goal to consume carbohydrates with 
a low GI. We would have expected to see significant improvements in glucose and/or 
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insulin levels, though neither was observed. Though a lowered GI may aid in feelings of 
satiety, decreasing carbohydrates without the accompaniment of resistance exercise, did 
not yield improvements in hormone levels. Once again, it is important to note that it would 
be expected that the required exercise component of the CC group would have a positive 
influence on markers of health, such as heart rate, blood pressure, lipids, and hormones.  
Further findings of the current study showed that CC also had the greatest increase 
in relative peak aerobic capacity (2.5±2.9 ml/kg/min, p<0.001) and was also the only diet 
group that increased in lower body (15.0±21.9% p=0.001) and upper body (8.7±12.5% 
p=0.001) strength. This too was to be expected after participating in a supervised exercise 
training protocol compared to the other diet groups, where exercise was only encouraged. 
Rock and colleagues [167] included a step-test as part of their study design, and found that 
all three groups: center-based Jenny Craig, telephone-based Jenny Craig, and the usual 
care group all showed improvements in cardiopulmonary fitness (p<0.001) as determined 
by the step-test protocol. However, since previous research of the other diet groups focus 
on a dietary intervention, the effects of those diets on fitness parameters have not been 
reported that we are aware. Also noteworthy, NS had the greatest intake of percent protein 
(26.9±5.3%), though not significantly greater compared to CC (25.7±6.6%, p=0.306). 
Nonetheless, NS did not experience improvements in lower (p=0.365) or upper body 
strength (p=0.182). Which, increased protein without resistance training would not expect 
to yield the same improvements that were seen in the CC group. It is evident that 
participation in an exercise protocol, as in the CC group, led to greater improvements in 
cardiovascular fitness as well as muscular strength. 
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After assessment of the cost of each diet group, estimated total costs were (CC 
879±147, WW 558±130, JC 2,600±101, NS 1,062±103, C 422±198 $/90 days) per 
program. As can be seen, the JC and NS were more costly than the CC and WW 
approaches, which may be a limiting factor for some individuals. These findings suggest 
that given the efficacy, the CC program was a more cost effective approach in terms of 
promoting fat loss and improving body composition. 
Conclusions 
As supported by our findings, diets that are higher in protein and lower in 
carbohydrates and fat combined with a structured resistance exercise protocol may be able 
to produce the greatest success [28, 31, 128, 209, 210] in a weight-loss program. The 
central hypothesis evaluated in this study was that adherence to a higher protein, 
carbohydrate restricted, low fat diet while participating in a supervised resistance exercise 
program would result in more favorable changes in body composition and better 
maintenance in fat free mass and resting energy expenditure during a weight loss program.  
Results of the present study support this hypothesis. In this regard, participants following 
the CC diet and exercise program had greater increases in overall physical activity and 
experienced greater fat loss, better maintenance of fat free mass, and greater reductions in 
body fat percent compared to other diet approaches. These improvements then led to more 
favorable changes in various markers of fitness and health. The approach of using meal 
plans for diet adherence and frequent contact with exercise professionals was also more 
cost effective than other approaches [208].   
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There are several factors that could have influenced the results. First, participants 
in the CC group had a much greater face-to-face interaction with exercise personnel and 
trained with other women who were following the diet, which could have enhanced 
adherence and dietary compliance. Second, individuals who complete a diet and exercise 
program where the cost of the program is provided and compensation is provided may 
have greater motivation to follow the diet and exercise protocol compared to an individual 
who would need to cover the expenses on his/her own. Further, participants in the CC 
group were not allowed to continue in the study if they did not maintain at least a 75% 
compliance rate for workouts (three of the four per week). Additional research should 
investigate whether dietary supplementation with purported health and/or weight loss 
nutrients may provide additional benefits. Further research should also continue to 
evaluate the cost to benefit ratio along with which population may benefit the most from 
a given diet protocol. Nonetheless, results indicate that participants adhering to the CC 
program that incorporated a higher protein, lower carbohydrate and fat diet while 
participating in a supervised resistance-exercise based program was more effective than 
other commercial weight loss programs.  
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APPENDIX A 
INFORMED CONSENT 
 
CONSENT FORM 
The effects of the Curves 90-Day Fitness Challenge on health outcomes in women 
 
Introduction 
The purpose of this form is to provide you information that may affect your decision as to whether 
or not to participate in this research study.  If you decide to participate in this study, this form will 
also be used to record your consent. 
 
You have been asked to participate in a research project comparing the Curves International fitness 
and weight loss program to other popular weight loss programs.  The purpose of this study is to 
determine the effects of the new Curves 90-Day Fitness Challenge on health outcomes in women.  
You were selected to be a possible participant because you met all entrance criteria for this study.  
This study is being sponsored/funded by Curves International.      
 
What will I be asked to do? 
If you agree to participate in this study, you will first be asked to sign an Informed Consent statement 
in compliance with the Human Subject’s Protection Program (HSPP) at Texas A&M University and 
the American College of Sports Medicine.  You will then be familiarized to the study requirements, 
food log recording and tests to be conducted during the study.  This session will take approximately 
one hour to complete.  Prior to reporting to the lab for baseline testing, you will record all food that 
you eat on dietary record forms for four days (including one weekend day).  You will not exercise 
for 48 hours nor eat for 12 hours prior to reporting to the lab for baseline testing.  You will then 
undergo a battery of tests as described in Table 1.  You will fill out a Demographic Form, a Health 
History Form, A Radiation Safety Form, a Quality of Life Questionnaire, a Body Image Questionnaire 
and an eating Satisfaction Questionnaire.  You will also be required to report any adverse side 
effects that you may experience on a weekly basis.  .   
 
You will then continue with the tests as described in Table 1.  You will first be weighed and have 
your resting energy expenditure (REE) determined.  This will involve lying down on an exam table 
and having a light blanket placed over you to keep you warm and placing ear plugs in your ears to 
reduce distractions.  A see through plastic canopy will then be placed over your neck and head so 
that the air that you breathe can be measured for oxygen and carbon dioxide.  You should stay 
motionless without going to sleep for 15-minutes so that your resting energy expenditure can be 
calculated.  You will then donate up to approximately 30 milliliters (6 teaspoons) of venous blood 
from a vein in your arm. Blood samples will be obtained by standard/sterile procedures using a 
needle inserted into a vein in your arm and will later be analyzed. Personnel who will be taking your 
blood are experienced in phlebotomy (procedures to take blood samples) and are qualified to do so 
under guidelines established by the Texas Department of Health and Human Services.  This will 
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take about 5-minutes.  You will then have your total body water determined using a bioelectrical 
impedance analyzer (BIA).  The BIA analysis will involve lying down on your back on a table and 
having two small electrodes placed on your right hand and your right foot.  The analyzer wires will 
be attached and a small and safe current (500 micro-amps at a frequency of 5- kHz) will pass 
through your body so that the amount of water can be measured. This analyzer is commercially 
available and has been used in the health care/fitness industry as a means to assess body 
composition and body water for over 20 years. The use of this device has been approved by the 
Food and Drug Administration (FDA) to assess total body water and the current to be used has 
been deemed safe.  Your body composition and bone density will then be determined by using a 
Discovery W dual energy x-ray absorptiometry (DEXA). This will involve lying down on your back 
on the DEXA exam table in a pair of shorts or a gown for about 6 minutes.  A low dose of radiation 
will scan your entire body to determine the amount of fat weight, muscle weight, and bone weight. 
You will be exposed to an x-ray dose that is similar to the amount of natural background radiation a 
person would receive in one month while living in College Station.  After this test, you will have 
resting blood pressure determined using a blood pressure cuff and stethoscope and heart rate 
determined by taking your pulse.  You will then be prepared to perform a maximal treadmill test.  
You will have your right and left shoulder, right and left part of your stomach, and several places 
around your upper chest and below your bra line rubbed with alcohol gauze.  Ten (10) 
electrocardiograph (ECG) electrodes will then be placed on your shoulders, chest, and stomach and 
you will be attached to an ECG to evaluate your heart.  You will then be positioned on the treadmill 
and a sterile mouthpiece will be placed in your mouth and a mouthpiece holder will be placed on 
your head.  A nose clip will be placed on your nose and that the air you breathe will be measured 
for oxygen and carbon dioxide content.  Once the equipment is attached, you will be given 
instructions to begin walking on the treadmill.  You will then perform an exercise test that involves 
increasing the speed and grade you are walking on the treadmill until you reach your maximal effort.  
Heart rate, ECG tracings, blood pressure and your ratings of exertion will be monitored throughout 
the test.  Once you reach your maximum, you will undergo a slow walking and seated recovery 
period.  This test will take about 30 minutes to complete.  You will then perform a one repetition 
maximum (1RM) and 80% of 1RM endurance repetition test on the bench press and hip/leg sled 
using standard procedures.  This will involve warming up and performing successive one repetition 
lifts on the bench press until you determine your 1 RM.  You will then rest for 5-minutes and lift 80% 
of your 1 RM as many times as you can.  You will then rest for 10-minutes and follow the same 
procedure in determining your 1 RM and 80% of 1 RM on the hip/leg sled.  These tests will take 
about 20 minutes to complete.  The same battery of tests will be performed at the post-study 
assessment 16 weeks into the study protocol.  All the assessments minus the exercise tests will 
also be performed at 4, 6 10 and 12 weeks into the study protocol.  Each testing session will take 
between 1.5 and 3 hours to complete.  In the event of an emergency during an exercise test proper 
emergency response protocols (calling 9-911 for serious injury or a medical emergency, calling 
Biosafety/EHS for cleanup assistance or spill team response, calling UPD for incidents in public 
areas, retrieving AED located in the lab, performing CPR or other First Aid techniques, etc.)  will be 
followed by the Exercise & Sport Nutrition Laboratory (ESNL) Staff depending on the severity of the 
emergency.         
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After baseline testing, you will be matched based on age, BMI, activity level and eating habits and 
randomized into one of six intervention groups as described in Table 2.  The Operating Systems 
(OS) Questionnaire (or Initial Assessment) will be used to help determine the group assignments.  
This will include a high protein/low fat diet group (30% CHO, 45% PRO, 25% FAT, N=40), a high 
carbohydrate/low fat diet group (45% CHO, 30% PRO, 25% FAT, N=40), a Weight Watchers diet 
group (N=40), a Jenny Craig diet group (N=40), a Nutrisystem diet group (N=40) and a control group 
(N=40).  If you are randomized into one of the first two groups (N=80 total) you will diet for 7 days 
at 1,200 kcals/day and then 1,500 kcals/day for the remaining 11 weeks of the study.  If you are in 
one of the first two groups you will meet weekly one on one with your weight loss coach for the 
duration of the study for weekly weigh-ins.  Each meeting will take place in the ESNL and will last 
approximately 15 minutes.  The coach will guide you through each phase of the program, assist 
with meal planning, assist with goal setting and provide accountability and encouragement in order 
to meet your fitness and nutrition goals.  If you are randomized into the third group (N=40) you will 
follow the Weight Watchers Momentum Program that is based on their four pillar approach (food, 
exercise, behavior and support).  Every food has a POINTS value, based on its calories, fat and 
fiber.  The Momentum program uses POINTS values to help keep track of what you eat.  A POINTS 
“budget” will be personalized for you at the weekly meetings.  You will be required to attend at least 
one meeting per week at the local Weight Watchers facility located at 4001 E. 29th Street, Suite 112 
in the Carter Creek Center in Bryan, Texas.  Membership dues/passes to the Weight Watchers 
program/facility will be covered for you during the duration of the study.  If you are randomized into 
groups four or five (N=80 total), you will follow the dietary guidelines set forth by those respective 
plans.  The sixth group (N=40) will act as a control group.  If you are randomized into this group you 
will not follow a prescribed nutrition program but will continue with your normal daily habits.  
Everyone, regardless of group assignment, will keep a food record and food frequency log to monitor 
dietary compliance.     
 
If you are randomized to participate in the first two groups (N=80 total) you will participate in the 
Curves 30-minute fitness program three times per week throughout the investigation.  The Curves 
program involves performing thirteen hydraulic resistance exercise machines that utilize 
bidirectional resistance that work all major muscle groups.  These are interspersed with floor-based 
calisthenics exercises designed to maintain an elevated heart rate.  Research has shown that 
exercise intensity averages 65% of maximal aerobic capacity and that participants generally perform 
50 – 75% of 1 repetition maximum on the main exercise machines.  The new Curves equipment 
includes the attached force measurement and feedback system.  You will be instructed to push hard 
enough to generate a green light on the feedback panel for each repetition.  You will be instructed 
to wear heart rate monitors (HR) to access exercise intensity.  All exercise sessions will be held in 
the ESNL.  Research Assistants will monitor your exercise sessions and record your attendance. 
You will also be given a pedometer and will be recording the number of steps taken each day. On 
the days you do not use the Curves equipment, you will be encouraged to walk for 30-minutes at a 
brisk pace (60 – 80% of heart rate reserve). If you are randomized to participate in third group 
(N=40) you will start by focusing on the food plan and then incorporate the specifics of activity a 
week alter once you have had the chance to get conformable with the eating plan.  After a week of 
reducing sedentary behavior, the POINTS Activity System is introduced.  In a way that complements 
the POINTS values of food, a formula that calculates the POINTS values for activity is used.  The 
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formula is based on body weight, the amount of time the activity is done, and the level of intensity.  
This method enables you to do any exercise or activity that is enjoyable and fits within your lifestyle.  
If you are assigned to groups four, five or six (N=120 total) you will not follow a prescribed exercise 
program but will continue your normal daily habits.  Everyone, regardless of group assignment, will 
be required to complete activity logs to monitor exercise frequency and intensity.       
 
Please do your best to:  1) follow the instructions outline by the investigators; 2) show up to all 
scheduled testing and training sessions; and 3) follow the diet prescribed and do not take any other 
nutritional supplements or performance enhancing aids during this study (i.e., vitamins/minerals, 
creatine, HMB, androstenedione, DHEA, etc).  In addition, please do not take any non-medically 
prescribed medications and report any medication that is prescribed for you to take during this study.  
If you take any other nutritional supplements or medications during the course of the study that may 
affect vitamin/mineral status, body composition, or strength you may be removed from the study.     
 
What are the risks involved in this study? 
The risks associated with this study are:  You will be exposed to a low level of radiation during the 
DEXA body composition tests, which is similar to the amount of natural background radiation you 
would receive in one month while living in College Station.  In addition, a very low level of electrical 
current will be passed through your body using a bioelectrical impedance analyzer (BIA). This 
analyzer is commercially available and has been used in the health care/fitness industry as a means 
to assess body composition and body water for over 20 years.  The use of the BIA and DEXA 
analyzers have been shown to be safe methods of assessing body composition and total body water 
and are approved by the FDA.  You will donate about 6 teaspoons (30 milliliters) of venous blood 
four (4) times during the study using standard phlebotomy procedures.   This procedure may cause 
a small amount of pain when the needle is inserted into the vein as well as some bleeding and 
bruising. You may also experience some dizziness, nausea, and/or faint if you are unaccustomed 
to having blood drawn.  The exercise tests that will be performed may cause symptoms of fatigue, 
shortness of breath, and/or muscular fatigue/discomfort.  The exercise tests may also cause short-
term muscle soreness and moderate fatigue for several days following the tests.  You may also 
experience muscle strains/pulls during the exercise testing and/or training program.  However, 
exercise sessions will be conducted by trained personnel and monitored to ensure you follow 
appropriate exercise guidelines.  You will follow a prescribed dietary regimen involving consuming 
1,200 or 1,500 calories per day during various phases of the program.  In addition, one group will 
ingest a high percentage of calories in the form of protein.  Although the total amount of total protein 
is not excessive (100-220 grams/day or 1.1 - 2.3 grams/kg/day for a 95 kg female) it may be higher 
than you are accustomed to ingesting and may exceed recommended protein intake for active 
individuals (i.e., 1-2 grams/kg/day).  As a result, you may experience weight loss or gain, feelings 
of hunger or fullness, and/or changes in appetite and/or mood during various phases of the dietary 
intervention.     
What are the possible benefits of this study? 
The possible benefit you may receive from participation in this study is increased physical fitness and 
improvements in body composition.  You may also gain insight about your health and fitness status from the 
assessments that will be performed.        
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Do I have to participate? 
No.  Your participation is voluntary.  You may decide not to participate or to withdraw at any time 
without your current or future relations with Texas A&M University being affected.   
 
Will I be compensated? 
You will receive $125 (i.e., $25 for each familiarization and experimental session) upon completion 
of the study.  Disbursement will occur upon completion of all sessions and after all study related 
materials (food logs, training logs, etc.) are turned in.  Those who do not complete the study will be 
compensated on a pro-rated basis depending on the total number of sessions completed (i.e. a 
participant who attends the familiarization session and completes only one experimental session is 
able to receive $50). 
 
Who will know about my participation in this research study? 
The records of this study will be kept private.  No identifiers linking you to this study will be included 
in any sort of report that might be published.  Research records will be stored securely and only Mr. 
Christopher Rasmussen and Dr. Richard Kreider will have access to the records.   
 
Whom do I contact with questions about the research?  
If you have questions regarding this study, you may contact Dr. Richard Kreider, 945-1333, 
rkreider@hlkn.tamu.edu or Mr. Christopher Rasmussen, 458-1741, crasmussen@hlkn.tamu.edu.  
 
Whom do I contact about my rights as a research participant?   
This research study has been reviewed by the Human Subjects’ Protection Program and/or the 
Institutional Review Board at Texas A&M University.  For research-related problems or questions 
regarding your rights as a research participant, you can contact these offices at (979)458-4067 or 
irb@tamu.edu. 
 
Signature   
Please be sure you have read the above information, asked questions and received answers to your 
satisfaction.  You will be given a copy of the consent form for your records.  By signing this 
document, you consent to participate in this study. 
 
Signature of Participant: ___________________________________________    Date: 
______________ 
 
Printed Name: 
________________________________________________________________________   
 
Signature of Person Obtaining Consent: _____________________________    Date: 
______________ 
 
Printed Name: 
________________________________________________________________________ 
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APPENDIX B 
PERSONAL HISTORY   
Texas A&M University 
EXERCISE & SPORT NUTRITION LABORATORY 
 
Personal Information 
 
Name:  
_____________________________________________________________________________
_                                                                                                                                                   
Address:  
____________________________________________________________________________ 
                                                                                                                                                  
 
City:                                        State:                Zip Code              SS# 
______________________ 
 
Home Phone:     (      ) ____________________  Work Phone: (      ) ____________________                                
 
Beeper:  (      ) ____________________  Cell Phone: (      ) ____________________
  
 
Fax:  (      )                               E-mail address: _________________________ 
 
Birth date:            /            /              Age:  __________  Height:  __________  Weight:  
__________                 
 
Exercise History/Activity Questionnaire 
 
1. Describe your typical occupational activities. 
 
 
2. Describe your typical recreational activities 
 
 
3. Describe any exercise training that you routinely participate.  
 
 
4. How many days per week do you exercise/participate in these activities? 
 
 
5. How many hours per week do you train? 
 
 
6. How long (years/months) have you been consistently training? 
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APPENDIX C 
MEDICAL HISTORY 
 
Texas A&M UNIVERSITY 
EXERCISE & SPORT NUTRITION LABORATORY 
 
Medical History Inventory 
 
Directions.  The purpose of this questionnaire is to enable the staff of the Exercise and 
Sport Sciences Laboratory to evaluate your health and fitness status.  Please answer the 
following questions to the best of your knowledge.  All information given is 
CONFIDENTIAL as described in the Informed Consent Statement. 
  
Name:___________________________________________ Age _____  
Date of Birth _______________ 
 
Name and Address of Your Physician: 
_____________________________________________________ 
 
MEDICAL HISTORY 
Do you have or have you ever had any of the following conditions? (Please write the 
date when you had the condition in the blank). 
 
____ Heart murmur, clicks, or other cardiac findings?  
____ Asthma/breathing difficulty?  
____    Frequent extra, skipped, or rapid heartbeats?  
____    Bronchitis/Chest Cold? 
____ Chest Pain of Angina (with or without exertion)?  
____   Cancer, Melanoma, or Suspected Skin Lesions? 
____ High cholesterol?     
____ Stroke or Blood Clots? 
____ Diagnosed high blood pressure?   
____ Emphysema/lung disease? 
____ Heart attack or any cardiac surgery?   
____ Epilepsy/seizures? 
____    Leg cramps (during exercise)? 
____    Rheumatic fever? 
 ____ Chronic swollen ankles?     
____ Scarlet fever? 
____    Varicose veins 
____    Ulcers? 
____ Frequent dizziness/fainting?    
____ Pneumonia? 
____ Muscle or joint problems?     
____ Anemias? 
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____ High blood sugar/diabetes?    
____ Liver or kidney disease? 
____    Thyroid Disease?   
____    Autoimmune disease? 
____ Low testosterone/hypogonadism?    
____ Nerve disease? 
____    Glaucoma?    
____    Psychological Disorders? 
 
 
Do you have or have you been diagnosed with any other medical condition not listed?  
_______________________________________________________________________
_______________________________________________________________________
__________________________ 
 
Please provide any additional comments/explanations of your current or past medical 
history.  
_______________________________________________________________________
_______________________________________________________________________
__________________________ 
 
Please list any recent surgery (i.e., type, dates etc.).  
_______________________________________________________________________
_______________________________________________________________________
__________________________ 
 
List all prescribed/non-prescription medications and nutritional supplements you have 
taken in the last 3 months.  
_______________________________________________________________________
_____________ 
 
What was the date of your last complete medical exam?   
_______________________________________________________________________
_____________ 
 
Do you know of any medical problem that might make it dangerous or unwise for you to 
participate in this study? 
(including strength and maximal exercise tests)  ____ If yes, please explain: 
_______________________________________________________________________
__________________________________________________ 
 
Recommendation for Participation (for ESNL use only):   
 
____ No exclusion criteria presented. Subject is cleared to participate in the study. 
____ Exclusion criteria is/are present. Subject is not cleared to participate in the study. 
 
Signed: ___________________________________ Date: ________________________ 
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APPENDIX D 
 
PHYSICIAN CLEARANCE FORM 
 
Dear Provider:  One of your patient’s would like to participate in a study entitled “The Effects of the 
Curves 90-Day Fitness Challenge on Health Outcomes in Women” that is being conducted by the 
Exercise & Sport Nutrition Laboratory at Texas A&M University.  In order to do so, she must meet 
the selection criteria described below and/or have approval from her personal physician to 
participate in the study.  The study will involve having sedentary and overweight female 
participants participate in the Curves exercise and weight loss program, the WeightWatchers 
Momentum program, the Jenny Craig Program, the Nutrasystem Program or a Control Program 
for 12-weeks.  The assessments to be performed are listed below.  Please check the test/tests 
you do not feel comfortable having your patient complete (if any).  In addition please staple a copy 
of your letterhead to this form to verify that it has been reviewed.       
_____Fasting blood       _____Fasting resting energy 
expenditure (REE)    
_____Bench press assessments     _____Bioelectrical Impedance 
Analysis (BIA) 
_____Leg press assessments      _____Bone densitometry 
(DEXA) 
_____Diet intervention (see table attached)    _____Maximal 
cardiopulmonary stress test (Bruce Protocol)  
Details about these specific tests are included below and in the attached subject consent form.  If 
you feel she meets the entrance criteria and/or any existing medical condition that she may have 
is under control and would not be a limitation for her to participate in the study, please sign the 
medical clearance below.   
Selection Criteria     
Approximately 240 sedentary and overweight female subjects (BMI > 27) between the ages of 18 
and 70 will participate in this study.  I understand that in order to participate in this study, a trained 
individual will examine me to determine whether I qualify to participate. 
 
Participants will not be allowed to participate in this study if they:    
1. have recent history of weight change (+7 lb within 3 months); 
2. have any metabolic disorders including known electrolyte abnormalities; heart disease, 
arrhythmias, diabetes, thyroid disease, or hypogonadism; a history of hypertension, 
hepatorenal, musculoskeletal, autoimmune, or neurological disease; if they are taking thyroid, 
hyperlipidemic, hypoglycemic, anti-hypertensive, or androgenic medications;  
3. have been pregnant or lactating within the past 12 months or are planning to become pregnant 
during the next 12 months;  
4. have participated in a planned exercise program or have exercised regularly (> 30 min/d 3 
days/wk) within the past three months;  
5. have taken any weight loss medications and/or dietary supplements that may affect muscle 
mass or body weight during the three month time period prior to beginning the study;   
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6. have any absolute or relative contraindication for exercise testing or prescription as outlined 
by the American College of Sports Medicine;  
 
The only exception to these selection criteria will be if the prospective participant has a medical 
condition or history that the participant’s personal physician feels is controlled and therefore would 
not be a limitation for them to participate in the study.   
 
Medical Clearance  
 
I medically clear ______________________ to participate as a subject in this study. 
  
Name   ___________________________  Date _________________ 
 
Signature  ___________________________ 
Diet Breakdown. 
 
Group 1 (N=40) - Curves 90-Day Dietary Intervention Program – High Protein (HPD) 
 
Diet Period Energy Intake Group Macro- 
nutrient 
Grams/ 
Day 
Kcals/ 
Day 
Percentage  
Daily Diet (%) 
90 Day 
Fitness  
Challenge 
 
Phase 1 
(1 Week) 
 
1,200 kcals/d 
 
HPD + 
Exercise 
 
 
 
  
 
 
PRO  
CHO 
FAT  
 
 
 
135  
90  
33   
 
 
 
540  
360  
300   
 
 
 
45  
30  
25   
 
 
90 Day 
Fitness 
Challenge  
 
Phase 2 
(11 weeks) 
 
1,500 kcals/d 
 
  
 
 
HPD + 
Exercise 
 
 
 
  
 
 
 
PRO  
CHO 
FAT  
 
  
 
 
 
169 
113  
42   
 
 
 
 
675 
450  
375  
 
  
 
 
 
45  
30 
25   
 
 
 
Group 2 (N=40) - Curves 90-Day Dietary Intervention Program – High Carbohydrate (HCHOD) 
 
Diet Period Energy Intake Group Macro- 
nutrient 
Grams/ 
Day 
Kcals/ 
Day 
Percentage  
Daily Diet (%) 
90 Day 
Fitness  
Challenge 
 
Phase 1 
(1 Week) 
 
1,200 kcals/d 
 
HCHOD + 
Exercise 
 
 
 
  
 
 
PRO  
CHO 
FAT  
 
 
 
90  
135  
33   
 
 
 
360  
540 
300   
 
 
 
30  
45  
25   
 
 
90 Day 
Fitness 
Challenge  
 
Phase 2 
(11 weeks) 
 
1,500 kcals/d 
 
  
 
 
HCHOD + 
Exercise 
 
 
 
  
 
 
 
PRO  
CHO 
FAT  
 
  
 
 
 
113 
169 
42   
 
 
 
 
450 
675  
375  
 
  
 
 
 
30  
45  
25   
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Blood Samples. Subjects will fast overnight for twelve (12) hours and then donate approximately 
4 teaspoons of fasting venous blood (20 milliliters).  Blood samples will be obtained using standard 
phlebotomy procedures using standard sterile venipuncture of an antecubital vein by laboratory 
technician’s trained in phlebotomy in compliance with guidelines established by the Texas 
Department of Health and Human Services. The phlebotomists and lab technicians will wear 
personal protective clothing (gloves, lab coats, etc.) when handling blood samples.  Subjects will 
be seated in a phlebotomy chair.  Their arm will be cleaned with a sterile alcohol wipe and sterile 
gauze.  A standard rubber tourniquet will then be placed on the brachium.  An antecubital vein will 
be palpated and then a 23 gauge sterile needle attached to a plastic vacutainer holder will be 
inserted into the vein using standard procedures. Two serum separation vacutainer tubes (red 
tops) and one EDTA vacutainer tube (purple top) will be inserted into the vacutainer holder for 
blood collection in succession using multiple sample phlebotomy techniques.  Once samples are 
obtained, the vacutainer holder and needle will be removed.  The needle will be discarded as 
hazardous waste in a plastic sharps container.  The site of the blood draw will then be cleaned 
with a sterile alcohol wipe and gauze and a sterile Band-Aid will be placed on the site.  The blood 
collection tubes will be labeled and placed in a test tube rack for later analysis.    
Resting Energy Expenditure Assessment.  Resting energy expenditure assessments will be 
made according to standard protocols using the Parvo Medics TrueMax 2400 Metabolic 
Measurement System.  This will involve the subjects lying down on an exam table, having a light 
blanket placed over them to keep warm and inserting ear plugs in their ears to reduce distractions.  
A see through metabolic canopy will then be placed over the subject’s neck and head so that 
metabolic measurements can be obtained.  The subject will lie motionless without going to sleep 
for 15-minutes. Metabolic measurements will then be obtained to determine resting oxygen uptake 
and energy expenditure.   
 
Body Composition Assessments (BIA & DEXA).  Subjects will undergo body composition tests 
in the ESNL.  Prior to each assessment, height will be measured using standard anthropometry 
and total body weight will be measured using a calibrated electronic scale with a precision of +/-
0.02 kg.  Total body water will then be estimated using a Xitron 4200 Bioelectrical Impedance 
Analyzer (San Diego, CA) which measures bio-resistance of water and body tissues based on a 
minute low energy, high frequency current (500 micro-amps at a frequency of 50 kHz) transmitted 
through the body. This analyzer is commercially available and has been used in the health 
care/fitness industry as a means to assess body composition and body water for over 20 years.  
The use of this device has been approved by the Food and Drug Administration (FDA) to assess 
total body water and the current to be used has been deemed safe. This is measured through four 
electrodes placed on the body: one electrode will be placed on the posterior surface of the right 
wrist, in between the radial and ulna styloid processes (wrist bones), another electrode will be 
placed on the posterior surface of the right hand at the distal base of the second metacarpal; the 
third electrode will be placed on the anterior surface of the right foot at the distal end of the first 
metatarsal.  Subjects will lie on a table in the supine position and electrodes will be connected to 
the analyzer.  After the subject is connected, age, gender, weight, height, and activity level are 
entered into the unit by the technician.  After the unit has measured the resistance, which takes 
approximately 30 seconds, the unit then calculates total body water and body water percent.   
 
Body composition/bone density will then be determined using a calibrated Hologic Discovery W 
dual-energy x-ray absorptiometry (DEXA) by qualified personnel with limited x-ray technology 
training under the supervision of Richard B. Kreider, PhD, MX. The DEXA body composition test 
will involve having the subject lie down on their back in a standardized position in a pair of shorts/t-
shirt or a gown.  A low dose of radiation will then scan their entire body for approximately six (6) 
minutes. The DEXA segments regions of the body (right arm, left arm, trunk, right leg, and left leg) 
into three compartments for determination of fat, soft tissue (muscle), and bone mass. Radiation 
exposure from DEXA for the whole body scan is approximately 1.5mR per scan. This is similar to 
the amount of natural background radiation a person would receive in one month while living in 
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College Station, TX.  The maximal permissible x-ray dose for non-occupational exposure is 500 
mR per year. Total radiation dose will be less than 5mR for the entire study.  Since women of child 
bearing age may serve as subjects in this study, each subject will complete a questionnaire related 
to their menstrual cycle timing, sexual activity, use of birth control pills, and desire to become 
pregnant (see attached).  DEXA tests will be performed within 14-days of the onset of their period 
in menstruating women of child bearing age who do not use oral contraceptives according to 
NCRP and ARP radiology standards in order to reduce the possibility of exposure of an unknown 
fetus to radiation.   
 
Strength Tests.  All strength/exercise tests will be supervised by certified lab assistants 
experienced in conducting strength tests using standard procedures.  Strength testing will involve 
the subjects performing one repetition maximum (1 RM) on the isotonic bench press and the 
Nebula Fitness Olympic Power Station.  Subjects will warm-up (2 sets of 8 – 10 repetitions at 
approximately 50% of anticipated maximum) on the bench press. Subjects will then perform 
successive 1 RM lifts starting at about 70% of anticipated 1RM and increasing by 5 – 10 lbs until 
the subject reaches their 1RM.  Subjects will then rest for 10 minutes and warm-up on the Nebula 
45° Leg press (2 sets of 8 – 10 repetitions at approximately 50% of anticipated maximum).  
Subjects will then perform successive 1RM lifts on the leg press starting at about 70% of 
anticipated 1RM and increasing by 10 – 25 lbs until reaching the subject’s 1RM.   
 
Cardiopulmonary Exercise Tests.  Cardiopulmonary exercise tests will be performed by trained 
exercise physiologists in accordance to standard procedures described by the American College 
of Sports Medicine’s (ACSM) Guidelines for Exercise Testing and Prescription.  This will involve 
preparing the subject’s skin s for placement of 10 ECG electrodes.  Electrode sites will be cleansed 
with a sterile alcohol gauze using a circular motion.  The site will be allowed to air dry or will be 
dried with a gauze pad.  Electrodes will then be placed on the right subclavicular fossa (RA), left 
subclavicular fossa (LA), right abdomen (RL), left abdomen (LL), 4th intercostals space at the right 
sternal border (V1), 4th intercostals space at the left sternal border (V2), equidistant between V2 
and V4 (V3), 5th intercostal space at the midclavicular line (V4), 5th intercostal space at the anterior 
axillary line (V5), and 5th intercostals space at the axillarly line (V6) of the chest.  The subject will 
then be attached to an ECG.  Resting blood pressure, heart rate, and a 12-lead ECG will be 
obtained.  The exercise specialist will then review the 12-lead ECG to ensure that no 
contraindications for exercise testing are apparent based on the ACSM guidelines.  Subjects will 
then be seated on a treadmill.  A sterile mouthpiece attached to a head harness will be secured 
on the subject.  The subject will then have a nose clip placed on their nose.  Resting expired gases 
will be collected using the Parvo Medics 2400 TrueMax Metabolic Measurement System.  Once 
the subject is ready to begin the test protocol, the subject will straddle the treadmill with both legs 
while the treadmill is turned on at a speed of 1.7 mph and at a 0% grade.  The subject will then 
use one foot to repeatedly swipe the belt in order to gauge the speed of the motion.  Once the 
subject is familiar with this speed, the subject will step onto the belt while still gripping the handrail 
with both hands.  Once the subject becomes comfortable walking on the treadmill, he/she will let 
go of the handrail and begin walking freely.  The subject will then perform a standard symptom-
limited Bruce treadmill maximal exercise test using the following speeds and grades: 
      
_____________________________________________________________________________ 
Stage             Speed           Grade(%)  Duration(min.)
 _________________________________________________________________________
  
 1    1.7    10  3 
 2    2.5    12  3 
 3    3.3    14  3 
 4    4.2    16  3 
 5    5.0    18  3 
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 6    5.5    20  3 
 7    6.0    22  3 
 _________________________________________________________________________ 
 
The subject will be encouraged to exercise to their maximum unless the subject experiences 
clinical signs to terminate the exercise test as stated by the ACSM’s Guidelines for Exercise 
Testing and Prescription (i.e., angina, dyspnea, dizziness, a decline in systolic blood pressure, 
dangerous dysrhythmias [increasing or multi-form premature ventricular contractions, ventricular 
tachycardia, supraventricular tachycardia, new atrial fibrillation, or A-V block], lightheadedness, 
confusion, ataxia, cyanosis, nausea, excessive rise in systolic blood pressure over 250 mmHg or 
diastolic over 120 mmHg, chronotropic impairment, failure of the monitoring system, or other signs 
or symptoms for terminating the test).  The test may also be terminated at the request of the 
subject.  Once the exercise test is complete, the subject will observe a 3-6 minute active recovery 
period followed by a 3-6 minute seated recovery period.  The normal exercise time to maximum 
of the Bruce treadmill protocol for untrained women is typically about 9 minutes (near the 
completion of stage III or just entering stage IV).  Heart rate (HR), ECG tracings, and expired gases 
will be monitored continuously throughout the exercise test.   Blood pressure (BP) and ratings of 
perceived exertion (RPE) will be obtained toward the end of each stage.  Subjects will be asked 
to report any unusual signs or symptoms to the exercise specialists during the exercise test.  These 
tests will determine maximal aerobic capacity and anaerobic threshold to determine the effects of 
the exercise training on fitness and exercise capacity. 
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APPENDIX E 
 
PHYSICAL ACTIVITY LOG 
 
 
Weekly Physical Activity Log 
Name:  ______________________________Date:  _________________________________ 
Instructions:   
1. List your daily activities 
2. Assign each an intensity level – (low, moderate, high)* 
3. Indicate the duration in minutes of how long each activity lasted 
*Low intensity activities include easy walking, house chores, light gardening, etc.  Moderate 
intensity activities include brisk walking, easy jogging, moderately-paced bicycling, etc.  High 
intensity activities include fast running, lap-swimming, jumping rope, heavy lifting, etc.   
 
Mon Tues Wed Thurs Fri Sat Sun 
Activities Activities  Activities  Activities Activities Activities  Activities  
Intensity:  Intensity:  Intensity:  Intensity:  Intensity:  Intensity:  Intensity:  
Duration:  Duration:  Duration:  Duration:  Duration:  Duration:  Duration:  
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APPENDIX F 
DIET FOOD LOG 
 
Name:        Day: 1   2  3  4  (Circle One) 
Instructions:  
1) Record everything that you eat for 3 weekdays AND 1 weekend day 
2) Precisely record the food item (brand if applicable), preparation method, and TOTAL quantity consumed 
3) Break down mixed dishes or recipes by listing their components 
4) For dairy and meat products, indicate fat level (i.e. low fat, extra lean, 2%, etc.) 
FOOD ITEM  
PREPARATION METHOD                                     
(i.e. baked, fried, grilled, etc.)  gm ml cups T or tsp. oz. Pieces Sm, Med, Lg Other 
Meal 1:                     
                      
                      
                      
                      
                      
                      
Meal 2:                     
                      
                      
                      
                      
                      
                      
Meal 3:                     
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Meal 4:                     
                      
                      
                      
                      
                      
                      
Meal 5:                     
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APPENDIX G 
EATING SATISFACTION SURVEY 
 
Texas A&M University – Eating Satisfaction Survey 
Exercise & Sport Nutrition Laboratory 
 
NAME ________________________________ Date _________________________________ 
 
INSTRUCTIONS 
 
Circle the number or dot between numbers that best indicates the degree you have felt 
the following symptoms during the last week: 
 
Appetite 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Hunger 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Satisfaction from Food 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
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Feeling of Fullness 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Amount of Energy 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Overall Quality of Diet 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
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APPENDIX H 
RADIATION EXPOSURE 
 
Texas A&M University 
 
EXERCISE & SPORT NUTRITION LABORATORY 
 
Radiation Exposure Questionnaire for Women of Child Bearing Age 
 
Radiation exposure may affect fetal development.  Although the DEXA test will only 
expose you to a small amount of radiation (1.5mR per scan), you should be aware that 
there is a possibility that if you become pregnant during the course of the study that the x-
ray exposure may be harmful to the fetus. Therefore, it is important to conduct x-ray tests 
within 10-14 days of the start of a female’s menstrual cycle if the she is of child bearing 
age, sexually active, and/or is not taking birth control pills.  The following questionnaire 
must be completed so that we know when it is an appropriate time to conduct the DEXA 
body composition tests.  Please be assured that this information will be kept confidential 
within the limits permitted by law. 
 
Current Age?                                                            _______            
 
Age of first period?                                                           _______
           
 
Date of last period?                                                           _______             
 
Normal length of menstrual cycle?                                             _______ 
 
Have you been sexually active within the last month?                                         _______ 
 
Do you use birth control pills?                                             _______ 
          
Are you pregnant or have a desire for pregnancy?                                           _______ 
 
Note:  If you happen to get pregnant during the course of this study, you must notify 
research assistants so that appropriate precautions can be made.     
I confirm that I have completed this questionnaire honestly and agree to notify researchers 
within the ESNL of any change in the length of my menstrual cycle and/or pregnancy 
status. 
 
Name ______________________________________ Date ___________________ 
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APPENDIX I 
POST STUDY QUESTIONNAIRE 
 
Texas A&M University 
Exercise & Sport Nutrition Laboratory 
 
Post Study Questionnaire 
 
NAME ________________________________ Date ______________________________ 
 
INSTRUCTIONS 
 
Circle the number or dot between numbers that best indicates how you felt about your 
experience in the study.   
 
Overall Impressions of the Curves 30-Minute Fitness Program 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Overall Impressions of the Weight Loss Program 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Rate the Difficulty in Adhering to the Fitness Program 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
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Rate the Difficulty in Adhering to the Diet 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Rate Your Satisfaction with the Improvements in Fitness that You 
Made 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Rate the Satisfaction in the Changes in Body Composition that You 
Made 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. . . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
 
Comments/Suggestions About the Curves Fitness & Weight Loss Program 
 
 
 
 
 
 
 
 
 
 
